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The work presented in this thesis was performed 
from %  to July 1979, during twelve months of
which : it was a full time comniitmeht - a sitUation made 
possible by a generous;grant from the National Kidney 
Research Fund; Moreover much of the initial/ motivation 
to develop an Interest in prolactin was as a result of 
studies performed by Dr. J.W. Dobbie, Senior Lecturer 
in Medicine, within the IJniversity h^partment of 
Medicine in the Royal Infirmary,
In the course of an ultrastructural reconstruction 
of the fish glomerulus, Dr. Dobbié Obseryed: a 
phehbmenon, in young rainbow trout and smoiting salmon, 
which he termed ’’occlusive glomerular hyperplasia” 
(Dobbie, Moss : and Kennedyji 19 77). In these fish 40?50% 
of the glomeruli showed hypercellularity involving 
endothelial, mesangial and epithelial cells which ; 
resulted in occlusion of capillary and urinary spaces 
(Fig. 1). These changes were not apparent in fresh 
water fish (Fig. 2). In many species this process of 
smblting ih controlled by prolactin (Lam, 1972) and 
Dr. Dobbie concluded that in these creatures smoiting 
involved a state of reversibie; glomerular cellularity, 
the instigating hormone/being prblactin.
: -' i
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Since proliferative glomerulonephritis is 
one of the most potent causes of irreversible renal 
failure in man, it was with interest that Dr. Dobbie 
noted the considerable similarity in morphological 
appearance of glomeruli in salt water fish and those of 
patients with severe proliferative glomerulonephritis 
(Fig. 3), It was tempting to speculate that prolactin 
might have some relevance in the control of cellular 
constituents in the human glomerulus.
Concurrent with those studies, an adolescent girl 
was admitted to the Renal Unit of the Royal Infirmary 
(Fig. 4) with rapidly progressive, crescentic glomerulo­
nephritis. Renal biopsy revealed that 1G0% of 
glomeruli were severely affected, with crescent ; formation - 
diagnostic of ’’irreversible” renal damage. The child 
was initially treated by intermittent peritoneal dialysis 
but as expected her kidneys showed no sign of recovery; 
she was anuric and uraemic. Active therapy was dis­
continued but she was given chlorpromazirie therapy 
as a sedative to ensure her comfort* Howéver, this 
drug caused considerable enlargement and engorgement of 
her breasts and the girl began to lactate.; Some days 
thereafter, the patient began to pass urine spontaneously, 
her blood urea fell and her general condition improved.
xvili.
The fortuitous presentation of this patient at a 
time when the morphological aspects of smelting were 
first described suggested that it might be of 
practical importance to attempt to define prolactin 
status in human renal disease.
Thus, this thesis describes the setting up and 
validation of a radioimmunoassay for human prolactin 
and its application in the assessment of prolactin 
status in normal individuals and in patients with 
diverse pathological conditions. Particular experience 
and expertise has been accumulated in the diagnosis and 
treatment of prolactin secreting tumours of the pituitary 
gland and in the relationship between serum prolactin 
levels and renal disease in man.
Xix,
. ' SUMMARY % _
Human prolactin was isolated in 1970 and 
thereafter sensitive, specific radioimmunoassays were 
developed for its measiireraent. This has enabled 
progress in understanding some of the factors which 
control serum prolactin concentrations in man; previously 
unrecognised prolactin secreting pituitary tumours may be 
diagnosed and the doncept of a hon-lactogenlc role for 
human prolactin has emerged.
In this thesis, Chapter 1 presents a review of 
selected aspects of human prolactin pathophysiology.
It is divided into sections and beginsiwith an account 
of the evidence for the separate existence, Of human 
prolactin and a description of its isolation. The 
iactotroph is described and there follows à detailed 
consideration of the physiological control of prolactin 
secretion. Selected clinical aspects of prolactin 
sécrétion are discussed together with examples of the 
various investigative approaches used to identify a 
non-lactogenic role for human prolactin. The chapter 
ends with a statement of the aims of the thesis.
Chapter II commences with a discussion of the 
several techniques available for the measurement of 
prolactin concentration and Includes an outline of the
principle of radioimniimoassay*. A description of the 
prolactin radioinuimnoassay used in the present studies 
follows, and includes a comparison of available reagents, 
details of the separation technique and method of 
calculation and analysis of results. Data on the 
specificity, accuracy of recovery and precision of the 
assay are provided together with a description of serum 
effects# parallelism studies and quality control data, / 
The chapter concludes with a discussion of the advantages 
in the assay system adopted, ; " / ■
Chapter III describes a study to assess the 
importance of some factors which relate to interpretation 
of prolactin status in health and disease. Detailed 
reference ranges of basal prolactin levels Wore determined 
in 921 subjects in defined groups, including normal 
children, adults, pregnant females, patients on medication 
known to affect prolactin status, including the oral 
contraceptive and patients with a variety of pathological 
conditions. Assessment of the incidence of stress 
induced hyperprolactinaemia was made together With a 
measure of intra and inter diem variation in circulating
WÜ—■-nil ■! É III _ T1WIW7HP
prolactin levels* Prolactin response to defined 
stimulation and suppression tests was determined both in 
males and females and finally, based on this data, a
XX 3.
Strategy to facilitate the laboratory assessment of 
prolactin status is presented*
ÎA; brief historical review of the "amenorrhoea- 
galactorrhoea” syiidrbme begins Chapter IV and there 
follows an account of 32 consecutive patients presenting with 
unexplained, symptomatic hyperprolactinaemia. Radiological 
abnormalities of the pituitary fossa suggested the presence 
of prolactinomas in 32% of these individuals but impaired 
prolactin response % to stimulation and loss of the normal 
sleep peak of prolactin secretion were reliable indices 
of tumour, even when radiology was normal. Trans­
sphenoidal microhyppphysectomy proved effective, selective 
and safe therapy for patients with prolactinomas.
Twenty five per cent of subjects had neither 
biochemical nor radiological evidence of prolactin secreting 
tumour and these haye been defined "functional” hyper­
prolactinaemia. The clinical, biochemical and radiological 
features of this group are described together with their 
response to bromocriptine therapy# and possible underlying 
diagnoses in the group are considered. The chapter 
concludes with a discussion of the usefulness of 
dynamic tests of prolactin secretion in the diagnosis 
of fadiologicàlly occult microadenomas and in the provision
XX ii*
of an objective criterion for the comparison of patients 
treated in different ways. Finally, a strategy, based 
on this study, is. described for the elucidation of 
unexplained hyperprolactinaemia.
Significantly elevated proiactin levels also occur 
in patients with renal disease and Chapter V deals with 
a survey of 35 7 patients with renal disease of variable 
severity and pathology. The prevalence of hyperprolactinaemia 
was determined and the relationship between hyperprolactinaemia 
and underlying pathology, creatinine concentration, duration 
of uraemia and drug therapy was examined. The arterio­
venous concentration difference of prolactin across the 
normal kidney was measured. it was concluded that 
hyperprolactinaemia not attributable to drug therapy, occurred 
commonly in renal failure but not renal pathology per se.
The relationship between prolactin and creatinine, reversion 
of prolactin levels towards normal after successful 
transplantation and arteriovenous concentration difference 
of prolactin across the normal kidney suggested that 
hyperprolactinaemia in uraemia may be accounted for, in 
part, by altered renal metabolism*
", Deranged hypothalamic pituitary function in uraemia 
was not excluded in the survey of prolactin and renal 
disease. Chapter VI therefore deals with this aspect and
•V '
/"«r
' xaïïi.
béginq with a goneral review of endocrine in
- 1lKqreef;;er$ytW studies are described, .(i) to' . 
detomine overall basal hypothalaMlo pituitary statua in 
patienta with.:.prograa5i# ur&emia and'^-aÀar renal 
 ^ t/#aplantatlon-'Cii) te define responaea of several
anterior pituitary hormones to Stimulation and aupproaaion 
in-# maintenance'RaoWdialyaia pà'tients and. in 6 potiehts:- 
- .^/#tor aWeôaefql"' renal transplantation, Bviden.ee is'/ 
provided both of hypothalamic and pituitary dysfunction in 
uraemia, not ameliorated by dialysis but reversed by 
successful renal tTsnsplantatlon, It is concluded that 
endocrine. dysfunction, and hjqporprolactinaemis ' in_ , 
phrt'iéular,maÿ,^M sensitive indices of non urea:-'and 
creatinine rèimttd uraemic toxicity, . "' '
' {'-,:Circuiat#g prolactinK like Other peptide hormones,...'.-., 
:/ occurs naturally .in 'seve#! '"fo.r#s# which though irnmmo- 
logically ittdistioguishahlc are separable on the basis ' /'
,.of site*'. Chapter :,p i  describes a study to identify in 
. ^ uraemic sera, compared to pregnancy or prolactinoma sera
or pituitary extracts# mm#change# Im molecular hetero- 
genOity as a result of altofed renal metabolism of 
. prqlaetln. ., Only one peak-bf immmoreactive prolactin.
%%iV
similar to prolactia# was seen in nraemio ; $
sera with nq/eyideace of aggregate or fragment formation, 
This unexpected finding provides additional data to 
suggest that hyperproiactlKaemla in uraemia^may bo of 
biological sig&lflG&Bce*s. , ' - , v- -
The thesis concludes {Chapter VIII) with^an i
assessment of the studios described and discussed 
earlier chapters and potentially productive areas 
for future study^arg considered.
1.
CHAPTER 1
INTRODUCTION AND HISTORICAL REVIEW
1 (1) Introduction
Although it had been established in the late 
1920s that the anterior pituitary contained some agent 
which stimulated milk secretion in the developed 
mammary gland. Riddle, Bates and Dykshorn (1933) first 
used the term prolactin to describe the distinct 
anterior pituitary: hormone which stimulated crop 
"milk" production when injected into pigeons or ring 
dOyeS. Ovine prolactin was isolated and purified by 
1937 (Nllitei Catchpole and Long, 1937) and in species 
other than primates little difficulty was encountered 
in identifying distinct lactogenic hormones in 
pituitary extracts by the use of appropriate bioassays 
(Nicoli ,1967, Frantz and Kleinberg, 1970)#
Phylogeneticaliy prolactin is probably the oldest 
of the pituitary polypeptide hormones and it serves a 
wide diversity of function in primitive vertebrates - 
over eighty physiological actions have been described 
(Bern and Nicoll^ 1968, Nicoll, 19 74) . Mammotrophic
and lactogenic activity occur in many species 
including teleost fish and in these creatures, prolactin 
is also a major osmoregulatory hormone enabling survival 
in both salt and fresh water environments. In lower 
vertebrates prolactin is a growth and development 
factor; it may control steroidogenesis, fat deposition, 
orythropoiesis and in - many birds it has important 
behavioural,effects.
1 (2) Evidence- for the separate, existence of 
human p r o l a c t i n .
Until.; the, early 1970s there was considerable'' - 
doubt whether the human pituitary secreted a separate 
prolactin molecule (Sherwood, 1971}. Supposed growth 
hormone or prolactin preparations from primate pituitary 
extracts invariably produced positive responses in both 
growth promoting and lactogenic ..bio'assays. Although ;
the ratios of growth hormone to prolactin activity 
varied .considerably in different '-preparatioiis;, nevertheless 
the view emerged that in man growth and lactation were 
controlled,by a single hormone (Bewley and hi, 1970).
However3 considerable clinical and experimental 
data were available to.suggest that this view was 
erroneous. (1) Few acromogallc patients with elevated 
growth hormone (OH) levels developed galactorrhoea and 
conversely in physiological and pathological lactation, 
it was rare to detect GH by available techniques*
3#
(2) Individuals whp had hereditary growth hormone 
deficiency could lactate quite normally (Rimoin et al*,
1968), (3) Extracts of a pituitary tumour from a
'patient with galactorrhoea had considerable lactogenic 
activity but no growth promoting activity (Peake et: al*,
1969)i (4) In post partum lactating females, lactogenic 
activity in plasma could not be neutralised with anti
h GH serum, whereas, lactogenic activity in plasma from 
acromegalic patients was neutralised (Frantz and Kleinberg,
1970) . (5) In vitro studies with jiuman pituitary tissue
culture demonstrated that the secretion of GH decreased 
with time but secretion of FRL, as measured by bioassay, 
increased with time (Pasteels,1972)* These clinical
and experimental observations were incompatible with the , 
suggestions that h G H  and h PRL were one and the same 
hormone,
i (3) Isolation of human prolactin
In 1970 and 1971 respectively, human and monkey :
prolactin (m PRL) were isolated and clearly differentiated 
from growth hormone (Friesen, Guyda and Hardy, 1970,
Guyda, Hwang and Friesen, 1971, Friesen and Guyda, 1971),
This followed the recognition, initially in immunofluorescence 
studies (Herbert and Hayashlda, 1970), that although h GH 
and h PRL are similar in physical, chemical and biological
4,
prppérties, in its iïmïiuîiolpglcal properties h PRL is 
, related to o PEL rather than to h GH. Hence although 
: antisera to h GH or human placental lactogen PL) do 
not localise in prolactin secreting cells of the human 
pituitary, antiserum to o PRL does localise in these 
cells. The eontrihut ion of Friesen and his group in : 
this field has been summarised (Friesen and Hwang, 1973).
Pituitary tissue fragments from both human and 
monkey sources were incubated in the presence of 
labelled leucine. Gel filtration of the proteins 
released into the incubation medium showed a single peak 
of radioactive material which cross reacted with antiserum 
to 0 PRL but not antiserum to h PL or h GH» Specific 
antibodies to h PL were then coupled to Sepharose and 
this imaiunoadsorbent was used to remove all GH from the 
pituitary fractions with retention of full PRL activity. 
Thus, primate prolactin Was-separated from growth hormone,
A method more suited to the larger scale purification 
of prolactin later described (Hwang, Guyda and 
Friesen, 1972),
Also in 1971, using polyacrylamide gel electro­
phoresis at alkaline pH, & distinct band just behind GH 
was isolated from a homogenate of pituitary obtained from' 
a female xfho died during pregnancy (Lewis et al,, 1971).
This baild, identified as PEL, proved identical to 
Friesen*s material.
: Immunisation of rabbits with these prolactin rich 
preparatibhs yielded specific antisera and thus sensitive 
homologous radioimmunoassays for human prolactin were 
established (Hwangs Guyda and Friesen, 1971, Sinha et al,,
in retrospect it is clear that two major factors 
contrihuted to the difficulty in isolating h PRL.
(1) The considerable physical, chemical and biological 
similarity ■betX'feen h GH and h PRL - indeed h GH has 
10-201 of the prolactin activity of the best o PRL 
standards. (2) h GH constitutes 5-10% of the dry 
weight of pituitary powder while the h PRL content is 
0.05**0.11 i.e. GH is present in a one hundred fold 
: greater, amount,
. Only in; 1977 xfas the entire linear amino acid 
sequence of h PRL reported (Shome and Parlow, 1977;
Fig, 5). Thé hormone, molecular weight 21,500 was 
composed of 198 amino acids with six half cystine 
residues. Extensive homology with p PRL (77%)
0 PRL (73%) r PRL (60%) was confirmed and contrasted 
with only 16% homology between h PRL and hGH, and 13% 
between h PRL and h PL.
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1 (4) Source of human prolactin
Human prolactin is secreted by the anterior 
pituitary. It had been known for many years that 
the pituitary enlarged during normal pregnancy as a 
result of increase in the number and size of "pregnancy 
cells" (Brdheim and Stumme, 1909) and in 1961 it was 
postulated that these pregnancy cells secreted prolactin 
(Purves, 1961), This has been confirmed by immunofluorescent 
studies and' it is how clear that prolactin secreting colls 
occur not only in pregnancy, when they constitute up to 
50% of all acidophils (Golüboff and Ezrin, 1969), but 
also in non pregnant females and males. The cells are 
visible on light microscopy by special staining techniques 
(Herlant and Pasteéls*196 7) and on electron microscopy 
their characteristic features include the presence of 
well developed endoplasmic reticulum and large pleomorphic 
secretory granules (Fawcett, Long and Jones, 1969).
The prolactin content of a normal pituitary gland 
has been variably reported as between 100-500 ug h PRL 
per gland (Friesen and McNeilly, 1977) and as such was 
initially the sole source of h PRL for purification*
However, the observation that in early pregnancy prolactin 
concentrations in amnio tic fluid xfore greatly in excess 
of those in either maternal or foetal serum (Tyson et al,, 
1972, Clements et al., 1977) caused speculation that its
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.origin might bo foctal (Fang and Kim, 1975) maternal 
(Schonkor, Ben-David and Polisliuki 197$) or placontal 
(Prioson- ot al$, 1972b). , ,This speculation romains" v\V-;- 
unresolved, although the observation has boeh inianimoiisly 
confirmed and amniotic fluid now provides a potent source 
of h PRL which is chemically and immtindlogically 
indistinguishable from human pituitary prolactin 
(Friesen at al., 1972b). Indeed àntisera raised to 
attracts of amniotic fluid have formed the basis of 
radioimmunoassays for h PRL '''(Cple,-,and.hoy^  .1973),#
1 (S) Physiological control of prolactin socretion
Concepts of the physiological control of prolactin 
secretion in man are i^rinciphlly derivecl from experimental 
studios' in animals (Tindal, 1974, Tindal, 19 ,
Both in vivo animal'studie.s and-in', vitro :'tissue 
culture data demonstrate that ptoiactiny tinliké other 
anterior pituitary hormones, ,.is under.; inhibitory, control 
from the hypothalamus (Moites and Clemons, 1972^ Pastools , 
1972) * , The cell membrane' .of- the iactotfoph'ris- thought
to be maintained in a state of hyperpolarisation by tho 
specific interaction of-a prolactin-' inb'ibiting factor , 
(FTP) with its receptor on the pituicyte/' The .cell/" 
is, thereby impermeable to Ca++ ions'-'required' for'-'-';'".. 
depolarisation and release of 'hoTOone^.-granulas,Thus
■ . . / ..
under normal cirdumstàhces lîio prolactin secreting 
cell is bathed in a constant, probably small supply 
of PIF the nature and origins of which are only 
recently apparent.
Although catecholamine and dopamine (DA)
.terminals abut directly on the portal capillary bed, 
suggesting that DA might be released directly into 
the portal circulation (Fuxe, 1963), initially, it was 
reported that injections of DA into portal capillaries 
failed to lower PRL lovels (Kamberi, Mical and Porter,
1971). In a further study, however, half a million 
pig hypdthalnmi xmre extracted aaid the fraction with 
greatest: PIF activity was iiot only devoid of polypeptide 
but xvas rich in catecholamines, dopamine in particular. 
Further, xfhen this preparation was dissolved in freshly 
made 5% glucose solution to protect it from oxidation, 
it did indeed inhibit PRL secretion when infused into 
pituitary portal vessels (Schally et al., 1974, Takahara, 
Arimura and Schally, 1974). Thus it xvds speculated that 
theieafly failure to demonstrate such an effect may have 
been due to oxidation and inactivation of dopamine.
%Shaar and Glemens (1974) have confirmed the above 
results using hypothalamic extracts from the rat add in 
addition, by measuring PIF activity and catecholamine
V'i
.‘i-
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content pf both untreated hypothalamic extracts and 
"purified" fractions, they have concluded that the 
prolactin inhibitihg activity of the hypothalamus can 
be totally accounted for by its catecholamine content. 
Thus there is now convincing eyidénce that PIF is 
dopamine itself| that it originates granules in 
terminals of neurones which abut directly onto, and 
discharge into, portal blood vessels.
The control of prolactin secretion in birds is 
the opposite of that in mammals, that is the brain 
facilitates prolactin release (Meites et al., 1972)*
Hence it was of interest that in mammals thyrotrbphin 
releasing hormone (TRIi) released PRL as well as 
thyrotrophin (TSH) in vivo and in vitro (Bowers etal.,
, 1971,VTashjian, Barowsky and Jensen, 1971). There 
has subsequently been speculation thpt TRH muy be a 
physiological control mechanism ; for PR! reiaasè (Bowers, 
Friesen and ÿoïkers, 1973). However, since post partum 
suckling, a potent stimulus for PRL release fails to 
release TSH (Gautvik Ü * ,  1974) and there is no feed­
back effect of thyroid hormones oh PRL rebase by TRH 
(L’Hermite et a l 19 74), in man, the action of TRH oh 
PRL secretion may be of pharmacolpgical significance only 
Nevertheless, there have been reports.of a PRF distinct 
"fro# TRH (Valverde-R, Chioffo and Reichlin, 1972, Dular 
et al., 1974) although the identity and physiological
10.
significance of this factor remain speculative*
Since in the rat a minor stress such às ether 
anaesthesia causes a rapid but relatively small release 
of prolactin, while suckling results in a slightly 
delayed much larger release, two separate mechanisms 
may evoke PRL release (Terkel, Blake and Sawyer, 19 72,
Blake and Sawyer, 1972)1 A specific PRF may cause the 
relatively minor immediate release induced by stress, 
while the delayed but much larger release triggered by 
suckling may be due to a decrease of PIF activity.
The neurotransmitter serotonin has also been 
implicated in the physiological control of PRL secretion 
(Smythe, 1977). It facilitates release of PRL both! 
in the rat (Lu and Meites, 1973) and in man (Kato ^  al., 
1974) and in addition, blockade of 5«HT synthesis by 
parachlorophenylalanine blocks the release of prolactin 
in response to suckling, the effect being overcome by 
administration of 5-HT (Korden èt al*, 1973/1974). The 
physiological significance of this mechanism once again 
is not clear but theoretically at least serotonin may 
affect PRL secretion either directly, by induction of a 
PRF or by depletion of PIF at hypothalamic level, the 
latter alternative being most likely. Perhaps a serotonin 
secreting neuron© may providé the between those
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cells directly involved in PRF or PIF synthesis and ;
pathways, leading to the higher centres involved in the 
control of prolactin secretion.
The central connections o£ those neurones involved 
in the control of PRL secretion are imperfectly understood 
and much available information is derived from electro- 
physiological studies and assessment of pituitary function 
following chemical implants, such as oestrogen, in 
defined areas of the hypothalamus (TindOI, 1978).
Detailed anatomical studies using specific immunofluorescent 
stains for individual noui*ones, have expanded knowledge 
especially on the relationship between the arcuate and 
periventricular nuclei, median esninehce and pituitary 
stalk (Fuxe»1963).
Neurones-involved in the control of PRL secretion  ^
have their cell bodies in thé arcuate and periventricular 
nuclei of the hypothalamus, the Vhypophysiotrophic areaF, 
where they are in close physical contact with neurones 
involved in the control of other anterior pituitary ; V r 
hormones. Fairly short cytoplasmic extensions sweep 
down through the median emiaience to abut onto the portal 
capillaries as previously described. The hypophysio- 
trophic area itself is connected to virtually all the 
other major brain centres* For example (I) the largest 
input direct from the cerebral cortex coraes from the
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hippocampus via the fornix system, and a smaller pathway 
derives from the orbito frontal cortex via the ciaustrum, 
external capsule and pre-optic area of the hypothalamus.
(2) The stria terminalis and sublenticular systems bring 
fibres which originate in the olfactory and temporal lobe 
areas and relay in the amygdaloid body. Also from the 
basal ganglia comes the ansa ienticularis which carries 
fibres from the globus paliidus of the lentiform nucleus.
(3) The large median forebrain bundle conducts signals 
from the reticular activating system in the mid and hind 
brain and the smaller dorsal longitudinal fasciculus 
brings input from the medial thalamic nuclei, ; > -
Some of these pathways terminate in the pro-optic 
area of the hypothalamus rather than directly into the 
arcuate and periventricular nuclei and, therefore, it has 
been postulated that "link" neurones may connect these 
two adjacent areas. One might speculate that these 
may be serotonin secreting neurones.
Finally, in rats having- intact pituitary glands, ;
and ectopic pituitaries transplanted under the renal 
capsule, PRL may exert a negative feedback, at hypothalamic 
level to inhibit further PRL release (Chen, Minagtichi 
and Meites, 1967).
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In summary, the physiological control of prolactin 
secretion may be visualised at two levels (1) the 
central connections of those neurones which are directly 
involved in the control of PRL secretion. These derive 
from the cerebral cortex, basal ganglia, mid and hind 
brain (Fig. 6a), (2) stimuli propagated via any of these 
major central routes must effect their influence via a 
"final common pathway", in which the major control upon 
PRL secretion is inhibitory (PIF) although there is 
evidence for the presence of one or more prolactin releasing 
factors (PRF) and other neurotransmitters, for example, 
serotonin may be involved at some level. Prolactin may 
exert negative feedback control over its o m  secretion 
(Fig. 6b).
It is clear then that in vivo, the widely differing 
psychic, physical, chemical and pharmacological stimuli 
which have been observed to affect PRL status may do so 
by interaction at any of several sites.
It is also apparent that close physical proximity 
of key groups of specific hypophysiotrophic neurones 
within the arcuate nucleus and median eminence must 
facilitate chemical communication between them. Therein 
might lie a mechanism whereby events in one group of 
trophic neurones may initiate either synergistic or
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reciprocal diaiî^ s in colls directly controlling the 
secretion of different pituitary hormones. For example, 
such interaction between-dopaminergic neurones and Gn RH -  
secreting neurones may be responsible for the failure of 
LH and PSHresponso to the clinical and biochemical 
hypogonadism typical of hyperprplactinaemic states.
Î (6) Clinical aspects of prolactin secretion
With the development of sensitive radioimmunoassays 
for h PRL there has been progress in understanding of the 
normal physiology of prolactin secretion and of its relevance 
in clinical practice (Noel ot al., 1972, Guyda and Friesen, 
1973, Ehara ^  ^1., 1973, Noel, Suh and Frantz, 1974). This 
will be discussed in Chapter SiI, Furthermore, knowledge of the 
control mechanisms involved in prolactin secretion has 
clarified many alterations in circulating prolactin levels 
after such drugs as L-dopa (Kleinberg, Noel and Frantz, 1971) 
antipsychotic agents (Gold 1976, de Rivera et al., 1976) methyl 
dopa (Steiner et al., 1976) and bromocriptine (del Fozo et al,
1972).
Appreciation of pathological prolactin secretion has 
advanced considerably since the early recognition that not 
all patients who have elevated prolactin levels have 
galactorrhoea (Friesen et al., 1972b) and conversely, that 
patients with profuse galactbrrhoea may have normal prolactin 
concentrations (Frantz, Kleinberg and Noel, 1972).
IS
lia f i d  iéîiéy-: o f  . p r o l a c t i n  e i t h e r  a l o n e  o r  in c o m b i n a t i o n  : 
with other hormone# ia rare (Twrki&gton,l97%, Carlson,
BrickmAa and ^qttasBo, 1977) ami in the adult, seems 
aaspcigtod'with- few. If any - ill effects «
B y  q b a t r n s t p  p a t h o l o g i c a l  h y p o r p r o l a c t l n a e m i a  ! » ■  a  ' ■ 
much more common abnormality and may hava many causas 
'(Table - l)\m\ ' Irrospoctive of Its underlying aetiology, 
hypor|m>lactin'amda in^ the fomalp is usually associated- 
with Amonerrbao&; infertility ansi in about 30% of .patients,.■ ■ 
galactbrrhoea (Jacob# ot'-al.1976). Th|is hyperprolactinaemia 
is'particularly , eommbn In'Infertile patients (Flunks 
197è) semoy:0fwhmtimay hhve' prolactin secreting tumour#, of y  - - 
the 'pithitayy {Frmks- ,al. # 1977) a disease from which 
males.::are hot - èxdmpt.;(Carter et al., 1978).
•. It,-is hnrdly surprising that initial interest and :'.•
research has centred on those aspects of prolactin function
mil malfunction related to- lactation mul reproduction. It 
- ■"- ■- .. .'■ ' ■ > ' . ■ ■:■. ■ 
is* hoWovor} perhaps surprising that in 1979, there persists-'
cohsidqrablo debate on the subject of nn appropriate strategy
foT./the -invoàtigàtidh- of pathological hyporprolactinaewia; ’
.ignorance- of . the. natùr'al-.history of prolactin secreting 
tumours mâ groat'uncertainty in respect of the diagnosis ■ 
and''ideal; troatm-ent,; if. indeëd any is required, for those 
commonest ' of.', all^pituitary tumours (New England Journal 
W\mdiOiao,ri979)v'
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1 (7) Search for a non-lactogenic role for human prolactin 
The recognition thht circulating PRL levels are 
considerably higher than those of any other pituitary hormone 
(Friesen,1973) together with the observation that the 
adult male has PRL levels only slightly lower than those of 
the adult, female (Guyda and Friesen, 19 73) has evoked 
considerable interest in the identification of a non- 
lactogenic function for PRL in the human, particularly in 
view of the wide divers It y of: phys iol og leal function serve d 
by PRL in the animal Kxngdom.
1 (7)(a) Exogenous administration of prolactin
Détermination of thé effects of exogenously administered 
prolactin is à theoretically attractive approach for the 
elucidation of its physiological functions. However, 
practical problems associated with such studies abound, in 
the form of availability, purity, dosage and specificity of 
puitdble preparations for administration. In the case of 
h PRL scarcity of suitable prolactin preparations is perhaps 
the greatest of these. Nevertheless, two interesting 
observations have been made following administration of 
ovine prolactin to human subjects.
In 1971 it was reported that intramuscular ovine 
prolactin when given to five healthy adult males resulted 
in decreased u j inary excretion of sodium, potassium, and
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water with consequent increase in serum osmolality 
(Horrobin et al,, 1971) , The aiithors thus concluded that 
prolactin, may be an osmoregulatoiy hormoxie in. man as it 
is in animals. Despite subsequent criticism,of.this 
work due to vasopressin cent imination of ovine prolactin 
preparations (Carey, Johanson and So if, 1977) the 
original investigators^-vigbro.ubly'.defend the validity 
of their observations and conclusions. .
In quite different circumstances, Jopson and McGarry - 
(19 74) demonstrated a signifieaht inçreàse la red cell 
mass in response to ovine: prola:ctia,\:in\a small number of 
patients with chronic * but hbt acuce, bope marrow failure 
thus confirming their pari1er observation that prolactin 
has an erythropoietic effect-'-'in the -,mouse;,
1 (7) '(b);'Metabolic disturbahces in hyperpfolactinaemia 
Further evidence that prolactin may have a non^ 
lactogenic function in the liuraan may derive from detailed 
analysis of metabolic disturbance Ihyindividuals who are 
'hyperprolactinsemic* Recently,-in teres# has focused 
on two such disturbances - namely, ■deranged androgen 
metabolism and, more controyerslaily, abnormalities in 
fluid and electrolyte balance, = ~
Infertility due to hyperprolactihaenxia is common 
and its cause remains unclear. In the %ale, there is 
some evidence that derangedhmetabplism'-of;fèstostefone •- -
may be involved (Magrini ©h al.,, 1976), Six normal males
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were mad©; hyperprolactinàemic by the acute admihlstratibn 
of sulpiride. Thereafter h CG stimulation, tests 
provoked the same#ipcreniént in; circulating testosterone 
(T) levels as in controls but significantly lower levels 
of thé more potent metabolite dihydrotestosterone (DHT) 
were seen in hyperprolactinaemic subjects. Thus in the 
male, acutely induced hyperprolactinaemia may decrease - 
S oreductase activity thereby decreasing conversion of T 
to its more active metabolite DHT. If persistent, this 
defect might ; effectively lower physiologically active 
androgen levels and contribute to hypogonadism.
In the hyperprolact.inaemic female,. deranged 
androgen metabolism also seems to occur but the relation­
ship it bears to hypogonadism,.if any, is unknown. A 
study of 35 hyperprolactinaemic females before and after 
bromocriptine therapy revealed significantly lower levels 
of the adrenal androgen dehydrbepiandrosterone julphate 
(DHAS) Cp <0.0005) after therapy, whilst levels of 
testosterone and androstenedione were unchanged (Carter 
et al.j 19 77). The authors concluded that prolactin 
stimulates adrenal androgen production in the female.
Similar results were obtained in smaller numbers d£ 
patients by Bassi et al., (1977), Kandeel et al.(1978) , 
and Vermeulen and Ando (1978). The latter authors also 
noted that acutely induced hyperprolactinaemia, either 
by means of TRH or sulpiride, did not result in elevated
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DHAS in normal individuals, suggesting that prolonged 
hyperprolactinaemia was required. They further 
observed that hyperprolactinaemic females on steroid 
replacement therapy did not show the anticipated 
increase in circulating DHAS levels and thus concluded 
that physiological ACTH secretion is a pre-requisite 
for the effect of prolactin on adrenal androgen secretion.
The relationship which prolactin bears to fluid 
and electrolyte balance in man is controversial and 
will be further discussed in Chapter ÿ. Initial reports , 
suggested that patients with prolactin secreting pituitary 
tumours exhibited significantly lower osmolar clearances 
in response to standard water loading thhn did controls 
(Buckman et al., 1976) but others failed to confirm this 
observation in acutely induced hyperprolactinaemia 
(Baumann and Loriaux, 1976).
1 (7) (c) Prolactin status in pathological conditions
Less direct evidence for a non-lactogOnic fundtion 
for human prolactin may be obtained by the detailed 
assessment of prolactin status in a variety of pathological 
conditions. Such studies have proliferated with the 
wider availability of radioimmunoassays for h PRL and a 
selected summary of some of these studies is shoxm in 
Table 2. >■
One suspects that many of the reported anomalies in 
prolactin status may be the result rather than the cause 
of disease states. In addition, in some studies
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conclusions are drawn from limited data obtained from 
small groups of patients whilst in others, no attempt 
is made to draw any meaningful conclusion from observed 
anomalies'. - .
Nevertheless, it is quite conceivable that 
irrespective of its aetio1pgy, in pathologlea1 situations 
hyperprolactinaemia may assume a significance not 
applicable in normal physiological circumstances. For 
example, it may be that stress induced hyperprolactinaemia’ 
may induce beneficial cqmpensatory salt and water retention 
in the fluid and electrolyte depleted diabetic, whilst 
the same mochanisms may aggravate pre-existing hypertension 
in the stressed businessman. Furthermore, it may be no 
coincidence that there is excessive hyperprolactinaemia In 
molar pregnancy r a disease characterised by early and 
severe: pre-eclampsia. Hyperprolactinaemia in renal failure 
may certainly be a significant factor in the development ! 
of hypogonadism but it might also be a compensatory 
erythropoietic factor Which serves to ameliorate the 
profound anaemia in these patients, Moreover, it is of 
considerable interest that there was an increased incidence 
of elevated prolactin levels in individuals at "high risk" 
of developing breast cancer when compared to subjects who 
actually had the disease. This may mean that in certain 
susceptible individuals, prolonged exposure to elevated
■21.
prolactin levels may itself induce, or be a co-factor for 
the induction of, prolactin dependent carcinomata and 
promote their growth.
1(7)(d) Diseases in which prolactin may play a 
"~”^sIoIbilcal role
In general, our ignorance of the significance of 
physiological let alone pathological prolactin secretion 
in the human, lends itself to fanciful hypotheses on 
the possible role of prolactin in diverse conditions » a 
selection of which are noted in Table 3.
However, proposals such as these clearly arise 
because there are pathological conditions which we do 
not fully understand; abnormal prolactin status for which 
we can offer no satisfactory or significant explanation; 
animal studies which revëal hormone actions which may or 
may not be applicable and relevant to the human subject. 
The hypotheses, therefore, merit serious consideration and 
critical evaluation.
1(8) Aims of this thesis
The aims of this thesis may be summarised:
(i) As a general introduction, to provide a brief review 
of selected aspects of human prolactin.
(ii) To describe a radioimmunoassay which has been 
validated and used for the measurement of circulating 
prolactin concentrations; in man.
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(ill) To provide a strategy for the laboratory 
assessment of prolactin status, based on data obtained 
in diverse physiological and pathological conditions.
(iv) To demonstrate the role of dynamic tests of 
prolactin secretion in the diagnosis of small, radiologically 
occult prolactinomas by detailed clinical, biochemical
and radiological assessment of a consecutive series of 
patients with unexpkined symptomatic hyperprolactinaemia - 
the "Aiîiehorrhoea^Galactorrhoea" syndrome*
(v) To define the incidence of hyperprolactinaemia in 
renal disease and provide evidence of altered renal 
metabolism of prolactin together with diffusely deranged 
hypothalamic pituitary function in uraemia.
(vi) To describe altered molecular heterogeneity of 
human prolactin in uraemic sera compared to other hyper­
prolactinaemic sera and pituitary extracts.
(vii) To provide an assessment of the studies described 
and suggest potentially productive areas of future study.
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CHAPTER II
PROLACTIN ASSAY
2(1) Introduction
Prolactin may be measured by bioassay, radios 
immunoassay and radioreeeptorassay* The sensitivity 
and specificity vary greatly and, therefore, the 
method chosen must depend upon the primary purpose of 
the estimation.
The pigeon crop sac assay
This is the original bioassay for prolactin and 
depends upon the ability of the hormone to stimulate 
proliferation and crop "milk" production by pigeon 
crop sac epithelium (Riddle £t al., 1933). Indeed this 
method remains the classic bioassay for prolactin and 
is still used for the comparison and standardisation of 
the biological potency of purified prolactin and lactogenic 
hormones. However, the technique is cumbersome, prone 
to non specific serum interference and even at its most 
sensitive (Nicoll, 1967) cannot detect normal circulating 
levels of prolactin. Moreover both h GH and h PL also
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produce positive responses in the assay system (Forsyth, 
Folley and Chadwick, 1965, Forsyth and Edwards, 19 72). 
Stimulation of lobulo-alveolar mammary tissue in vitro 
Four methods have been described ifhich depend on 
the ability of prolactin to stimulate suitably prepared 
and maintained mammary gland ju vitro. Two of these 
methods have a histological end point with an arbitrary 
assessment of the amount of secretion accumulating in the 
alveolar lumina and use either mid pregnant mouse mammary 
gland(Frantz and Kleinberg, 19 70) or pseudo pregnant 
rabbit mammary gland (Forsyth and Myres, 19 71) . Two of 
the methods have biochemical end points and use mid 
pregnant mouse mammary glands. They depend on either 
the prolactin stimulated incorporation of "P into casein 
(Turkington, 19 71) or the stimulation of N-acetyllactosamine 
synthetase activity (Lowenstein et , 1971).
These assays are more sensitive than the pigeon crop 
sac assay but still do not measure normal basal prolactin 
levels; they both lack specificity, are imprecise, 
require specialised facilities, are time consuming and 
manpower intensive and have limited sample capacity,
2(i)(b) Radioimmunoassay
Radioimmunoassay (RIA) is a saturation analysis 
technique, the requirements for which are (i) a specific
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antiseruiii for the antigen to be measured (ii) antigen
I ? ^
which may be labelled with radioisotope ( I) and 
retain immunological activity (ill) antigen for 
standardisation (iv) a technique for separation of 
antibody-bound and free fractions.
In principle, a trace amount of radioactively 
labelled antigen is incubated with a constant; limiting 
concentration of antiserum, binding about 50% of labelled 
antigen alone. Unlabelled antigen competes with, and 
progressively displaces antibody bound labelled antigen. 
Thus there is an inverse relationship between unlabelled 
antigen concentration and the amount of antibody bound 
labelled antigen. Quantitation depends upon efficient 
separation of antibody bound and free fractions.
The technique was first used to measure circulating 
levels of thyroxine (Ekin#,1960) and insulin (Yalow and 
Berson, 1960) and with the isolation of primate prolactin 
as discussed in Chapter 1, radioimmunoassays for human 
prolactin became feasible. Heterologous systems word 
described - that is RIAs in which the antiserum used is 
raised to prolactin of one species and tracer is prolactin 
from another species (Hwang et al., 1971, Jacobs, Mariz and 
Doughaday, 1972) but these were superseded by homologous 
RIAs in which prolactin of human origin was used for
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immunisation, labelling and as standard (Friesen ejt al., 
1972b,Sinba et M . , 1973) .
The major Advantages of this technique are 
sensitivity (e.g. the ability to measure normal basal 
prolactin levels), specificity (e.g. no cross reaction with 
h GH or h PL), sample capacity and simplicity.
2(1)(c) Radioreceptor assay
The recurring criticism of radioimmunoassay is that 
it measures immunological activity which may be distinct 
from biological activity. Discrepancies between immuno- 
reactivity and bio-açtivlty do occur. For example, a 
hormone precursor may be immimologically but not biologically 
active as may a paftially degraded hormone fragment.
Thus in an effort to augment the established technique 
of radioimmunoassay, radioreceptor assays have been 
developed in which the binding agent is the physiological 
hormone receptor on the cell membrane of target tissues. 
Theoretically,these receptors bind only biologically 
active hormone and in the case of prolactin may be 
prepared from mammary glands of pregnant or pseudo- 
pregnant rabbits (Shiu and Friesen, 1976). The sensitivity 
add precision of such methods is usually much greater than 
conventional bioassays but the problem of lack of specificity 
recurs in that h GH and h PL cross react in the prolactin 
radioreceptor assay and non specific serum interference
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is a practical problem (Friesen and McNeilly, 1977). 
Moreover, those assays measure only hormone binding 
and although this may be a pre-requisite for biological 
activity, may not be equated with it.
Nevertheless the development of radioreceptor assays 
represents an advance towards comparison of biqlogicar 
and immunological activity at relatiyely low hormone 
levels, a prospect not feasible ûith conventional 
bioassay techniques.
2(2) Radioimmunoassay of human prolactin
A homologous radioimmunoassay has been used to
measure human prolactin concentrations in all of the
studies presented in this thesis. Both the purified 
human prolactin and the antihuman prolactin serum 
were prepared in the laboratories of Professor H.G. Friesen 
add were kindly supplied by Dr* A, McNeilly.
Using these reagents, assay conditions were optimised
to provide two systems; one for routine use, in which J
the mean sensitivity was 38 mU/1, rang© 2 7-54 (Table 4) 
and a more sensitive assay with moan sensitivity of 
6 mU/1, range 2-15 (Table 5). Standard curves typical of v 
each of those systems are shown in Fig. 7.
2(2)(a) Reagents 
Tracer ,
Highly purified human pituitàry prolactin (FR 75.7.10) , 
5 ug, was iodinated by the lactoperoxidase method (Thore11
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and Johansson, 1971, Table 6)* Lactopéroxidase (LPO) 
was supplied by Sigma London, bovine serum albumin 
(BSÀ) by Armour, hydrogen peroxide 30% w/v by BDH 
Chemicals and I o£ specific activity 13-17 mCi/pg 
(IMS-30) was from the Radiochemical Centre, Amersham.
The iodination reaction was terminated by simple 
dilution.
2 X 10 ul aliquots of the iodination mixture were
removed, diluted with 90 pi 0.05M phosphate buffer
pH 7.5 then applied to calibrated paper chromatographic
strips (Whatman 3 mm) and electrophorosed for one hour
(voltage SOOv); incorporation and specific
activity (SA) were calculated as described by Landon,
1 2 5 'LivanDU and Greenwood (1967). Mean I incorporation 
was 79%; range 71-84 and mean SA of labelled prolactin 
was 174 pCi/ug, range 162-194 in 14 iodinations.
The remainder of the iodination mixture was applied 
to a 40 X 1 cm column of G150 Sephadex which had been 
primed with 5% w/v BSA in phosphate buffered saline 
(pH 7.5, Q.05M phosphate, 0»9% w/v saline) (PBS), The 
column was eluted with 0.1% w/v BSA in PBS. Elution 
volumes of approximately 1 ml were collected using a 
Model 1200 Pup Golden Retriever automatic fraction 
collector (Instrumentation Specialties Co.). Measured
■■
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aliquots of each individual fraction were then counted 
in the gamma counter and an elution profile constructed 
(Fig. 8), The monomer peak was clearly separated from 
both "aggregated** prolactin and free iodine. It was 
possible, therefore, to select and pool appropriate
fractions from the "monomer** peak and retain these at
o ’ "  ^ ' . " ■■
-20 C for use as assay tracer.
# e n  maximal binding of this monomeric tracer was 
assessed in antibody excess (anti human prolactin serum 
FR AR 7-13, final dilution 1:5000), 941 of the tracer 
was bound and in assay binding of 50~g0% was consistently 
obtained in the roqtine system,
A comparison of standard curves using tracers 
derived either from the "monomer** or "aggregate* peaks 
of the iodination profile is shown in Fig, 9. Moreover, 
the correlation between results obtained in 30 test 
sera using a 5 day old tracer compared with those using 
the same tracer 40 days old, was poor (r « 0.71), thus 
repurification was carried out on each occasion prior to 
addition of tracer to an assay. A disposable 10 ml 
pipette containing 0150 Sephadex was used and the column 
eluted with 0,1% (w/v) BSA in PBS. Serial repurificâtion 
profiles of the same tracer are shown in Fig, id and 
increasing aggregate and free iodine concentrations are
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evident with time. However, significant amounts of 
''monomeric’* tracer persisted for 4-6 weeks and thus 
piovidod a satisfactory Ilk span for the tracer.
Alternative préparations of purified human prolactin 
were assessed for their suitability as source of assay 
trAcer (Table 7). The most appropriate material was 
foinid to be PR 75.7.10 on the basis of high immunological 
activity, low non specific binding |îSB), increased assay 
sensitivity and proibnged working life span with
The more conventional4iodination technique using 
the oxidising agent chloramine T (Hunter and Greenwood, 
1962) was compared with lactoperoxidase iodination and, 
in agreement with Wood, Shahwan and Marks (1975), tracer 
produced by the lactoperoxidase method gave higher 
binding in assay,y lower non specific binding and assays 
of greater sensitivity than those using tracer prepared 
with chloramine T (Table 8). The latter also had a 
shorter working life span.
' Antibody -v:'
r The rabbit anti human prolactin serum (FR AR 7-13) was 
used at a dilution of 1:28,000 to give 50-60% binding of 
tracer alone (Fig. 11), ■
VLSy 4 anti human prolactin serum (kindly supplied 
with Vis f 3 h fkl for iodination, by the National
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Institute of Arthritis Metabolism and Digestive Diseases . 
as part of their hormone distribution programme) was 
also tested at a final dilution of 1:30,000 and 
irrespective of whether this antiserum was used with 
VLS / 3 tracer (NIH system) or with FR 75,7.10 tracer, 
it gave consistently lower binding in assay (by 10-201), a 
consistently higher NSB values (by 2-2.Sx) with assays 
less sensitive than those using the routine Friesen 
system (FR AR 7-13 antiserum with FR 75,7vl0 tracer).
For objective comparison, 30 test sera which had 
been assigned values in the routine Friesen system, 
were re-assayed in two other systems (1) the NIH system
(2) a Mixed System using FRAR 7-13 antiserum with 
VLS / 3 tracer, A closer correlation to the Friesen 
system was seen with the Mixed System (r ,0*94) than 
with the NIH system (r « 0.88) suggesting ah antibody 
related discrepancy (Fig, 12).
Standard
Since March 1977, the first international 
reference preparation of human prolactin MRC 75/504 (650 
mill! international units/ampoule, from the National 
Institute for Biological Standards and Control, Holly 
Hill, Hampstead, London) has been used as a working 
standard, made up in assay diluent.
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Prior to this working standards were prepared from / :
Lowry Batch 3 purified human pituitary prolactin and 
were standardised using the MRC Research Prolactin 
Standard A 71/222 (10 milli units/ampoule) for 
absolute reference. / A
23 mU/1 was equivalent to approximately 1 ng/ml} 
of the VLS “NIH preparation;, ' A y ' ;
2 (2) (b) Separation technique A ^ /
Bound and free fractions were separated by a doublé 
antibody technique using a donkey anti rabbit sérum 
(Wellcome Reagents Code RD 17) at a final dilution of 
1:80 and carrier non-immune rabbit serum at a final 
dilution of 1:1000, which gave maximum precipitation 
of the bound fraction.
After an overnight incubation at 4 C, separation 
was by centrifugation at AyC for 30 minutes at 2000 xg, 
after which the supernatant was aspirated and thé 
precipitate counted in an automatic LKB Wallac 80000 
gamma'Sample counter. A: yy;,yy ; ; , . ;:v
2 (2)(c) Calculation and analysis of results
Paper tape print-out from the automatic gamma 
counter was fed into a Hewlett Packard Model 10 programmable 
calculator via a Hewlett Packard Model 9863A paper tape ; 
reader. A plot of free 'fraction divided by bound ^
33.
fraction against antigen concentration (the F/B plot) 
gave a standard curve which was close to linear. Little 
distortion was, therefore, involved if the standard 
curve was considered as a series of straight lines 
connecting adjacent points and this linear interpolation 
method was used to derive results automatically 
(Chkliand, Ratcliffa and Rataliffe, 1975). Final 
results were printed using the Hewlett Packard calculator's 
alpha printer facility, along with parameters such as 
A; values for all duplicates, standard curve mid point, 
assay mean, and a histogram of the A values obtained 
during the assay run,
2 (2)(d) Assay validation
No significant cross reaction was demonstrated 
with either h^ ^^ # or h PL over the range 0-5000 ng/ml 
and 0-100,000 ng/ml respectively (Fig. 13).
Accuracy of Recovery
Varying known concentrations of h PRL were added . 
to aliquots of a horse serum which had been pre-assayed 
in the routine system and found to contain undetectable 
levels of hPRL. Six duplicate estimations of each 
of these (horse serum + h PRL) preparations were than
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made in the same assay and within the range of prolactin 
levels tested, viz 49-300 mU/1, recovery of added h PRL 
was 97-108% (Table 9).
Serum effect
In the routine prolactin system described non 
specific serum effects were observed both with some 
horse sera (n “ 4) and with "prolactin free" human 
sera from six patients being treated with the prolactin 
suppressing agent, bromocriptine (Fig. 14a). In the 
routine assay, the effect was small (<10% suppression 
of % tracer bound) but the effect was volume related 
(Fig. 14b).
In the assay conditions routinely used, the effect 
was judged sufficiently small to enable a diluent standard 
curve to be used.
Parallelism Studies
As a crude assessment of the comparability of the 
prolactin used as assay standard (MRC 75/504) and that 
measured in the clinical situation, sera from a series 
of patients who had elevated circulating prolactin levels 
of diverse aetiology were studied at serial dilution in 
assay diluent to ensure that they were parallel to the 
diluent standard curve. Typical examples of such 
parallelism studies are shown in Fig. 15.
Parallel serial dilutions were obtained in pregnant 
sera, pituitary tumours, drug induced hyperprolactinaemia, 
hypoglycaemic stress induced hyperprolactinaemia and in 
uraemic sera.
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Precision within assay
Within assay precision was assessed by measurement 
of prolactin levels in twenty duplicate specimen^^ of 
each of five sera which had mean prolactin levels 70,
140, 280, 360 and 560 mU/1. Coefficients of variation 
for each of these sera were 3%, 4.9%, 4%, 7.8% and 13% 
respectively.
Precision between assay
Between batch precision was assessed by the inclusion 
of four quality control sera at the beginning and end of 
every assay performed. The mean prolactin concentration 
in each serum was 70, 190, 360 and 560 mU/1 respectively. 
Over a period of IS months during which 217 prolactin assays 
were performed, the between batch coefficient of variation 
in each of these sera was 8.4%, 5.41, 7.8% and 9.2% 
respectively.
Quality control
In addition to the inclusion of internal quality 
control sera in all assays, the laboratory participated in 
the external National Quality Control Scheme for human 
prolactin (Dr. S. Jeffcoate, London).
For the 14 month period up to July 1978, results 
had a mean% difference from the all method mean of -34,
SD 14. Two factors may have contributed to this 
discrepancy (i) the lack (at that time) of a widely 
available reference preparation for use as working 
standard (ii) the lack of uniformity of reagents and 
methods used by participating laboratories causing some 
groups to return consistently high results e.g. horse
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serum reading 1200 mU/l. Clearly such high values cause 
skewing o£ the all method meani
On a limited number of observations (n ** 5) the 
moan inter assay C.V. of eight pools with prolèctin 
levels in the rang© 40-1553 mU/l, was 8.1%.
The assay discriminated well between horse serum 
and a low human pool e.g. <42 mU/1 (Routine system) 
compared to an all method mean of 192, and <31 (Routine 
system) compared to 176 (all method).
2(5) Statistics
Since the distribution of prolactin levels observed 
in healthy control subjects and in diverse pathological 
conditions was non-Gaussian, the Mann Whitney test was 
applied to assess statistical significance, by means of 
a Wang 600 programmable calculator (Wang Laboratories Inc.) 
2(4) Discussion
For routine clinical use radioimmunoassay is the 
most suitable currently available technique for the 
measurement of prolactin concentrations. The system 
described has proved accurate, precise, sensitive and 
specific. Only small serum volumes were required arid 
results of high diagnostic accuracy were available 
within one week. Although the method was entirely 
manual and hence labour intensive, one person was able 
to cope with a routine throughput of approximately 100 
samples per week, each sample assayed neat and at 
dilution on the first occasion.
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The method involved a wo11 established technique 
for the separation of bound and. free fractions and the 
method of calculation and analysis of results was one 
which was already validated and in routine use for 
other hormones within the radioiimaunoassay unit.
Friesen*s reagents proved the most suitable <f those 
tested with high % binding in assay, low non specific 
binding and the tracer produced by lactoperoxidase 
iodination had a prolonged life span with repurification 
and hence was saving of iodination material and labour.
À clear advantage of the reagents used was the 
considerable flexibility which they conferred on the 
system. The routine system was robust, gave good 
precision over the normal range of prolactin concentrations 
and discriminated well between levels xdiich were normal 
and those which were elevated. Moreover, minor 
modification of assay conditions such as the use of a 
disequilibrium time course, increase in standard/sample 
si&e and halving of working antibody titre produced a 
considerably sensitized system xdiich was of particular 
valuo in th© chromatographic studies of the molecular 
species of prolactin present in sera and pituitary 
extracts . (Chapter %jh): »,
: Non specific serum effects may occur in radio­
immunoassays and if present usually involve suppression
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o£ thé percentage of tracer bound at a given antigen
concentration. The effect may be so marked as to
■ V  - . ■ ■ -, .. . .   ^  ^ . ' V
necessitate preparation of standard solutions in
antigen free serum rather than assay 
diluent, to avoid distortion as a result of comparison 
of serum samples to diluent standards.
The minor non specific serum effects observed 
in this assay enabled routine use Of a diluent 
standard curve and hence avoided the necessity to 
identify and/or prepare a constant supply of prolactin 
free serum.
Finally, the parallelism which: was demonstrated 
on serial dilution of various hypérpfolactinaemlc 
sera enabled confident, accurate measurement of 
prolactin levels, by dilution, in pathological 
hyperprolactinaemia.
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CHAPTER III
THE LABORATORY ASSESSMENT OP PROLACTIN STATUS
3(1) Introduction
Measurement of serum prolactin concentration is 
now an essential part of the routine investigation o£ 
Xjatients with suspected hypothalamic - pituitary 
dysfunction (Friesen et , 1972a, Kleinberg, Noel 
and Frantz, 1977); indeed, hyperprolactinaemia is 
probably the most frequent hypothalamic « pituitary 
disorder seen in clinical practice, commonly presenting 
with amenorrhoea and infertility in females and 
impotence in males (Friesen and Hwang, 19 73, Tyson et ab,
1975), Cross abnormalities of prolactin secretion are 
readily detected by measuring basal prolactin levels and 
in general, the higher the level, the greater the chance 
that the patient has a prolactin secreting adenoma 
(Kleinberg et al., 1977). However, pituitary micro- 
adenomas are often associated with relatively modest 
degrees of hyperprolactinaemia and as such may be
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difficult to distinguish from the many physiological 
and pathological conditions also associated with this 
biochemical finding (Table 1).
To assess the importance of some of th© factors 
which are relevant to the interpretation of basal 
prolactin levels, detailed reference ranges in defined 
groups of patients xmre determined. In addition, 
serum prolactin responses to standardised dynamic tests 
were compared in normal subjects since these tests 
be useful in the diagnosis of pituitary microadenomas 
in patients with modest hyperprolactinaemia (<1000 mU/1) 
and normal pituitary tomography. Moreover, the use of 
such tests may provide information about the pathophysiological 
factors involved in diverse hyperprolactinaemic states.
3 (2) Subjects studied and methods
Prolactin levels were studied in 921 subjects. None 
were receiving drugs known to affect prolactin secretion 
unless stated. Samples were taken between 09.00-12.00 
unless otherwise indicated. Abnormal prolactin levels 
were confirmed on at least one further specimen. The 
following groups were studied.
3(2)(a) Normal subjects 
Basal levels
Hospital Personnel: 100 subjects (50M, 50F mean age 31y,
range 17-S5).
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Hospital in-patientsî SO subjects (30M, 20F mean age 
48y, range 18-86) xfithout évidence of renal, endocrine 
or malignant disease.
Hospital out-patients I 163 females (mean age 39y, 
range 17-71) attending a gynaecology out-patient 
clinic for the first time. Patients with amenorrhoea 
and infertility were excluded, lfh.ere prolactin levels 
were elevated, a second specimen was taken at the 
following visit to obtain an estimate of possible stress 
factors related to hospital attendance.
Females On oral contraceptive preparations as the sole 
drug; 104 subjects (mean age 28y, range 17-38), Samples 
were taken at routine clinic visits between 14,00-15*00. 
Children with benign, non-endocrine disease: these
comprised 11 normal babies (6M, 5F) aged less than 
3 months and 30 children (13M, 17F) mean age 5y, range 
3-13. .
Serial levels
Within day variation xfas studied in six subjects (4M,
2F mean age 2 7y, range 24-30). Blood samples were 
taken via an intravenous Cannula at hourly intervals 
from 08,00-20.00 during which time, subjects maintained 
normal activity.
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Day to day variation was studied in ten subjects 
(6M, 4F mean age 28y, range 19-39) sampled daily 
for five days between 09.00“12.00.
Possible stress of venepuncture was studied in 12 males 
(6 hospital staff and 6 patients; mean age 2 7y, range 
25-34). The patients were to undergo elective surgery 
for non-endocrine conditions the following day. Samples 
were taken from an intravenous cannula at 10 minute 
intervals for 90 minutes.
3(2)(b) Pathological Conditions 
Hypothalamic-pituitary disease
Miscellaneous hypothalamic-pituitary disorders. This 
heterogenous group consisted of 27 patients (ISM, 12F 
mean age 31y, range 12-64) with the following disorders; 
Kallman’s Syndrome n « 4 (M)
Nelson's Syndrome n « 3 (IM, 2F)
GH deficiency n = 5 (4M, IF)
Craniopharyngioma n - 5 (F, 2 patients post
surgical treatgient,
1 patient post radiation 
.. U therapy) - , :
Gonadotrophin (Gn)
deficiency n = 4 (M)
Panhypopituitarism n « 6 (2M, 4F)
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Diagnosis in all cases was made on clinical, biochemical 
and radiological evidence and all patients were untreated 
at the time of sampling apart from the three patients 
noted above. Patients with "panhypopituitarism" had 
no clinical or biochemical evidence of any specific 
endocrinopathy,
Pituitary tumours
This group consisted of 42 patients (lOM, 32F 
mean age 32y range 16-69) in the following categories: 
Prolactinoma n « 16 (IM, ISF)
Acromegaly n =* IS (6M, 9F)
Cushing's disease n = 11 (3M, 8F)
Diagnosis in all cases was established on clinical and
biochemical grounds together with light and electron 
microscopy and immunopefoxidase studies on surgically 
removed tissue. In a number of cases samples were 
obtained both pro and post selective, curative 
surgical treatment.
Idiopathic hyperprolactinaemia
This group consisted of 10 females (mean age 26y, 
range 16-34) Who presented with galactorrhoea and/or 
amenorrhoea and infertility and who had persistent
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hyperprolactinaemia (l.é; elevated PRL levels on 
at least two separate occasions) with normal pituitary 
tomography and ho Other factor identified to account 
for their elevated prolactin levels.
Chronic Sick /
Twenty subjects (8M, 12F mean age 42y, range 
2 7rS9)xdio had chtpnic progressive arthropathy for 
more than three years Were studied. All patients, 
x/ere taking non steroidal anti inflammatory agents as 
the sole medication.
Renal failure
62 subjects (32M, 30F mean age 41y, range 17-45) 
with moderate chronic renal failure (creatinine <600pmol/l) 
were studied along with 13 patients (9M, 4F mean age 37y, 
range 18-49) xdxo had severe chronic renal failure 
(creatinine >600 pmol/1). Thirty seven subjects 
on regular dialysis treatment (mean creatinine 1300 ppol/l 
il7M, 20F mean ago 33y, range 16-52) xmro also studied.
None of these patients was on any drug therapy 
known to affçct prolactin levels nor had they evidence 
of clinical ehdocrinopathy apart from five of the male 
dialysis patients who were impotent.
Primary Hypothyroidism
This group consisted of 50 female patients (mean 
ug© 44yj, range 24-78) with gross primary hypothyroidism 
(mean T4 27 nmol/1, range <11-48; mean T3 0,6 nmol/1,
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rang© <0.4-1.8; TSH all >50 mU/1). None o£ these 
patients had clinical evidence of any other endocrine 
abnormality*
Pituitary Ablation
This group comprised five patients (3M; 2F 
mean age 32y; range 27-49) xvho were insulin dependent 
diabetics and who had had attempted total hypophysectomy 
as a therapeutic manoeuvre for severe proliferative 
retinopathy« Macroscopiçally; hypophysectomy had been 
complete and samples were obtained from seven months 
to two years post surgery*
Drug Therapy
Samples were obtained from 68 patients (38M,
30F mean age 37y, range 16-72) who were on long terra 
therapy with drugs which may affect basal prolactin 
levels viz., phenothiazines n « 21, Wethy1 dopa n » 35, 
tricyclic antidepressants n « 8, metoclopramide n 2, 
reserpine n - 2.
3(2)(c) Dynamic tests of prolactin secretion 
Thyrotrophjn Releasing Hormone (TRH-Roche) 2OOug 
was given intravenously to 24 healthy subjects (14M, lOF 
mean age 29y, range 24-33) and blood was collected by 
serial venepuncture at 0*j 20* and 60* after TRH 
administration^
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MetPC1opramide monohydroch1or ide (Maxo1on-Bb©cham)
10 mg was given intravenously to 12 subjects (6M, 6F :#A
mean age 28y; range 2 5-33) and.blood samples withdrawn 
at O', 15*, 30*, 60* and 12Q* after m.etoclppramide..
L-dopa. (Roche) SCO mg orally xvas taken by eight 
subjects (SM,. 3F mean age 29y, range 26-33) and blood 
samples withdrawn at 0*, Ih, l.Sh, 2h, 3h, 5h and 7h -/ 
following ingestion of the drug* . , % -
Bromocriptine (Parlodel-Sandoz) 2.5 mg orally was 
taken by three subjects (2M, IF mean age 28y, range 
2^  30) following a meal and blood samples collected 
at 0*., Ih, 1.5h, 2h, 3h, Sh and 7h thereafter*
Whereas in the TRH test blood was collected 
by repeated venepuncture, in all other tests, samples 
were taken via an indwelling intravenous cannula kept 
patent by heparinised saline. All subjects dtudied 
were fit and healthy on no drug therapy and. they 
maintained normal activity during these tests. No 
side effects were noted apart from postural hypotension 
and vomiting following bromocriptine administration, thus 
restricting the number of subjects receiving this test.
3(2)(d) Radioimmunoassay of prolactin was by the routine 
system described in Chapter II. Prolactin levels in. 
sérum and plasma were not significantly different, nor -
47.
in specimens frozen immediately in a dry ice mixture 
or allowed to freeze at -20^C. Serum samples were 
routinely assayed, blood being separated within 12 
hours of sampling and serum stored at -20°C until assay.
3 (2)(e) Statistical analysis was by the Mann Whitney test.
3(5) Results
3(3)(a) Normal subjects
Basal levels
The range of prolactin levels seen in hospital 
personnel and in-patients (the cbntrpl range) was 60-375 mU/1 
(Table 10, Fig. 16). When compared to controls, 
significantly elevated prolactin levels, (p <0.0005) were 
noted even in the first trimester of pregnancy and 
concentrations rose until term, with a wide scatter.
Oral contraceptive therapy and long term therapy with 
other defined drugs were associated with significant 
hyperprolactinaemia (p <0.005).
Eighteen of the 163 patients (111) attending a 
gynaecology clinic for the first time were found to have 
prolactin levels outwith the control range. On 
subsequent sampling 12 patients (71) were found to have 
levels within the upper end of the control range whilst 
the remaining six patients had persistent hyperprolactinaemia, 
Four of these patients subsequently were found to be
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taking drugs knofe to be associated with hyperprolactinaemia 
(oral contraceptive therapy n » 3 ; metoclopramide n « 1).
Two patients (1000 and 1614 mU/l) had unexplained 
hyperprolactinaemia and detailed assessment subsequently 
revealed one of thesé to have a pituitary tumour;
No significant sex difference in basal prolactin 
levels was observed as may be seen in Fig. 17 which 
shows the relationship between prolactin level and age 
in both male and female adults as well as children. 
Significantly elevated prolactin levels (p <0.005) were 
seen in infants under the age of three months, when 
compared both to older children and adults. Although 
in males; there was a trend towards lower basal prolactin 
levels with increasing age, this did not reach statistical 
significance. In females, however, the trend was more 
marked, and women >50y had significantly lower prolactin 
levels (p <0.005) than younger women.
Sérial levels
There was no significant trend in basal prolactin 
concentration in any of the 12 subjects who were 
venesected at 10 minute intervals after insertion of an 
indwelling intravenous cannula, the mean C.V. for the 
group being 11% (range 7-17%).
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..-Throughout the day, however, a clear clrê&dl&n .
pattern of prolactin secretion was observed (Fig. IS). '"
Between 08.00-09;00h (ma&n PBL &36 mU/1# range 100*414)
arid between 17,00*30.00^ (mean fPJ* IBS mO/1, range
J6-2IU) prolactin levels were significantly higher '
p <0.00S) th&n batweea 09.00-12,00h (mean PRL 1&3 mU/1,
range 71*208}, - :
A . In addition, from day te day, circulating
prolactin varied in the same individual^ the degree of
variability'being'slightly, though not algmificaatly,
more marked in female© (moan C.V. 28% range 2S-3&) than /
i n  m a l e s  ( m o a n  C . V .  2 0 %  r a n g e  # * 2 9 )  ( P i g .  1 9 ) ,  • y
3(8)(b) Pathological conditiOBs ' ^  ^    .
The range of prolactin levels seen in a defined 
selection of pathological conditions is shown in-Tablé --II, ■>■' ' 
Pig. -20 . '  . .  ' . ' - - - "  .
Of p&tie&ta with miseellaîieons hypoth&l&mic~pitwitary 
disease, oniy....three diagnostic categoriea were associated 
with abnormal prolactin -levels-'viz:
(1) Craniopharyngioma * in which one untreated 
pàtiomt had an elevated prolactin level of 600 ..mU/1 and 
&.further.patient, treated by external irradiation had 
a grossly elevated level of 2800 mU/1. .
(ii) One out of four patients who- had Isolated 
gonadotrophin deficiency, had a persistently modestly 
elevated basal prolactin level at 480 mll/1*.
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(iii) Three of tile five patients who were 
otherwise paiihypopituitary were found to have modestly 
elevated prolactin levels ( <750 mU/l) and this ■
contrasted sharply with the uniformly.undetectable 
levels seen in patients rendered panhypopitultary by 
elective surgical pituitary ablation*, (
Most patients, tdio-had prolactin secreting tumours . 
of the pituitary gland* as expected, had grossly elevated 
circulating prolactin levels* However, five of these 
patients,3 (31%) had moderately elevated levels ( <1200 mlJ/l) 
and there was overlap in basal prolactin levels with 
patients who- had idiopathic hypérprolactinaemia*
Seven of the IS (47%) untreated acromegalic 
patients were found to have hyperprotactinaemia and in 
all but two of the nine patients who were studied before 
and after selective, curative surgical treatment, pro,lactln.)r 
levels were significantly reduced (p <0*005).
Patients with active Cushing’s disease, as a group,; 
had prolactin levels significantly .higher (p <0.05) than 
those in control subjects although only three patients 
had frankly abnormal levels* As in acromegalic subjects., ;
selective, curative microsurgery was associated.with a 
fall in prolactin level*
The prevalence of hyperprolac.tinaemia, in female : 
patiënts who were, hypothyroid, was 40% (20 patients), 
levels ranging from 360-2400 mU/l> .
Hypérprolactinaemia occurred In 10 patients (16%) 
with moderate chronic renal failure but was more common 
both in sever© chronic renal failure (77%) and dialysis 
patients (78%)* ^ /
Patients with chronic progressive arthropathy 
had.prolactin levels within the reference range*
3(3)(c) Dynamic tests of prolactin secretion
Administration of TRH (Fig. 21) and metoclopramide 
(Fig. 22) resulted in a prompt rise.in circulating prolactin 
levels. The response evoked was greater in magnitude 
(p <0.005) and more prolonged in duration following 
metoclopramide. In response to both stimulation tests, 
female subjects had significantly greater prolactin 
reserve thah did males. This contrasts with the prolactin 
response to suppression tests in which the pattern of \ 
response was similar for both male and female subjects. 
L-dopa administration (Fig. 23) resulted in suppression 
of prolactin levels which was smaller in magnitude and 
shorter in duration than after bromocriptine administration 
(Fig, 24), The range of prolactin responses to stimulation 
and suppression tests is shown in Table 12,
3(4) Discussion
The basal prolactin levels seen in healthy neonates,, 
children and adults in this study, are consistent with “ 
those previously described, in smaller groups of subjects , 
(Erieben and Hwang, 19 73, Guyda and Friesen, 1973).
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Even in healthy individuals, however, several factors 
may affect prolactin status and appropriate interpretation 
of a given result demands adequate reference data in 
relation to factors such as sox* age, circadian rhythm,. 
puls&tility of secretion, stress and drug ingestion 
(Jeffeoato »1978).
Mean basal prolactin levels are usually higher 
in females than in males (Bhara et al., 19 73, Friesen 
and Hwang* 1973) though with a considerable overlap 
in their ranges (Frantz,1978) and in the present study, 
no statistically significant sex difference was observed, 
although no account was taken of the stage of the 
menstrual cycle in female subjects* Some authors have ‘ 
demonstrated significantly higher prolactin levels in 
the peri pvulatbry and luteâi&phases of the cycle when : 
compared tp fpllicular phase levels (Franchimont et al.,  ^ :
1976) but other investigators have failed to demonstrate 
any consistent pattern in circulating prolactin during 
the menstrual cycle (Bhara ©t al*, 1973, McNeilly and / 
Hagonf1974). It is of interest, however, that in 
post menopausal females, a slgxdficant fall in prolactin 
levels was observed, which may well be oestrogen related, 
since no similar fall was seen in ageing males,.and
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Thorner and his colleagues (19 77) have demonstrated a 
rise in serum prolactin levels which correlates with 
oestradiol levels in pubertal girls, but not boys.
Thus, age, is also a factor which may affect basal 
prolactin status, at least in the female. The origin 
of the hypeI’prolactinaemia in neonates is unclear but 
is presumed to be of foetopTacental origin (Gtiyda and 
Friesen,1973) although it also may be oestrogen related.
It is established that considerably elevated 
prolactin levels occur during the hours of sleep 
(Sassin et al., 1973, Ehara ot £l,, 1973) and it has 
been reported that in the early hours of the morning, 
prolactin levels may still be significantly elevated 
(Friesen and Hwang, 1973). The present data would 
confirm this, and, in addition, suggest a diurnal 
variation in prolactin secretion during waking hours, 
with higher prolactin levels in the early morning and 
a trend towards higher levels again in the evening.
The ideal sampling time thus would be 09.00-12.OOh when 
prolactin levels are at their nadir. The degree of 
individual variability in prolactin secretion from day 
to day is modest, but is more marked in females than in 
males an observation which again may be related to the 
oestrogen status of the subject. This modest variation
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in prolactin levels from day to day, together with the 
relative consistency in prolactin concentrations noted 
over a much shorter period of time (90 minutes), would 
suggest that for confirmation of Hyperprolactinaemia, 
repeated sampling on several different days may be of 
more value than the usually advocated repeated sampling 
over a short period, .via an indwelling cannula «
Prolactin release arising from the stress 
associated with major surgery or insulin induced hypo*- 
glyeaemia is well established (Noel et , 1972). The 
incidence of hyperprolactinaemia, attributable to the 
’’psychid” stress of either hospital attendance or vene­
puncture is poorly documented, however, although a recent 
study suggests that 19% of women attending an infertility 
clinic have elevated prolactin levels, following clinical 
interview (Konihckx,19 78)* in the.present study, 
there was no rise in prolactin level as a result of 
venepuncture per se, but 7% of females attending a 
general gynaecology clinic for the first time were noted 
to have elevated prolactin levels, which were normal oh 
subsequent sampling, and thus may have been related to 
the stress of hospital attendance. It is clearly 
necessary, therefore, to confirm consistent elevation of 
prolactin levels before attributing any clinical 
abnormality to hyperprolactinaemia*
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The relationship between prolactin and oestrogen 
levels in pregnancy is familiar and the stimulant 
effect of oestrogens on prolactin, secretion has also 
been demonstrated experimentally (Carlson, Jacobs and 
Daughaday, 19 73). Hence it is not surprising that 
patients taking oestrogen containing oral contraceptive 
preparations have a mean prolactin level higher than -
control Subjects. Indeed 44% had frankly abnormal
levels. Similarly, other drugs have been associated 
with hyperprolactinaemia e.g. amethyl dopa (Steiner et ai, 
19 76), phenothiazines (de Rivera et al., 1976) and 
metoclopramide (McCallum ©t al., 1976) and in the present 
study, long term therapy with amethyl dopa, phenpthiazines, 
tricyclic antidepressants, metoclopramide and reserpine 
were all associated with significantly elevated prolactin 
levels. The degree hyperprolactinaemia, however, was 
modest, 95% of patients having levels <700 mU/l. This 
finding may account for the fact that none of these ;
patients had ahy symptoms or signs which might be 
attributed to hyperprolactinaemia.
This Study confirms that several pathological 
conditions may be associated with elevated prolactin levels 
although hot Ohronic ill health, per se. The postulated 
aetiological mechanism involved in the production of
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hyperprolactinaemia are diverse; e.g. disruption of 
the hypothalamic-pituitary stalk as may occur in pituitary 
tumours with supra-sellar extension; deranged hypothalamic 
control mechanisms to account for idiopathic hyperprolactin­
aemia; excessive stimulation by naturally occurring agents 
such as TRH in primary hypothyroidism and altered renal 
metabolism of prolactin with progressive uraemia.,
Autonomous production of prolactin by pituitary adenomas 
clearly results in the highest circulating levels of 
prolactin (Kleihberg et al., 1977, Frantz, 1978) but in 
this series 30% of confirmed tumours were associated with 
minor elevations in basal prolactin levels, such that 
they could not be distinguished from other causes of 
hyperprolactinaemia on this basis alone.
Since the early reports that TRH and L-dopa 
evoked, respectively, stimulation and suppression of 
prolactin levels in normal individuals (L’Hermit© ©t al, 
1972, Friesen et al., 1972a) it has been hoped that these 
tests of the autonomy of prolactin secretion would prove 
of value in the Identification of tumour associated 
hyperprolactinaemia. Initial results were disappointing 
(Lamberts, Birkenhager and Kwa, 1976) but more recently, 
dynamic tests, particularly stimulation tests, have been 
found of value in the identifi-cation of prolactin secreting
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tumours, particularly when the degree of hyperprolactin­
aemia is modest and pituitary radiology is entirely 
normal (kleinberg £t al., 1977, Chapter IV).
It is now established that metoclopramide is a 
potent stimulus to prolactin secretion (McCallum et al.» 
1976, Delitala et al., 1976, Judd, Lazarus and Smythe, 1976) 
and indeed not only is the magnitude of prolactin response 
greater than that seen following TRH, but it is also 
more prolonged in duration. In response to both TRH 
and metoclopramide stimulation, prolactin release is 
considerably greater in the female - à finding which 
may reflect greater oestrogen related prolactin reserve 
despite remarkably similar basal levels in both males 
and females. Acute administration of L-dopa and 
bromocriptine result in prompt suppression of prolactin 
levels in males and females alike; the extent and 
duration of suppression of prolactin levels, however, is 
much greater following bromocriptine. These different 
patterns of prolactin suppression in response to the 
acute administration of L-dopa and bromocriptine may 
well be related to the observed failure and success of 
these respective agents in the long term treatment of 
hyperprolactlnaemic syndromes (Friesen et al., 1972a, 
Thorner et al., 19 74). :
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3(5) Strategy for the laboratory assessment of 
Trolactxn status
As a result of the studies described in this
chapter, a strategy was drawn up for the laboratory
assessment of prolactin status, in individuals with
clinical presentations suggestive of hyperprolactinaemia;
1. Draw blood sample, under resting basal conditions, 
ideally, between 09.00-12.OOh though sampling 
between 09.00-17.OOh is acceptable.
2. If an elevated prolactin level is demonstrated, 
when compared with appropriate age and sex related 
control subjects, exclude
(i) drug therapy (including oral contraceptive)
(ii) pregnancy 
(iii) primary hypothyroidism
(iv) chronic renal failure 
(v) hypothalamic-pituitary disease 
Relate level to appropriate reference ranges 
in groups (1) - (v).
3. Repeat sample;
(i) If both levels >700 mU/1, this is unlikely 
to., be due to stress 
(ii) If both levels >1000 mU/l, this is likely 
to be due to pituitary tumour.
4. If levels are modest and unexplained, and pituitary 
tomography is normal, undertake stimulation tests of 
prolactin secretion and compare responses with 
appropriate male or female control subjects.
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CHAPTER IV
The Amonorrhoea - Galactorrhoea Syndrom©
4(1) Introduction
In view of the current interest and controversy 
surrounding the amenorrhoea - galactorrhoea syndrome, 
it is somewhat chastening to learn that Hippocrates 
first described the clinical abnormalities over 2000 
years ago, "If a woman is not with child, nor has 
brought forth, have milk, her menses are obstructed" 
(Bryner and Greenblatt, 1977).
By 1935 little progress had been made either in 
récognition of the syndrome or in study of its patho­
physiology, since in that year, a historical review of 
"the syndrome embracing utero-ovarian atrophy with 
persistent lactation" cited only three such cases (Sharp, 
1935). Two of these were described by Ghiari, Braun 
and Spaeth in 1855 and the remaining case was reported 
by Frommel in 1881 - hence the "Chiari-Frommel" syndrome 
is used to describe onset of the characteristic features 
after parturition. Many years later it was recognised 
that the syndrome may arise do novo (Argonz and del 
Castillo,1953) and in 1954, Forbes and her colleagues
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demonstrated that the typical syndrome may occur in the 
presence of a pituitary tumour (Forbes et al., 1954).
She further postulated: that this tumour might be prolactin 
secreting - an astute speculation in view of contemporary 
doubt as to the existence of a distinct prolactin 
molecule in man.
Currently, the clinical syndrome of amenorrhoea, 
galactorrhoea and infertility, due to hyperprolactinaemia, 
is increasingly recognised (Thorner ©t al., 1974, Tyson 
et al., 1975, Jacobs ^  al., 1976) and it is further 
recognised that elevated prolactin levels occur in the 
male and may result in impotence (Franks et al., 1978). 
Moreover, hyperprolactinaemia and its associated clinical 
features may occur in a variety of conditions e.g. drug 
therapy, hypothyroidism, chronic renal.failure ( as 
discussed in Chapter iii)but nevertheless when those have 
been excluded, it is important to distinguish between 
patients who have discrete prolactin secreting tumours 
and those who have not.
In the past, radiological abnormality of the 
pituitary fossa has been Judged the most useful diagnostic 
criterion of a pituitary tumour (Vezina and Sutton, 1974) 
but small changes revealed by radiology are difficult to 
interpret (Swanson and du Boulay, 1975). The diagnosis
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of small prolactinomas Is important, because treatment 
of large pituitary tumours with gross changes may bo 
less effective (Werder et al., 1978, Tindall, McLanahan 
and Christy, 1978).
The aim of thé present study of 32 hyperprolactin- 
aemic patients was twofold (1) to investigate the value 
of dynamic tests of prolactin secretion in the diagnosis 
of pituitary adenomas (2) to assess the results of 
therapy in patients who had evidence of pituitary tumour 
and those who did not.
4 (2) Subjects studied and methods 
4(2)(a)Subjects studied
Thirty two consecutive patients (IM, 31F mean age 
28y, range 16-40) presented with amenorrhoea, infertility, 
galactorrhoea or visual disturbance. All had hyper­
prolactinaemia on at least two separate occasions (range 
basal PRL levels 480-18,000 mU/1; normal reference 
range 60-360). :No other factor was identified to 
account for their clinical abnormalities and persistent 
hyperprolactinaemia. Clinical details of the patients 
are shot/n in Table 13.
4(2) (^Methods
Serial linear tomography of the pituitary fossa 
All patients were investigated by tomography of the 
pituitary fossa using the Mimer unit with a thickness of 
cut 0.27 cm. Films were independently reviewed without
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knowledge of the clinical or operative findings and the 
appearance and volume of the pituitary fossa was 
determined (normal <1S00 mm ),
Anterior pituitary function
Anterior pituitary function was assessed in all 
patients by hormone measurements after an intravenous 
bolus of soluble Insulin (G.1 U/kg) combined with 
thÿrotrophin robbing hormone (TRH, 200 yg, Roche) and 
gonadotrophin releasing hormone (Gn RH, 100 pg, Ayerst). 
Normal minimal responses were defined as: cortisol
increment >200 nmol/1 and peak growth hormone levels 
>16 mU/1 in response to hypoglycaemia <2,2 mmol/1;
TSH increment >3.6 mÜ/1 at 20 min; LH increment 
> 3,0 U/1 and FSH increment >1.0 Ü/1, The test was 
performed with the patient ât rest, after an overnight 
fast and samples were obtained via'.an indwelling 
cannula at 0, 20, 45* 60, 90 and 120 minutes after 
administration of the drugs. Cannulae were in situ 
for at least 30 minutes before the test.
Dynamic tests of prolactin secretion 
% Circadian variation was assessed by blood sampling 
via an indwelling cannula during sleep and at mid 
morning, mid afternoon and mid evening during a 24 hour 
period.
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Stimulation tests were TRH (Roche) 200 pg 
intravenously and metoclopramide (Beecham) 10 mg 
intravenously. Sampling details and reference data 
are shovm In Table 12 and Figs 21 and 22.
Suppression tests were L-dopa (Roche) 500 mg orally 
and bromocriptine (Sandoz) 2.5 mg orally. Sampling 
details and reference data are provided in Table 12 and 
Figs. 23 and 24. .
Patients were not fasted and maintained normal 
activity during these tests. No side effects were 
observed in any of the subjects studied.
Treatment
The treatment offered to any Individual patient 
depended on the presumptive underlying diagnosis. If a 
prolactinoma was suspected, treatment was by trans­
sphenoidal microhypopliysectomy. If there was ho 
radiological or biochemical evidence of pituitary tumour, 
then bromocriptine therapy was given to suppress prolactin 
levels into thé control range.
Tumour histology
Histology was investigated by light and electron 
microscopy and immunoperoxidase staining for prolactin- 
secreting cells'.;
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Post-operative assessment
Basal prolactin levels were measured 1-3 weeks 
post-operatively and anterior pituitary function was 
assessed as described above to define the selectivity 
of therapy. At least three months after therapy, 
prolactin response to TRH and metoclopramide was re­
assessed, Objective clinical response was taken as 
the return of normal function i.e. regular menstruation, 
ovulation and/or restored fertility.
Hormone Assays .
Serum prolactin was measured by the routine system 
described in Chapter I !.. . All other hormones were 
measured by standard radioimmunoassays except serum 
cortisol which was measured by the method of Mattingly 
11962),
4(3) Results
Using the investigative protocol described, two 
categories of patient were identified (1) those in whom 
there was biochemical and/or radiological evidence of 
pituitary tumour (Groups 1-3) and (2) those in whom 
there was neither biochemical nor radiological evidence 
of prolactinoma (Group 4 "Functional" hyperprolactinaemia)
Twenty four patients (75%) had biochemical and/or 
radiological evidence of prolactin secreting tumour.
Six of these patients (nos. 19-24, Group 3) are awaiting 
surgical identification and treatment of their tumours.
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In all eighteen patients who have been treated, the 
presumed pre-operative diagnosis of prolactinoma was 
confirmed at operation (Table 14). Histologically 
nine tumours were chromophobe, six were amphophilic 
and three were eosinophilic (Fig, 25), ImmunoperoXidase 
staining showed that all tumours were composed of 
prolactin secreting cells (Fig. 26) and electron microscopy 
confirmed the presence of plentiful, typical large 
pleomorphic secretory granules (Fig. 27).
Clinical details (Table 13)
Irrespective of the size of the tumour and the 
degree of hyperprolactinaemia, the commonest presenting 
complaints were amenorrhoea and infertility, galactorrhoea 
occurring in only 44%. The onset of symptoms was related 
either to childbirth or cessation of an oral contraceptive 
in 46% of patients.
Radiology (Table 14)
In ten of eighteen treated patients (56%), the 
pituitary fossa was radiologically normal (Group 1), 
and typical examples of normal pituitary radiology are 
shotm in Figs. 28, 29 and 30 respectively. At operation, 
direct observation confirmed that nine of these ten 
patients had no bony abnormality, while a minor alteration 
in bone texture was detected in one.
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The remaining patients had either general 
enlargement or localised abnormality of the pituitary 
fossa (Group 2),. In one patient there was simple 
enlargement of thé pituitary fossa, in one there was 
a minor loss, of cortical definition, and in the 
remainder the floor of the fossa was asymmetrical, 
apart from the oiie male patient (18) whose pituitary '
fossa was virtually destroyed. Selected pituitary 
radiology of patients in Group 2 are shovm in Figs 31-36. ,
In Group 2, basal prolactin levels were significantly 
higher, tumours were larger and the duration of symptoms : , 
was longer than in those patients with normal radiology.
Abnormalities of anterior pituitary function, other 
than hyperprolactinaemia, were identified in three Group I 
patients; two patients had a significantly impaired  ^ H 
cortisol and growth hormone response to adequate hypoglycaemia 
and one had a delayed ÏSH résppnso to TRH. In two of 
these patients, antei’ior pituitary function became 
normal after successful removal of their tumours. One 
patient in Group 2 had an impaired growth hormone reserve / 
which was hot affected by .tumour resection.
Dyaamic tests of prolactin secretion 
A consistent abnormality in both groups xms the 
complete absence of sleep associated increment in prolactin
6#.
levels (Fig 37). Both groups had grossly impaired 
prolactin responses to TRH (Fig 38) and metoclopramide 
stimulation (Fig 39)* With minimal responses in patients 
with larger tumours*
Prolactin suppression patterns were less consistently 
abnormal although the mean prolactin response to L-dopa 
(Fig 40) and bromocriptine (Fig 41) was low normal in 
both groups. Only five patients failed to suppress 
normally after bromocriptine*
Treatment .
Removal of the pituitary tumour was "curative" in 
fifteen of eighteen patients (mean basal prolactin 227 mIÎ/1, 
range 88-340), In the other patients, one from Group 1 
and two from Group 2 (IF, IM) prolactin levels were 
significantly reduced (2S00 mU/1 to 600; 9000 mtJ/1 to
1000; and 18,000 mU/1 to 1000).
Postloperative assessment of prolactin response to 
stimulation tests has been made in ten "cured" patients 
(Group A). Uniformly, they show reversion to normal 
prolactin response after TRH and metoclopramide stimulation 
(Table IS). In contrast, patients whose basal PRL levels 
were significantly reduced, but not normalised (Group B) 
retained their grossly subnormal responses to stimulation.
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Treatment was "selective" in all patients i.e. no ' ) 
subject developed anterior pituitary dysfunction post- 
operatively.
No operative morbidity was observed apart from 
transient diabetes insipidus. Five patients are now 
pregnant (four from group 1), nine are ovulating (six 
from group 1) and galactorrhoea has been abolished.
4(3)(b) Patients with "functional" hyperprolactinaemia
Bight patients (25%) had neither radiological nor 
biochemical evidence of prolactin secreting tumours 
and thus were defined as having "functional" 
hyperprolactinaemia (Table 16),
Clinical details
On clinical grounds these patients (Table 13, Group 4) 
were indistinguishable from those patients with prolactin 
secreting tumours.
In all patients, the pituitary fossa was radiologically 
normal both in its volume and contour.
Anterior pituitary function
No patient in this group demonstrated any abnormality 
of anterior pituitary function, other than persistent 
hyperprolactinaemia.
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Dynamic tests of prolactin secretion
Subjects with "functional" hyperprolactinaemia had 
a normal diurnal variation in circulating prolactin 
levels* Although prolactin response to TRH and 
metoclopramide stimulation was less than in control 
subjects (p <0,05) it was significantly greater than 
in patients with confirmed prolactinomas (p <0.005). 
Indeed, a graded impairment of prolactin response to 
stimulation tests was seen from patients with "functional" 
hyperprolactinaemia to patients with small prolactinomas 
and subjects with larger tumours.
Like patients with prolactinomas, subjects with 
"functional" hyperprolactinaemia showed a normal 
suppression of prolactin levels following L-dopa and 
bromocriptine administration.
Treatment
All patients in this group were given bromocriptine, 
a dopamine agonist, in a final dose of 5 mg/day. At 
this dose, prolactin levels were normal in all subjects 
(mean basal PRL 74 mU/1, range 50-140), galactorrhoea was 
abolished and ovulation restored. No side effects of 
treatment were observed,
Three patients (25, 26 and 28) were given a six 
month; course of the drug which vms then stopped* In all 
three subjects, prolactin levels have remained within 
the normal range and there has been no recurrence of 
symptomatology (post bromocriptine follow-up ranges 
from 3-11 months)*
The remaining patients continue on their course 
of therapy apart from one patient who is now 27 weeks 
pregnant and well.
4(4) Discussion
These results suggest that prolactin secreting 
tumours of the pituitary gland can be identified 
reliably by biochemical methods pre-operatively, even 
in patients in whom conventional tomography is mrmal. 
Impairment of the sleep associated increment in prolactin 
levels and prolactin responses to stimulation by TRH 
and metoclopramide provide an accurate means of 
diagnosing radiologically occult microadenomas,
Hitherto, the diagnosis of pituitary tumours has 
relied on radiological studies (B1 Gamma1, 19 77) which 
even experienced neuroradiologists find notoriously 
difficult to interpret because the anatomy of the fossa 
is variable and the characteristic radiological chaxiges 
associated with microadenomas are subtle (Vezina and
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Sutton, 1974)* In addition, minor changes are frequently 
seen in skull radiographs of patients in whom there is 
no suspicion of endocrine abnormality (Swanson and du 
Boulay, 19 75). Furthermore, small pituitary tumours 
may not result in surrounding bony abnormalities and so 
would elude the most sophisticated techniques (Jacobs 
et al., 1976, Thorner,1977). This was so in nine 
patients in Group 1 in whom pituitary tomography was 
normal and in whom at operation the absence of a 
defect in bone structure around the tumour could be 
seen directly.
Gross abnormalities of prolactin secretion are 
readily detected by measuring basal prolactin levels and, 
in general, the higher the level, the greater the chance 
that the patient harbours a prolactin secreting adenoma 
(Kleinberg et al., 1977). However, 39% of patients 
with confirmed prolactinomas had modest hyperprolactinaemia 
(590-1600 mU/1) with levels characteristic of many 
associated physiological and pathological conditions 
(Chapter III). Although it was hoped that tests of 
autonomy of prolactin secretion might help in the 
recognition of prolactinomas (Friesen et al., 1972a)
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recent reports have concluded that such tests have 
little diagnostic"",value (Jacobs ©t ^#,1076, Tolls 
et al., i9?4, Laroberts et al., Xr/6, Hoaly et al., 1877). 
However, several of these studies have assumed that normal 
radiology excludes a pituitary tiimour. Thus the 
significance of altered prolactin rospoaslvenoss in 
hyperprolactinaemic patients with normal tomography, 
may have- boon overlooked.
The results In patients with radiologically occult 
prolactinomas contrast with those in patients with 
physiological hyperprolaetlnaomla 9#g. post partum ' ■
lactàting women, in whom significant prolactin responses 
to stimulation,(Barharino et al,, 1978) and suppression 
(Muller, GenaBzaniahd Wurru, 197#) have boon demonstrated. 
It may he concluded, therefore, that' dynamic tests .such 
as TEH and metoclopramide stimulation are of considerable 
value in identifying hyperprolactlnaemic patients with 
prolactin-secreting adenomas, particularly those which are 
inapparent radiologically-.
The ideal treatment of prolactinomas romains to bo 
determined although-several therapeutic approaches, of 
varying success, have boon described (Thorner et al»» 1974, 
W&rdar et al,, 1978, Tihd&ll ot al,, 1978, Hardy,1973,
^ ^ aaiÉW » wm m tM ^ ^  V f *”
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Kelly et ,1978) Early recognition o£ suçh tumours 
should ensure optimal results from microsurgical 
techniques (Guiot, 1978) and in this series trans­
sphenoidal îîiicro hypophysectoniy has proved effective, 
selective and safe. In particular, the observed 
restoration p£ normal prolactin responsiveness to 
stimulation tests, following removal of tumour, 
suggests that prolactinomas represent discrete pituitary 
lesions. Hence removal of such adenomas should result 
in lasting cure. In contrast, the persisting absence 
of normal prolactin responsiveness in patients whose 
basal prolactin levels, although substantially reduced, 
were not normalised, is highly suggestive of residual 
tumour.
The importance of early diagnosis of prolactinomas, 
when they are small, is emphasised by the presentation and 
outcome in the one male patient in the series (18) who 
represents a typical male prolactinoma. He presented 
late in the course of his disease, with visual field 
defect due to a large tumour with cystic suprasellar 
extension (Figs 31a) b) and he was panhypopitultary prior 
to any attempted surgery. Complete excision of his 
tumour was impossible, the patient required post-operative 
radiation therapy and is on permanent hormone replacement.
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A more satisfactory outcome wàs noted in patient 3 
whose amenorrhoea and infertility led to an early 
presentation, with biochemical diagnosis of a radiologicaliy 
occult microadenosaa (Fig 28) and selective trans-sphenoidal 
microsurgery effected clinical and biochemical cure with 
the patient now some 34 weeks advanced in pregnancy.
The dopamine agonist bromocriptine is also 
advocated for the treatment of the,Emenorrhoea-galactorrhoea 
syndrome (Thorner et al., 1975) but unfortunately its use 
has been associated occasionally, with rapid expansion of 
pre-existing tumours in subsequent pregnancies (Lamberts 
âi*» 1977, Bergh, Nillius and Wide, 1978). In contrast, 
there have been recent reports that bromocriptine may 
effect reduction in size of large pituitary tumours in man 
(McGregor et al., 1979, Wass et al., 1979). However, 
as yet there are no definitive reports of cure of small 
prolactinomas by medical treatment. In any case, 
the identification of radiologically occult microadenomas 
by biochemical tests might allow selection of patients 
who require detailed supervision during and after 
bromocriptine induced pregnancy.
In general, a reliable practical: method of 
identification of small prolactinomas, irrespective of i; 
radiological findings, will permit the choice between f 
alternative methods of management to be made more rationally.
It will provide also aïi objective criterion, for 
comparing.groups of patients treated in’difforent ways.
The diagnostic strategy described in this study has boon 
reliable and clinically useful in'the identification of 
patients with prolactinomas* For -routine purposes, 
the complete range of tests may not be.necessary and 
assessment of the circadian prolactin profile and 
prolactin responsiveness to TRH and motoe1opramide 
stimulation, together with tests of anterior pituitary 
reserve should enable accurate diagnosis of microadenomas 
which are radiologically occult,
Patients .with "functional" liyporprolactinaemia 
(Group 4) are of particular interest* Biochemically, 
they are clearly■distinguished: from patients, with 
similar modestly elevated basal prolactin levels, who 
harbour ràdlologically inapparont micro-adenomas (Group 1)• 
Since'none' of the patients with "functional" hyporprolactim- 
aemia has undergone exploration of the pituitary, it is 
impossible to knew that they do not have small microadonomas 
or indeed that they.may develop these over the next few years 
The pattern of increasingly impaired prolactin responsiveness 
to stimulation in Groups 4, 1 and t might be interpreted 
as a progressive- phenomenon; patients in Group 4 may 
represent micro-adenomas at their earliest possible stage,
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that is, xfhen they are both radiolo^ically and 
biochemically occvilt. Group 1 consisting of radiologically 
occult, biochemically evident micro-adenomas and Group 2 
comprising tumours which are clearly apparent radiologically 
and biochemically*
However, the extent of the difference in response 
to stimulation between Group 4 and Group 1 patients is 
so great that it is barely conceivable that such a 
difference could be related to a smaller discrete 
pituitary lesion than the 2-3 mm micro-adenomas seen in 
Group 1 patients. Moreover, as previously mentioned, 
it has been demonstrated that patients with physiological 
hyperprolactinaemia in the puerperium stimulate and 
suppress basal prolactin levels, although not "normally", 
in a manner clearly different from patients with 
pituitary tumours* Further, three patients with gross 
hypothyroidism and modest hyperprolactinaemia (800, 1200 
9S0 mU/l) have demonstrated a similar pattern of response 
to dynamic tests of prolactin secretion to that seen in 
subjects with "functional" hyperprolactinaemia; none 
of the hypothyroid patients had any evidence of pituitary 
enlargement and all have reverted to normal prolactin 
status following thyroxine therapy alone. Findings in
r h
the puerperium and in hypothyroidism would thus suggest 
a true "functional", that is, hypothalamic "defect" 
in the control of prolactin secretion and I suggest this 
is the most likely explanation for "functional" 
hyperprolactinaemia.
The excellent clinical and biochemical response to 
bromocriptine therapy seen in hyperprolactinaeraic patients 
is not new (Besser et ali, 1972, Franks et al., 19771 
Donald, Bspiner and Livesey, 1978); Usually, however, in 
patients with tumours, withdrawal of. the drug results in 
recurrence of symptomatology and biochemical abnormality. 
Further evidence that "functional" hyperprolactinaemia 
may be a true hypothalamic defect, is that three of the 
eight patients who have hox\r completed a six month course 
of bromocriptine therapy have thereafter remained ■
clinically* radiologically and biochemically normal, 
suggesting that normal physiological control of prolactin 
secretion has returned.
4 (5) Strategy for the elucidation of unexplained 
ï^ p0'%"roïacti^ h ' '  " — -- ■
Finally, a strategy for the differentiation of tumour 
associated and "fimctional" hyperprolactinaemia is given 
in Fig 42. This should enable a rational attempt at
differential therapy for hyperprolactiiiaemlc states 
and clearly long term follow up both of patients with 
confirmed prolactinomas and those with presumed 
"functional" hypothalamic disorders should provide 
clarification and confirmation of preliminary diagnoses
■ ■ ': V -  . . CHAPTBirV^.
Prolactin- and Renal Disease Î ■
5(1) - I n t r o d u c t i o n — .jv- 
È lova ted serW prolactin concentrations occur '.y-
commonly in pa'tlonts with renal disease# . CKirito, Qônda 
and Frieson (197-2)reported that. 20% of patients with . t.: 
•chronic-renal failure had hyperprolactinaemia, and elevated 
prolactin concentrations were described in patients on 
maintenance haéBîûdialysis. by Nagei et al#,, (1973) and ■: 
Cze.rnicliow et- al* » (1976) .
The sigaificance. of these -Observations was not 
clear, however, ' -since/ patients ■ xfith - renal disease commonly 
t'akb drugs* such as methyl' .dopa, which are known- to alter ::;i 
serum prolactin and the role of the kidney in prolactin \'/^- 
metabolism has not been defined#
; ■ In tills study, the prevalence of hyperproiactihaemia
in 357 patients vnlth renal;-disease has been determined* ■ - , 
:ÏE addition, the relationship between hyperprolactinaemia 
and .underlying- pathology, creatinine concentration, 
duration of uraemia dad drug therapy has been assessed 
and arteriovenous concentration differences of prolactin
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across the normal kidney have also been measured.
5(2) Patients studied and methods 
5(2)(a) Patients studied
Blood samples were taken from 357 patients 
(187M, 170F, mean age 34*7y, range 14-75) with renal 
disease. The patients comprised two main groups: 
Patients with impaired renal function
This group consisted of 210 patients in the 
following categories:
Moderate chronic renal failure (GRF) n * 87
(creatinine <600 pmol/1)
Severe chronic renal failure n » 28
(creatinine >600 pmol/1)
Regular dialysis therapy (RDT) including n * 52
home and hospital dialysed patients 
Post renal transplantation n * 43
Patients with normal renal function
Those patients had normal rénal function but had 
renal disease of the following pathologies:
"Glomerulonephritis" (GN) h “ 56
Chronic pyelonephritis (GPN) n » 38
Recurrent urinary tradt infection (UTI) n “ 12
Calculus disease n • 14
Polycystic kidneys , n “ 12
Systemic lupus erythematosus (SLB) n » IS
ai.
The diagnoses were made by clinical, radiological and, 
where appropriate, histological criteria.
Patients undergoing elective cardiac catheterisation 
Samples were also obtained from the renal artery and 
renal vein in seven patients undergoing elective left 
and right heart catheterisation for diagnostic purposes. 
None of these patients had any evidence of renal or 
endocrine disease, nor were they taking any medication 
known to alter serum prolactin concentration.
5(2)Cb) Methods ,
All renal patients studied were hospital outrpatients 
and samples were taken at routine clinic visits, the 
majority being taken between 09*00-12.OOh under conditions 
of minimal stress. Dialysis patients were venesected 
immediately before haemodialysis. An elevated prolactin 
concentration whs Confirmed on at least one further sample.
Meticulous drug histories were taken from all 
patients, with particular reference to drugs known to 
affect prolactin concentrations. The most commonly 
prescribed drugs taken by the patients with renal disease 
were methyl dopa, prednisolone, and tricyclic anti- 
depressants. All dialysis patients were taking vitamin 
supplements (as orovite, fefol and ascorbic acid) and
82.
aluminium hydroxide capsules, Four dialysis patients 
were taking 1 ahydroxy vitamin for renal osteodystrophy, 
All patients after renal transplantation received 
prednisolone and a^athioprino.
The control group of patients comprised those 
described in Chapter III, including 20 "chronic sick" 
patients with chronic progressive arthropathy of at 
least three years’ duration, requiring numerous hospital 
admissions.
Serum prolactin concentrations ware measured in 
the routine system described in Chapter II, All renal 
artery and renal vein samples were assayed in the same 
batch.
The Mann îVhitney test was used to assess statistical 
significance.
5(3) Results
5(3)(a) Control subjects
The reference prolactin range obtained as described 
in Chapter I H / was 50-360 îaÜ/1 (mean 168). "Chronic 
sick" patients had prolactin levels within this reference 
range.
5(3)(b) Patients with renal disease
Elevated prolactin concentrations (>360 mU/l) were 
found in 113 (32%) of all renal patients. In 53 (47%)
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of these patients, elevated concentrations (range 400- 
6454 mU/l, mean 1049) were possibly attributable to drug 
therapy (methyl dopa a ^ 39, prednisolone a = 8, tricyclic 
aatldèpressaats a * 5), Not all patients on these drugs 
had elevated prolactin concentrations, however, and the 
prevalence of hyperprolactinaemia in patients receiving 
those drugs Is shown in Table 17.
Excluding patients receiving one or more of these 
three drugs, prolactin concentrations were not 
significantly elevated in patients with renal disease 
and normal renal function (Table 18, Fig 43), The single 
exception was a 42 year old female with glomerulonephritis, 
who was post menopausal but had had primary infertility : 
and who had persistently elevated prolactin concentrations 
(mean 1400 mlJ/l) * Further investigation of this patient 
has revealed that although she has normal visual fields, 
there is marked asymmetry of the pituitary fossa on 
tomography with evidence of bone erosion, suggestive of 
the presence of a pituitary tumour.
In contras t, serum prolact in concentrât ions in 
patients with impaired rénal function were significantly 
elevated (p <0.005, Table 18), both in patients on drug 
therapy (Fig 44) and in those not taking any medication 
known to affecf seriim prolactin (Fig 45). There was a
significant correlation (p <0,005) between prolactin and
creatinine concentrations (r « 0.45) but no correlation
was found between prolactin concentrations and age, sex,
underlying diagnosis or duration of uraemia. Patients
who had undergone successful rénal transplantation had
significantly lower prolactin concentrations than those
patients undergoing regular dialysis treatment (p <0.001)
5(3)Cc) ArterlovénOus concentration difference in PRL 
ihe hormaTnETdndy .
There was a significant decrease in prolactin 
concentration across the kidney in seven patients with 
non-renal* non-endocrine disease (Table 19, Fig 46).
5(4) Discussion
This study demonstrates that hyperprolactinaemia is 
commonly associated with renal disease, 32% of all renal 
patients studied having concentrations above the upper 
limit of the reference range ( >360 mO/1). Various 
coKiimonly proscribed medications e.g. methyl dopa and 
neuroleptic drugs àrè knom to affect prolactin 
concentrations (Steiner et ai., 19 76, de Rivera et ah, 
1976, Turkington, 1972) and in the present study drug 
therapy was a possible setiolbgical factor in 53 (47%) 
of all patients with hyperprolactinaemia. Methyl dbpa
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and tricyclic antidepressants specifically were associated 
with hyperprolactinaemia but in addition, many patients, 
notably those with SLB, who were taking prednisolone 
therapy, had elevated prolactin concentrations. This 
may represent a true association between prednisolone 
and hyperprolactinaemia, or alternatively, the relation­
ship may be between hyperprolactinaemia and SLE itself. 
However, in the case of methyl dopa administration, the 
data indicate that 52% of patients with impaired renal 
function have elevated prolactin concentrations compared 
with 38% of those patients with normal renal function.
This suggests that within the renal failure group, some 
patients had hyperprolactinaemia which was not solely due 
to drug therapy. Excluding patients taking these drugs, 
it was found that renal patients with normal kidney 
function had prolactin concentrations within the reference 
range, indicating that renal pathology, per so, was not 
associated with an elevated serum prolactin concentration.
In contrast, patients with impaired renal function 
had significantly elevated prolactin concentrations, 
confirming earlier reports (Chirito ejt , 1972 , Nagel 
^  1973). In addition there whs a progressive rise
in prolactin concentration as renal function deterl.emted, 
in patients both on and off drug therapy known to affect
8 6.
prolactin secretion» The correlation between creatinine
and prolactin concentrations confirms that reported by 
Chirito et al.. (1972) and the changes after renal 
transplantation support the view that restoration of 
renal function is associated with reversion of prolactin 
concentrations towards normal.
Those findings, in conjunction with the observation 
that there is a consistent fall in prolactin concentration 
across the normal kidney, suggest that hyperprolactinaemia 
in renal failure, is attributable, in part, to altered 
renal metabolism. This mechanism may also explain the 
elevated concentrations of other hormones found in chronic 
renal impairment e.g. 3MSH-like immunoactivity (Gilkes 
et al., 1975, Smith et al., 19 75). In man, there is 
evidence for the renal extraction of other peptides, 
e.g. insulin (Fine et al., 1976) and the isolated, perfused 
dog kidney has been shown to degrade parathyroid hormone 
with production of immunoactive fragments (Hruska et al.,  ^
1977). Moreover, using a fluorescein- labelled double 
antibody technique, it has been shown that in the rat, 
ovine prolactin gains access to the proximal tubular 
cells of the kidney by means of the glomerular filtrate 
(Donatsch & Richardson, 1975). It is therefore suggested i 
that as the glomerular fütration rate falls with progressive
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renal failure, plasma hormone clearance also declines, 
resulting in elevated circulating concentrations.
These data do not exclude the possibility of 
deranged hypothalamic-pituitary control mechanisms 
in chronic uraemia. Llm et al., (19 77) have given a 
detailed account of thyroid dysfunction in chronic 
renal failure, which includes a subnormal pituitary 
TSH response to TRIî; this abnormality has also been 
noted by Czernichow et al., (19 76) who, in addition, 
observed an impaired prolactin response to TRH 
stimulation.
The significance of the hyperprolactinaemia of 
renal failure in man remains speculative. It is 
established that prolactin has a fundamental osmoregulatory 
role in many species of fish and amphibians (Lam, 1972) and , 
Bobbie et al., (1977) have reported that the prolactin 
related ^occlusive glomerular hyperplasia" seen in 
migrating fish shares many features with proliferative 
gloraerulonephritis in man (Preface). It has also been 
demonstrated that prolactin concentration affects the 
severity of the chronic progressive nephropathy seen 
in some spèciVsvOf rat (Richardson & Luginbuhl, 19 76).
In man the possible role of prolactin as an osmoregulator 
remains controversial. Since the initial observation
(Horrobin ot , 1971) that intra muscular ovine 
prolactin reduced renal excretion o£ water, sodium and 
potassium in normal males, it has been reported that 
oral water loading of normal subjects produces a SOI 
suppression of serum prolactin from baseline concentrations 
and that this test is a useful discriminator between 
"functional" and tumour-associated hyperprolactinaemia 
(Buckman et al., 1973)> These authors have also 
reported a decrease in osmolar clearance by the kidney 
in six subjects with small pituitary adenomas, associated 
with hyperprolactinaemia (Buckman et al., 1976). However, 
others have failed to confirm these results (Adler ^  ah, 
1975, Baumann & Loriaux, 19 76, Baumann et al., 1977) and 
the latter authors conclude that prolactin is not an 
important osmoregulatory hormone in man.
/ CHAPTER VI
Prolactin and Renal Disease II
6Cl) Introduction
Isolated clinical and biochemical endocrihe '
abnormalities have bean described in uraemia, in addition 
to hyperprolactinaemia (Klein and Kurokawa, 19 78).
However, the aètiological mechanisms involved in their 
production and the relationships between clinical and 
biochemical status have often remained obscure. It 
is difficult to define the relative contribution of 
factors such as primary hypersecretion of a Hormone 
compared to secondary "feedback" stimulation or 
prolonged half life as a result of impaired renal 
excretion or metabolism. Moreover, there may be altered 
biological activity of endogenous hormone in the grossly 
deranged biochemical milieu of uraemia.
For pxample, abnormal carbohydrate metabolism is 
comnton in uraemia and is related to decreased sensitivity 
of peripheral tissues to insulin (de Fronzo nt , 1978); 
immunoreactive insulin levels are increased and there is
?0.
7a, delayed and diminished glucose response to exogenous - 
insuliUi Conversely, insulin response to sustained y 
hypdrglycaemia is bjphasxc with an early burst.pf:''\f"'^ %,. 
■Jihkulin secretion followed by gradually ihcreasing 
Ci^ r^culat levels.c.'" HowevéryxèievatedAbusai'-' ■
growth hormone levels and paradoxical growth hormone 
release during a glucose tplèrânceÆèst also occur in 
uraomit patients and may contribute to their glucose 
intolerance (Orskov and Christensen, 1971). In 
addition, bypergiucagohaemia may be present (Bilbrey 
et al.,1974) as a significant contributing factor 
(Sherwin et al., 1976). , 7
y The clinical, radiological and biochemical features 
oi secondary hyperparathyroidism are also common in 
chronic renal, disease (Arnaud, 1973) as a result of 
impaired renal excretion of phosphate, lowered circulating 
Ca++, enhanced secretion of parathormone (PTH) and, in 
severe renal impairment, defective vitamin D synthesis ; 
Indeed* this feedback mechanism forms the basis of 
hriçkbr’s "trade off" hypothesis of uraèmic toxicity 
:(Bricker and fine, 1978). Howeyor, in addition to 
hypersecretion of PTH infuraemia, impairod renal 
metabolism of the hormone results an accumulation of 
imunpre active fragments of pro longed half life, both 
in man (Frèitag et al., 1978) and iii the dog (Hruska 
19?7).
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. _ Himilariyi,factors Influencing .hyporgoBtrinaomla'
in dialysis pationts are not fully understood but, 
novorthdloss,. elevated gastrin/Vloyols may bo-of. 
considerable clinical sigdlf icanco. " in' relation to- '. 
the increased'gastric d c i d  Output and Increased incidence •- 
Of /recurrent peptic- ulcoratioxi-.occurring' in tHOso'-'-,,, - 
individuals .(Doherty,.. 1978) . V • .
Overall,assessment'Of'hypotbalamic-pituitary- ‘ : /. ..
status - in urnomia is poorly.- documented although : isolated / - 
abnormalities, of/individual anterior-'pituituiry-iiormones  ^
kaVo boon - r e p o r t e d . © .g,. iSH (Gbn# 1 0 z^Barcèiià ;ot ■ à f ., 1973, 
Rakirof. at l§.76'*-'blm"0t- al#'*-1977)-, 'GH (Ûrskov-^ and •
Gkristonson, 1971, Czern jckW o t al. 1976)1 PEL (Nagol
1973) -'and / g M8.EI-liko' Immunordact.iviti^.-;:'!G llkos . 
ét all, ^1975, . S m i th 'et'a l . * -1975) whilst ACT.H levels -. '
mm i^ m -'iwmwtiu   ^ “  mm<mrn inmtnm  ^  #
dre normal# ■.- .in general,- it has boon a s s u m o d ■ that.7' 
impalro'd rmial' motab.olism, ls-.'thOv.prodpminant .-underlying 
abnormality to .account .-for elevated-hormone 1 eye Is. 7- 
. . Certainly impaired renal metabolism o f ’prolactin 
may , a c c o u n t , in p a r t ,7 for the 'elev&tod levels of this- 
hormone, in ^ ronal" failure hut this does .-not." exclude the 
possibility of hypothalamic-pituitary., dysfunction. ■ .Thé ' 
following study therefore 7was'an attempt .-.to :;def
(i)'.basal hypdthalamic/pltultary ; status with-progressive 7%
9(3 .. '
uraemia (ii) responses of several anterior pituitary/ 
hormones to stimulation aiad suppression tésts both in 
patients undergoing regular maintenahco haemodialysis
y//.
y:
/?/;
•y/:i ■.
/'//
/'
and following successful renal transplantation ; Moreover,
\ , - ' '/ y. ' ^
assessment of more than one pituitary hormone might yy y
enable patterns :pf abnormality to be identified.
6(2) Subjectsyjstudlëd and methods
6(2)(a) Basalyhypothalamic pituitary status in uraemia 
Patients studied ;
ygiood samples were > obtained from 231 patients 
(131M, lOOF,ym0ah7yàge/32.4y,\,range 14-75) \ in- the following 
ha»,.rias: - ' k : ' ' : : / ; " : / ' . / -
V- ' : Y/y : 'y '
Moderate ÇRP (ereatinine <600 impl/l) n « 89 7
Sevoro CRF (creatlhine >600 ymol/l) n “ >30
./--%:y/y-'/./.Ppst .renal-y'tfahsplantation n'« '46Y7
Apart from prednisolbne and azathxoprina taken by
>.//patjents following renal transplantation, the only drugs
taken were aluminium hydroxide * oral iron and vitamins.
No patient h a d  c l i n i c a l  é v id e n c e  o f  e n d o c r in e  d y s functionwÿ
O th e r  t h a n  five d i a l y s i s  p a t i e n t s  who x fe re  im p o t e n t ;
">■>■-■/w i f e / y'y^ '-'y ■ ■ -'"7' -
.Y;§
.yyy-yyy-/
'/y#37<;
All subjects studied were hdspital out-patients
and smnples were taken at routine clinic vis its, the
■-Y> Y ' 7
-.y
/■y.
■ /"I:
-Î , . . r
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majority betî^ een 09.00-12.00h under conditions o£ 
minimal stress. Dialysis patients were venesected 
prior to haemodialysis. Any abnormal result was 
confirmed on at least one further specimen.
In each patient, the following were measured;
Total thyroxin© (T^), total tri-iodothyronine (T^), TSH, 
Oestradiol (OE^) in females, Testosterone (T) in males, 
sex hormone binding globulin (SHBG):
LH, FSH
Prolactin (PRL)
II hydroxycorticosteroids.
6(2) (b) Tests of anterior pituitary reserve 
Patients studied
Anterior pituitary assessment was made in 19 patients 
(12M, 7F, mean age 33y, range 14-56) undergoing regular 
maintenance haemodialysis. Mean creatinine level was 
1100 umol/1, range 890-1400 and mean duration of dialysis 
was 14 months, range ;2mOhths-7^
Six patients (3M; 3F, mean age 29Y, range 17-36) 
who had undergone successful renal transplantation at 
least six months previously* were also studied (mean 
creatinine 110 pmol/1,, range 94-122).
Dialysis patients/received aluminium hydroxide 
capsules and oral iron and vitamin supplements; after
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renal transplantation, subjects received prednj;éolone 
and azathipprine*
Methods
All subjects underwent the following tests;
(i) TRH (Roche) ZOO u&. was given, by intravenous 
bolus and blood collected at 0*, 20* and 60* for 
measurement Of basal T^, T^, TSH, PRL, GH and response of 
TSH, PRL and GH to stimulation.
(ii) Gn RH (Ayerst) 100 yfi by intravenous bolus with 
blopd samples at 0*, 20* and 60* for measurement of 
basal OEg in females, T in males, FSH, LH and FSH/LH 
responses to stimulation. Ten of 19 dialysis patients 
and all post transplant patients received: i
(iii) Metoclopramide (Beecham) 10 mg intravenously 
with blood samples at 0*, 15*, 30*, 60* and 120* for 
PRL estimation.
(iv) L-dopa (Roche) 500 mg- orally with blood samples y 
at 0, 1, 1.5, 2, 3, 5 and 7h for PRL estimation.
(v) Bromocriptine (Sandoz) 2.5 mg orally with 
blood samples at 0, 1, 1.5, 2, 3, 5 and 7h for PRL estimation 
Tests were performed before dialysis in Uraemic 
patients and blood was collected by an ihtravenous 
cannula which was in situ for at least 30* prior to 
the start of the test. No side effects of drug 
administration occurred.
9S.
All patients had serial linear tomography of ■ 
the .pituitary fossa - performed as. . closeribod. in Chapter IV# 
Films' woro reviewed without Imowlodg# of eliBieal or 
biochoffiieal status.-,.. ■
#(%)(&) Control subject#
Eighty sovou healthy volmtoors (52M, .3SF, mean 
age Sly* range with normal renal fimetWn
received'TBII. 4S), Cm Hi (a IS)# metoclopramide 
(n * 10}# .i-dopa (n ■“■ S) and hremoei^ iptino (a « S). ,
0(2)(d) Assays ■
■ Prolactin concentrations were measured hy, the . 
routine system described in Chapter II. All other 
hormones wore measured by - standard radioimmunoassays 
with, the exception„of serum, "certisoIV which was 
measured by the method e# Mattingly- (1962) and ..SîIBO- was - 
assayed by a modification of the method of Rosner (1972). 
6(S)‘Results ,
6(5)(a) Basal hypothalamic pituitary status in uraemia 
Irrespective of category,- all patient# had moreel . 
basal levels"'of "certisol" (mean eoncentration #2 nmol/I# 
fange 2S0-S40; reference range 270“090) and SHBi (mean ’■ 
concentration in males, .$2 mm# 1/1 #_.range #*4G; ■ reference 
range 5-4S; 'momi concentration in females S4 nmol/I# 
range 30-68.; -"roforoaco,'range 2S^-’*6S)-,# '
m.:
Elevated basal PRL concentrations, irrespectlye o£ 
drug therapy, occurred even in moderate chronic renal 
failure. Levels rose with progressive uraemia, were 
not normalised following institution of maintenance 
haemodialysis but did return towards normal after >
successful renal transplantation (Fig 45).
Basal gonadal status was also deranged in severe 
urciémia and biochemical abnormalities were reversed 
following restoration of normal renal function (Fig 47). 
Mien renal impairment was modest, basal levels of T,
OB^, FSH and LH were within the reference range in 
contrast to PRL. However, with progressive uraemia, 
concentrations of gonadal steroids fell significantly 
(p <0.0005) and there was a concomitant rise in FSH 
and LH levels. Concentrations of the latter hormones, 
however* were less than might be expected for the degree 
of suppression of gonadal steroids. Moreover, there 
was a fall in FS.H and LH levels in dialysis patients 
compared to undialysed patients with comparable uraemia, 
which did not reflect the progressive fall in gonadal 
steroids in these two groups.
In patients with moderate chronic renal failure, 
basal T^, and TSH were normal (Fig 48). Concentrations
9%,
o£ ànd Tg fell significantly (p <0*005) as uraemia 
p^jOf ànd Tg fell significantly (p <0*005) as uraemia
^^^prpgressed and continued to do so despite maintenance
^^jhaembdialysia^^ Although TSH concentrations rose with
uraemia, they were within thé reference range and hence -
were inappropriate for the low T^ and T^ levels in
returned to normal after successful renal transplantation. 
6(3)(b) Tests of anterior pituitary reserve
TRH /;// ' . ;
Basal indices of thyroid function in the 19 dialysis 
patients given TRIi are shown in Fig. 49. As expected,
T^ and T^ concentrations were low compared to controls 
Cp <0.005) but whereas the mean TSH level was higher 
than in the control group, it was not significantly so.
In dialysis patients, TSH response to TRH (Fig 50)
was significantly blunted at 20* but continued to rise 7 /> 
until the end of the test*
Seven of 19 uraemic patients had resting basal GH
levels >10 raU/1 (Fig 51)# with basal glucocorticoids 
uhifofmly unstressed, in the normal range. As a group, 74
the dialysis patients demohstfated a heterogenous GH 
response to TRH, including those with a prompt and 
significant rise, those with delayed response and those 
with no response whatever*
HDeranged hormone responses to TRH reverted to normal 
after successful renal transplantation (Table 20).
■ Gn RH
Basal parameters of gonadal status in 12M dialysis 
patients are shown in Fig 52. Testosterone levels were 
low and two patients (30y and 42y) had evidence of gonadal 
failure with LH and FSH values >SOu/l# Of the remainder,
LH levels were significantly greater than in controls 
whereas FSH levels, though tending to be higher, did 
not reach statistical significance. In 7F dialysis 
patients (Fig 53) the same pattern emerged viz. low 
basal OEg, elevated LH, FSH similar to controls. One 
56y old female had appropriate post menopausal levels 
of gonadotrophins.
Patients with gonadal failure excluded, LH response 
to Gn RH in uraemic males (Fig 54) was normal by 60* but 
there was a clearly subnormal FSH response. Similar 
results were seen in female dialysis patients (Fig 55).
Following transplantation, gonadotrophin responsiveness 
was normal (Table 20).
Tests of PRL secretion
The moan basal PRL level in 19 dialysis patients 
was 843 mU/1, range 196-4000.
9%..
In both male and female patients, a significantly 
blunted PRL response to TRH (Fig S6) and metoclopramide 
(Fig 57) was demonstrated, irrespective of basal PRL 
level* Moreover, there was no significant suppression 
of PRL levels either by L-dopa or bromocriptine (Fig 58) 
in uraemic patients compared to control^ *
Patients with normal renal function after successful 
renal transplantation had basal PRL levels in the normal 
range and normal PRL responses to stimulation and 
suppression (Table 20)*
6(3)(c) Pituitary radiology
Tomography of the pituitary fossa was normal both 
in dialysis patients and in those with functioning 
renal transplants*
6(4) Discussion
This study demonstrates that prolactin is but one 
of the abnormal pituitary hormohes in uraemia* Indeed, 
virtually every hormone studied was deranged either 
basally or in response to dynamic tests but nevertheless, 
even when abnormalities were gross, restoration of 
normal renal function by successful renal transplantation 
resulted in return of physiological endocrine atatus.
It is now well established that^in sever© uraemia 
circulating levels of thyroxine and tri lodothyronine
100
are low despite normal levels of thyroid binding ' 
globulin aaid albumin (Ramirez et al,, 1976, Lim et ai,, 
1977), The present results are in agreement with this.
It has been suggested that an inttathyroidal defect in 
thyroid hormone metabolism may account for low circulating 
thyroxine levels (Jpasoo et al., 1974) and in addition 
there is deranged peripheral conversion of thyroxine to 
t3ri-"io do thyronine (Lim et al. , 1977). Previously, a 
high incidence of unexplained goitre has been reported 
in dialysis patients e.g. 58% compared to 8% in a 
comparable non uraemic population (Ramirez £t al., 1973). 
None of the present patients had goitre or any clinical 
evidence of thyroid dysfunction*
; The inappropriately low baéal TSH levels in dialysis 
patients provides evidence, in addition, for a hypothalamic- 
pituitary defect in the control of TSH secretion in 
uraemia, as does the blunted and delayed TSH response to 
TRH stimulation. 4 ÿpthers have reported that the TSH 
response to TRH stimulation in severe renal impairment, 
although delayed, is prolonged and have attributed this 
to prolonged half ii.fe of TRH and TSH in uraemia (Gonzalez - 
Barcena et al., 1973), Whereas this may well be the 
case, the more striking abnormality is the failure of
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normal feedback stimulation of endogenous TSH in response 
to low circulating thyroid hormones and the relatively 
sluggish response to direct Stimulation by exogenous TRH.
Deranged hypothalamic-pituitary-gonadal status in 
uraemia is perhaps more clearly related to overt clinidal 
abnormality than hypothalamic-pituitary-thyroid dysfunction. 
Progression of renal failure is commonly .associated with 
re duce d 1ib ido, iApoten ce in males, amenorrhoea in 
females and infertility in both sexes (Bailey, 1977). In < 
males, testicular biopsy shows varying degrees of 
spermatogenic arrest resulting in oligospermia or 
azoospermia, whilst Leydig cells appear morphologically 
intact (Lim and Fang, 1975).
Previously, as in the present report, low levels of 
gonadal steroids with normal concentrations of sex hormone 
binding globulin, have been a consistent finding in 
uraemic subjects (Lim and Fang, 1975, C^lgaard, Hagen and 
McNeilly, 1975, Hagen et al^, 1976).
Reports of gonadotrophin levels in uraemia, however, 
have been variable. Lim and Fang (1975), in addition to 
observing clinical and biochemical gonadal failure in 
several young uraemic males, found basal LH values to be 
modestly elevated whilst basal FSH levels were normal.
10%.
The present data is in close agreement with their results 
and moreover, a recent report suggests diminished renal 
clearance o£ LH occurs in uraemia (Holdsworth, Atkins 
and de Kretser, 1977).
Lim and Fang (1975) also comment on the 
inappropriately low basal levels of FSH and LH in uraemic 
males. Although they demonstrated a normal gonadotrophin 
response to clomiphene administration, they suggest that 
a defect in hypothalamic responsiveness to feedback 
control may be present in uraemia to account for the 
inappropriately low basal levels of LH and FSH. The 
responses of LH and FSH to direct pituitary stimulation 
by Gn RH, in the present study^ would be consistent 
with this hypothesis, but also demonstrate diminished 
release of pituitary FSH to direct stimulation. Whilst 
the present data is consistent with that of Fang and Lim, 
others have reported significantly elevated FSH levels 
in uraemic females (^Igaard et al.., 1975) and in uraemic 
males (Hagen £t al., 1976). These differences may 
reflect different populations under study and, in 
particular, differences in age and duration of dialysis.
Thus, in uraemia, there is evidence of (i) primary 
gonadal toxicity with clinical and biochemical gonadal 
failure (ii) hypothalamic-pituitary dysfunction with
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inappropriate basal gonadotrophins and impaired FSH 
reserve to direct Gn RH stimulation.
Lack of fRL responsiveness to suppression and 
to stimulation, irrespective of basal prolactin level, 
is further evidence of diffuse hypothalamic-pituitary 
dysfunction in uraemia and dannot be accounted for 
solely by prolonged half life of the hormone. Impaired 
PUL response to stimulation by TRH has been reported in 
children (Czernichow et al., 19 76) and the present 
results closely parallel those of Lim, Kathpalia 
and Frohman, (1979) who failed to show any suppression 
of PEL levels in uraemic patients during dopamine 
infusion. As in the present study, these authors 
noted reversal of prolactin abnormalities after 
renal transplantation. Thus, elevated basal prolactin 
levels in uraèmia may result both from altered renal 
metabolism and from hypothalamic pituitary dysfunction. 
Hyperprpiactinaemia is one of the most sensitive 
endocrine abnormalities in uraemia, occurring in 
patients with even moderate chronic renal failure and 
it seems likely that it will contribute to hypogonadism 
in uraemic patients no less than in those with 
prolactinomas (Chapter 13) . The significance of 
elevated prolactin levels on renal function, blood 
pressure, and anaemia in dialysis patients remains 
speculative. ;
The'present $tWy /Conflrm# that ^ l^ mtml bRg&l #1 
'ievels occur ./in iialysis imtiaats mâ abhormml :'GH 
respem»lmm#$ 'to 'T#/'. atImmlmtIm mgain stîggâtts 
flerahged hypèth&lâmâc*#ltu&tmry control mechaai&ms, 
.Simliar;abnormal Cf-i releaso may occur im acromegalic. 
pationtg ct ml#, 1973) Wt in
ÜH mbmorm&lltl##,- like byfarprolactimwim, are early , 
m«mlÏ0mtmtioi4ie\of t&#' syàdrm'e occurring-in' patient®
'with -mild rearnï; Imiluro M â i *  * 1&7B)*
Thus, in mimmmry, overall #@#eaameat of hypothalamic- 
isituiti’mry stmtwm in. urmfismia'-%m® mliowm’ tlmt gross 
ahmommlitlos of several pituitary hememes' exist# There 
Is'evidence to sàggamt hotK'tiyputhmlsmic defects o|g., > 
inmpproprimt® ferns ml TSfl,'till,, FS.ll, GH-mnd-FFL level# m<! 
pituitary defects o#g* abnormal TSH respmso 'tq TÉII mâ-, 
impalr'éd F #  réspma# to #  Ell#
It li'.-Vt'biklsg that, \ mpmrt from a mWost effect m  
gosméotrophin levels, ■institution-of malntonmee 
Imomodimiymis doom hot result ,im amelioration of 
éncloeriaè iy.s£mctioh., ■’whilo ' suecassfwl renal transplanta- 
tioE afeolishos all mûQ^tiné- abnormalities# -^ Inm many 
hormonal ahaormallties may arise primarily m  a result 
of direct'.^uraemic toxicity" which is not #rc# or 
creatinine related#
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Several substances have been termed "uraemic toxins" 
simply on the basis that they accumulate in the body 
fluids of patients with uraemia (British Medical Journal, 
1977) but objective evidence that they are indeed 
"toxic" to humans or animals, is lacking # In view 
of the poor, correlation between the toxic manifestations 
of uraemia and levels of creatinine and urea in serum, 
several theories emerged to account for this discrepancy 
(Bergstrom, 1975); the 'Small molecule" hypothesis 
incriminates substances such as methylguanidine as 
uraemic toxins; "middle molecules" with molecular weight 
500-5000 will accumulate with conventional dialysis 
techniques and molecules in this range have been isolated 
from uraemic sera and are "toxic" in in vitro systems; and 
the "trade-off" hypothesis suggests that certain hormones 
may exert toxic effects as they accumulate due to 
homeostatic adaptations to the reduced glomerular filtration 
rate. It seems likely that clinical "uraemic toxicity" 
will result from a combination of these factors rather 
than one alone (Bergstrom and Burst, 1978),
Nevertheless, however mediated "uraemic toxicity", 
particularly at hypothalamic-pituitary level may contribute 
to the deranged hormone levels e,g* hyperprolactinaemia, 
Which occur with impaired renal function.
106.
CHAPTER VII 
Size Heterogeneity of Human Prolactin
7(1) Introduction
Total immimoreactive hormone may not necessarily 
represent a homogenous population of molecular species# 
Rather, peptide hormones occur naturally in several forms, 
which though immunologically indistinguishable, are 
separable on the basis of si m  e.g. insulin (Roth, Gordon 
and Fastsn, 1968) , m  (herson and Yalow, 1968), AGTH 
(Yalow and Barson, 1071), GH (Goodman, Tanenbawm and 
Rabinowitt, 1072), : Prolactin has also been shown to 
exist in more than one immunoreactive form In serum 
(Rogol and Rosen, 1074), amniotic fluid (Fang and Kim, 
1075), pituitary extracts (Suh and Frantz, 1074) and 
cerebro spinal fluid (Kiefer and Maiarkey, 1078),
Studies of hormonal molecular heterogeneity under 
different conditions, along with pulse r chase experiments 
are often employed to investigate the synthesis, secretion 
and interaction between precursor, pro-hormone and 
hormone molecules# In the present study, the aim was 
somewhat the reverse viz, to identify in uraemic sera, 
compared to pregnancy or prolactinoma sera or pituitary 
extracts, any changes in molecular heterogeneity as a
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result of altered renal metabolism of prolactin. :
7(2) Materials.  ^■ ./:
?(&)(#) B#r,^ m, end '• extracts. ,.
#iood mmplea /i-mre obtained "from two- patients- With 
uncomplicated ■prcgnaiic.ios, ' l,S:j.nié 28 weeks advanced 
rospoctivoly; , two fomalos--.wltk proiaçtinomas, 8»C», and 
E#€..j two patient# (114, -IF)'- m\ regular maintenance 
kaomodialyais for 11 momths- i(cr#at im in# level 940 and 
1004 pmol/1 roopocti^mly) 4: ■ ' .
Sorwm'w&s sop&rAtèd in a'rofr&gêr&tod Goatr&fwgo 
and stored at - until used’{not more than two weeks') #
'A normal pituitary obtained ..at post mortem,
/ <12 hours after dêhth, along with portion»' of prolactinoma 
rmm\mé Mt seleetlvo trmkssphenoldal, hypophyeectomy from 
patienta S.C, # d  P#0, whoso blood sample», had already 
boon Ubtaincde - , "
Pituitary'tisauo was lyophill&od tp a constant . .
weight and atored at -7#%'until used (not more.than 
3 week»)#
Goîùmn
.gpphadox (fiai) colmma (00 x 1 cm) wore -
prepared by packing slurries of previously swollen gel ■'■.
; ih' degds-sod phosphate te'ffarod aalino (pH. 7,5, 0#0$N .phosphate,
Ids*
0,9% ù/v saline) {BBS),, containing 0,021 w/v sodium 
&%&do#-■ -Before.w&@, gol column®' wore eluted for 4Bh
with ’FES containing W  m$/ml hnmn serum albumin. All 
f&ltratlo&a were carried out at 4^G using PBS diluent 
Goataiming 0*03%-w/v sodium m'iéo m  eluant.
Constant, .volume fraction# (1,# ml)/wore collected 
im polystyra&Q tubes usimg an.ill' 7000 Ultrorac fraction 
ceilüctor.# Fraction»-wo.ro frozom at -7#C until' '; ■ 
assayed,
To correct for small differences in elation volume
m  éiïforoot coiumas mû im difforoïit filtrations on the 
same columm, fractions wore plotted m  perce&t&ge of 
olutioa volume hotwoom him doxtraa (void marker) and 
(salt imrlwr)'.
. -Th#'recovery of P1&- iœmoreaetivity raogod^  Jrom 
81% to &&%;'
'"'âSElÊâ
' 0ao ml aliqttots of o^rum samplos wro fortified 
with tracer momto 'o'f h i m  dextran and before 
colmm application,
Eyophillaod pituitary' tissue -was 'resnspeWod in - 
Z ml fMh After miximg by rotation for IS mins at,
4^C and centrifuging at 2SCKI rpm im 10 mlm at the 
smm temporatur#, the, supernatants were withdraw and
1 0 9 .
1 ml aliquots fortified with tracer amounts of blue 
dextran and prior to column application.
7(2)(c) Prolactin radioimmunoassay
Prolactin concentration in serum, pituitary extracts 
and filtration fractions was measured by means of the 
routine or sensitive prolactin assay systems (described 
in Chapter 15 as appropriate.
7(2)(d) Refiltration studies
Three fractions from peak 3 (monomer) h PEL, 
obtained from sérum of prolactinoma patient S.Cr and the 
same fractions from uraemic serum A, were separately 
pooled, freeze dtièd and resuspended in 1 ml horse 
serum. They were refiitered through similar columns 
and the PRL content in the refiltered fractions was 
assayed# Each elution pattern was compared to its 
■original.
7(2)(e) Parallelism studies
Each fraction of peak 1 (void peak), 2 (201 elution 
volume peak) and 3 (monomer.peak) from the 28w pregnancy 
serum, together with fractions of peaks 1 and 3 from 
prolactinoma patient S.C’s serum and fractions from 
peak 3 of uraemic sera A, were assayed at several 
dilutions. Results were used to construct dose- 
displacement curves which were compared to the curve of 
h PRL standard 75/504.
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7(2)(f) Standard
Six mill! units o£ MEG reference h PRL preparation 
75/504 were chromatographed as previously described.
7(3) Results
7(3)(a) Heterogeneity of h PRL after gel filtration 
Immune re a ét ive h PRL appeared as three distinct 
peaks in MRC 75/504, normal pituitary extract and 
normal pregnancy sera (Fig 59). Three peaks with 
similar elution characteristics were observed in the 
pituitary extract and serum of prolactinoma patient 
S.G. (Fig 60) and patient P.C. (Fig 61).
Peak 1 eluted around the voidlolume, peak 2 
had a mean S elution volume of 20 and peak 3, the 
major component in all samples, had a mean^S ©lution 
VOlime of 33. The latter peak represented 87% of 
MRG 75/504 h PRL reference preparation and %ms assumed 
to b© monomeric prolactin.
Immunoreactive h PRL in uraemic sera appeared as a 
sol0j broad but symmetrical peak with elution volume 
similar to that of monomeric prolactin (Fig 62).
Quantitative data on the distribution of prolactin 
heterogeneity is given in Table 21. Prolactin of direct 
pituitary origin was similar in filtration profile 
irrespective of whether the pituitary was normal or
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tumorous (peak 1 representing 7-16% of total iramuno- 
reactivity, peak 2, 6-20%). In sera from prolactinoma 
patients, there was a greater percentage of high 
molecular weight, peak 1 immunoreactivity (10-31%) 
compared to pituitary tissues, but peak 2 was comparable. 
Similarly, as pregnancy advanced, the relative 
contribution of peak 1 to total prolactin immunoreactivity 
was greater than in early pregnancy*
7(3)(b) Refiltration studies
Fractions of peak 3 from both prolactinoma and 
uraemic sera when refiltered, retained their original 
positions with elution volumes 32.8 arid 33*9% respectively. 
7(3)(c) Parallelism studies
Fractions from peaks 1, 2 and 3 all gave parallel 
dose-response curves compared to the standard reference 
preparation MRG 75/504.
7(4) Discussion
Although the heterogeneity in molecular size of 
human prolactin in blood and pituitary is well 
established, the nature, source and inter-relationships 
between the various molecular species is poorly understood 
Wliile an early report of sefum filtration (Rogol 
and Rosen, 1974) identified orily two immunoreactive
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prolactin peaks (similar to peaks 2 and 3 in the 
present study), subsequent authors have repeatedly 
shown the presence of three major immunoreactive 
components of circulating prolactin, as in the 
present study. Peak 1 in this study has previously 
been termed aggregate (Suh and Frantz, 1974) void 
fraction (Gala, Van de Walïe and Hoffman, 1977), big- 
big prolactin (Gamier et ad., 1978); peak 2 in the 
current study has previously been termed big prolactin 
(Suh, and Frantz, 1974, Guyda>1975, Garriier et al., 1978) 
and medium prolactin (Fang and Refetoff, 1978) and peak 3 
in,this report has almost unanimously been termed little 
or small prolactin.
The formal identity of these three immunoreactive 
peaks is yet to be established but their respective 
molecular weights have been determined chromatographically 
to be 170,000 daltons (peak 1); 48,000 daltons (peak 2)
and 23,000 daltons (peak 3) (Fang and Refetoff,1978).
They have been found in the circulation (Suh and Frantz, 
1974, Guyda,1975, Gamier et al., 1978), in amniotic 
fluid (Fang and Kim, 1975), pituitary extracts 
(Suh and Frantz, 1974) and cerebro spinal fluid (Kiefer 
and Malarkey, 1978) . Garnier e^ , (1978) in a study 
of normal sera after TRH stimulation found the percentage 
distribution of prolactin immunoreactivity between peaks 
1, 2 and 3 to be 5,1 * 1.7, 9.1 + 0.9 and 85.8 + 2.3
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respectively. These values agree well with the 
distribution found in MRG 75/504 reference preparation 
and in normal pituitary extract in the present study.
The factors which may influence the pattern of 
prolactin heterogeneity and possible interconversion 
between one component and another, remain speculative.
Peak 1 is generally presumed to be aggregated 
material (Suh and Frantz, 1974) and indeed it may 
simply be an artefact of freezing or storage (Garnier 
£t al.., 1978) . Certainly, it has been shoim to occur 
in increased amounts after freezing and thawing of 
serum (Suh and Frantz, 1974, Kiefer and Malarkey, 1978) 
and in addition, the latter authors noted increased 
peak 1 immunoreactivity in the same serum filtered at 
4^C rather than 23^C. They also describe considerably 
increased peak 1 component in cerebro spinal fluid, 
when compared either to Serum or pituitary tissue and 
Gala et al., (1977) similarly found increased void 
immunoreactivity in serum after glucose tolerance testing. 
No satisfactory explanation has been offered for these 
findings.
Fang and Refetoff (1978) in observing the 
distribution of I labelled prolactin in human sei 
have also claimed that peak 1 may be an artefactual
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product caused by binding of prolactin to serum proteins.
They suggest that the void peaks obtained in human tissue 
may result from blood contamination and the present 
observation of increased peak 1 immunoreactivity in sera, , 
compared to normal or tumorous pituitary in the same 
patient, would support this view.
Peak 2 prolactin immunoreactivity has been variously 
identified as (i) a prolactin dimer, produced naturally _ 
or as tin artefact of handling (Rosen and Rogol, 19 74)
(ii) monomeric prolactin loosely associated with another 
component of as yet undetermined nature (Suh and' Frantz,
1974) (iii) a prolactin prohormone (Guyda,1975).
Certainly in the present study the immunoreactivity 
of all three components was stable and their immunochemical 
properties were similar. This is consistent with previous 
reports (Rosen and Rogol, 1974, Suh and Frantz, 19 74 and 
Guyda, 1975). Less consistent, however, are reports of 
interconversion of the various components. Suh and Frantz 
(1974) reported that peak 2 might redistribute between 
peaks 1 and 3 after repeated freezing and thawing and this 
observation was confirmed by Garnier ^  , (1978) # However,
others have demonstrated no interconversion on refiltration 
of prolactin from tumour or sera (Guyda, 1975, Kiefer and 
Malarkey,1978, Fang and Refetoff, 1978),
115.
Radioreceptpr assays have been used to assess the 
rpiatlye binding activity:of the various filtration peaks 
and again results 2'àre ■ cOhfiictihg#- Similar immunological -■ -
and receptor activity in all three components was found 
by Guyda (1975) and by Fang and Refetoff (1978). Garnier 
et al>, (197S) however» reported that peak 2 immunoreactivity 
was much less active than monomeric prolactin in radio- 
receptqf assay.
The latter authors conclude that,peak 2 prolactin 
immunbrèactivity?fOFresent a native prolactin dimor; linked 
by intOrmolecular disulfide bonds, arising in the lactotrbpli 
as a post-synthetic product or derivative. They believe 
it does hot represent a true precursor prohormone. This 
view is strongly supported fey the work of Evans, Huckp 
and Rosenfeld (1977) who demonstrated that siRNA isolated 
from a line of functional rat pituitary tumour cells (GH^) 
added to a cell free protein syhthes%zirig system detived from 
wheat embryo^ caused biosynthesis'of only One protein ■ 
limunoprecipitated by prolactin apt is drum. The protein
"pre?pfblactin" represented the initial product of :
:transi a t i o n . m R N A  and was only 2000-3000 daltons greater : 
in mass than prolactin, The authors aiso demonstrated 
that the mRNA was; not. Ihrge;- enough to code for . the. larger 
forms of iniiiuiioreactive prolactin demonstrated by gel
i
i ,  ■
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The finding of only one peak of ijnmundreactive 
prolactin in uraemic sera was unexpected* In parallel 
with pregnancy and prolactinoma sera in which circulating 
levels of prolactin were similar, and hecause of the 
presumed prolonged half life of prolactin in uraemia, 
one might have expected an increase ih peak 1 immuno­
reactivity. None was detectable nor was any peak 2 
reactivity demonstrable.
A possible explanation for this observation may 
be that circulating uraemic toxins result in disaggregation 
rather than accummulation of void volume components and 
in addition, capse cleavage of the putative disulphide 
bridges linking constituent molecules of peak 2.
Moreover, although the monomer peaks in uraemic 
seta were broad and may consist of several components, 
the mean elution volume of the peak was similar to that 
of monomeric prolactin in hyperprolactinaemic sera and 
pituitary extracts; dose-respohse curves of this peak 
were parallel to that of MRG 75/504 reference preparation 
and there was no evidence of low molecular weight 
immunoreactive fragments (analagous to FTH fragments) as 
a result of altered renal metabolism of prolactin.
Whereas this finding was unexpected, it provides 
additional data to suggest that the elevated levels of 
prolactin in uraemic sera, however mediated, may well be 
of biological significance and hence of clinical relevance.
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CHAPTER VIII
REMARKS
It has been suggested that prolactin may be 
"the" ancestral pituitary hormone, derived from a 
primordial peptide by gene duplication and evolving into 
placental lactogen and growth hormone (Schwartz, 19 73).
Its apparent antiquity, versatility of action and 
physiological evolution during the course of vertebrate 
phytogeny have made prolactin the focus of much attention 
from comparative endocrinologists, neUroendocrinologists 
and zoolgists* However, only recently has it been possible 
for the clinician to study human prolactin status in 
health and disease and thus gain some appreciation of 
its relevance in clinical practice.
Clearly a pre-requisite for such studies is the 
availability of sensitive and specific methods for 
prolactin assay and,the development of homologous 
radioimmunoassays as discussed in Chapters I and II, 
has provided this. However, suitable assay reagents 
remain scarce and thus currently in the United Kingdom 
there is no standardisation either of reagents or methods.
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Consequently results from different laboratories may 
not be comparable and thus each centre should accumulate 
adequate control data using their own system (Chapter III) 
before embarking on routine diagnostic or special research 
studies. Only then may accurate interpretation of 
results be possible with knowledge of the precision of 
the method, the distribution of levels in healthy 
populations and appreciation of the endogenous physiological, 
pathological and pharmacological factors which may influence 
the result. ;
Presently, there is a national quality control 
scheme for prolactin, organised by the Chelsea Hospital 
for Women, London (Dr. S. Jeffcoate) whoso aim is to make 
participating laboratories aware of their errors and to 
improve comparability of results through adoption of 
common reagents and procedures e.g. us© of the new 
International reference preparation MRG 75/504 is now 
strongly recommended. In the future, hopefully, a 
plentiful source of compatible antiserum and tracer, 
such as those used in the present studies, will be 
identified and adopted, along with a common assay protocol.
In clinical practice, the diagnosis and treatment 
of prolactin secreting tumours of the pituitary, remain 
problematic for a variety of reasons. The natural
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history of prolactinomas is not known; certainly, some 
tumours do progress with time (e.g. patient 16 in the 
present series) but others may not, and currently, the 
clinician cannot predict which course is likely in any 
individual patient. Moreover, there is little knowledge 
to enable even evaluation of the relative risk of 
progression of an untreated tumour. In the past, there 
have been diagnostic difficulties since it was suspected 
that normal pituitary radiology did not exclude the 
presence of a small prolactinoma and therapeutic problems 
have arisen with the availability of alternative forms of 
therapy viz. surgery and medical management, neither of 
which are without risk.
The present studies clearly demonstrate that small 
prolactinomas may exist even when pituitary radiology is 
normal and moreover a pattern of prolactin responsiveness, 
reliably indicating prolactinoma, has been identified.
The possibility that some patients may harbour micro- 
adenomas that are both radiologically and biochemically 
occult (false negatives) has not been excluded and it is 
also possible that with further experience, patients may 
be encountered with absent responses to sleep, TRH and
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metoclopramide who do not have prolactinomas 
(false positives). Evaluation of these possibilities 
requires further data on the spectrum of biochemical 
responses and natural history of prolactinomas. 
Nevertheless, the diagnostic strategy described has 
been clinically useful and provides a significant 
improvement in sensitivity of detection of small prolactin­
omas over conventional tomography.
In the future, gênerai adoption of a combined 
biochemical and radiological classification of hyper- 
pfolactinaemic subjects should enable comparison of 
groups of patients treated by different methods and 
hence form the basis for a more rational approach to 
therapy. Moreover, patients with small prolactinomas, 
identified biochemically, may be followed prospectively 
and thus provide objective data on the natural history 
of prolactin secreting tumours.
One might anticipate that dynamic tests of prolactin 
secretion other than those discussed in this thesis may 
prove equally, if not more effective in the identification 
of radiologically occult prolactinomas. For example, the 
advantages of a single diagnostic test are obvious and 
recently it has been suggested that nomifehbine, an 
antidepressant drug, fails to suppress prolactin levels
121
in patients with prolactinomas whilst doing so in 
patients with puerperal hyperprolactinaemia 
(Muller et al., 1978). The report however requires 
confirmation and the present strategy provides the 
basis for an objective comparison of the diagnostic 
accuracy of nomifensine and any future diagnostic 
agents.
The clinical relevance of hyperprolactinaemia in 
uraemia remains speculative. The data presented in 
(Chapters V, VI and VI I define prolactin abnormalities 
in human renal disease and provide evidence of at least 
two aetiological mechanisms to account for hyperprolactin­
aemia in chronic renal failure. They do not, however, 
contribute to understanding the significance of hyper­
prolactinaemia other than indirectly, by the demonstration 
of large quantities of apparently intact monomeric 
prolactin in uraemic sera. Assessment of the biological 
activity of this material, or perhaps more realistically, 
the binding activity in radioreceptor assay, would 
further strengthen the conviction that elevated prolactin 
levels in uraemia may indeed be of biological significance
Elevated prolactin levels may affect the uraemic 
patient in two ways (1) by contributing to hypogonadism 
as in prolactinoma patients (2) by affecting renal
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morphology ànd function. . The first of these 
alternatives is likely and since symptomatic hypogonadism 
is both common and distressing in young uraemic males, 
there is ample justification for a suitably controlled, 
therapeutic trial of bromocriptine to improve clinical 
and biochemical gbhadal function. Since acute 
administration of a small dose of bromocriptine fails 
to lower circulating levels of prolactin in uraemic 
subjects, high doses of the drug over prolonged periods 
may be required for effect.
The second alternative, that hyperprolactinaemia may 
affect renal structure and function in uraemic subjects, 
is more difficult to test in man. A multiplicity of 
factors relating to the patient’s general condition and 
non-feasibility of serial renal tissue for examination, 
make it improbable that such a study would provide 
results which were easily interpreted or conclusive.
Under these circumstances, animal studies may be 
an alternative approach. Standard kidney micropuncture 
techniques would provide an ideal opportunity to document 
the effect of prolacfln infusion on glomerular and 
tubular function in the isolated nephron of the rat.
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Both healthy arid diseased animals might be studied 
under the influence of physiological and supra physiological 
levels of prolactin. In addition, experimentally induced 
acute renal failure in the rat would enable sequential 
study Of endocrine status with progressive uraemia and 
further, the effect of prolactin or bromocriptine pre- 
treatment, on the development of nephropathy, might be 
observed. Such studies might provide evidence to ' 
justify a therapeutic trial of prolactin stimulating 
or suppression agents in humans with declining renal 
function.
Finally, in man, it is also possible that endocrine 
dysfunction and hyperprolactinaemia in particular, may 
be a sensitive index of non Urea and creatinine related 
uraemic toxicity and thus may provide a useful "marker" 
for the assessment of new dialysis schedules and 
techniques.
Thus, a knowledge of prolactin status in health 
and disease is now essential to a wide spectrum of 
clinicians from neurosurgeons to nephrologists. Hyper- 
prolactinaerfiia is common, has many causes, and although
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currently knowledge of its consequences is restricted to 
effects on reproductive function, this may not be thot 
case for much longer as the search fori/ a non lactogenic 
function for human prolactin continues .m The present 
studies have been concentrated on limited and specific 
aspects of prolactin status in health and disease but the 
potential for fascinating, clinically relevant research 
into prolactin pathophysiology in diverse situations, is 
enormous. .4'-: . ' '
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S U M M A R Y
Basal prolactin concentrations in 357 patients with renal disease o f defined patho­
logy have been compared with those in 210 control subjects. Elevated prolactin 
concentrations were found in 113 renal patients (32%) including 53 patients in 
whom elevated concentrations were possibly attributable to drug therapy. In the 
remaining 60 patients who had hyperprolactinaemia not attributable to drugs, 
elevated concentrations (F <  0.005) were found exclusively in patients with im­
paired renal function. A significant correlation was observed between prolactin 
and creatinine concentrations in these patients {r =  0.45 R <  0.005) and prolactin 
reverted towards normal after successful renal transplantation. A significant arterio­
venous prolactin concentration difference across the kidney (mean 16% range 
8-29% F <  0.02) was found in seven patients with non-renal non-endocrine disease.
It is concluded that the hyperprolactinaemia found commonly in patients with 
impaired renal function is only partly attributable to drug therapy. The positive 
correlation between prolactin and creatinine reversion o f prolactin towards normal 
after successful transplantation and arteriovenous hormone concentration differences 
across the normal kidney suggests that the kidney has a important role in prolactin 
metabolism. Abnonnal regulation of prolactin secretion in renal failure may also 
be involved.
Elevated serum prolactin concentrations occur commonly in patients with renal disease. 
Chirito et al. (1972) reported that 20% o f patients with chronic renal failure had hyper­
prolactinaemia, and elevated prolactin concentrations were described in patients on main­
tenance haemodialysis by Nagel et al. (1973) and Czernichow e/'a/. (1976). The significance 
o f these observations is not clear, however, since renal patients commonly take drugs, such 
as methyldopa, which are known to alter plasma prolactin and the role o f the kidney in 
prolactin metabolism has not been defined.
C orrespondence: Dr E. A. C ow den, R adioim m unoassay U nit, D epartm ent o f B iochem istry and Tenovus 
K idney Diseases Research U nit, R oyal Infirmary, Glasgow.
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We have determined the prevalence o f hyperprolactinaemia in 357 patients with renal 
disease and assessed the relationship o f hyperprolactinaemia with the underlying pathology, 
creatinine concentration, duration o f uraemia and drugs administered. Arteriovenous con­
centration differences o f prolactin across the normal kidney have also been measured.
M E T H O D S
Patients studied
Blood samples were taken from 357 patients (187 M, 170 F, mean age 34.7y, range 
14-75y) with renal disease. The patients comprised two main groups: (1) Patients with 
impaired renal function  (n =  210): These included moderate chronic renal failure (CRF) 
(creatinine <  600 Mmol/1) (n — 87), severe C.R.F. (creatinine >  600 jumol/1) (n — 28), regular 
dialysis tlierapy (R.D.T.) (n =  52), including both home and hospital dialysed patients, and 
patients after successful renal transplantation (n =  43). (2) Patients with normal renal 
function, but renal disease o f the following patliologies: ‘Glomerulonephritis’ (G.N. ) (n =  
56), Chronic pyelonephritis (CPN) (n — 38), recurrent urinary tract infection (UTI) (n =  
12), calculus disease (n =  14), polycystic kidneys (n =  12) and systemic lupus erythe­
matosus (SEE) (n =  15).
The diagnoses were made by clinical, radiological and, where appropriate, histologjcal 
criteria.
All renal patients studied were hospital outpatients and samples were taken at routine 
clinic visits, the majority being taken between 9.00 am and 12 mid-day under conditions 
of minimal stress. Dialysis patients were venesected immediately before haemodialysis. An 
elevated prolactin concentration was confirmed on at least one further sample. Meticulous 
drug histories were taken from all patients, with particular reference to drugs known to 
affect prolactin concentrations. The most commonly prescribed drugs taken by the renal 
patients were methyldopa, prednisolone and tricyclic antidepressants. All dialysis patients 
were taking vitamin supplements (as orovite, fefol and ascorbic acid) and aluminium hydroxide 
capsules. Four dialysis patients were taking la  hydroxy vitamin D3 for renal osteodystrophy. 
All patients after renal transplantation received prednisolone and azathioprine. Samples were 
also obtained from the renal artery and renal vein in seven patients undergoing elective left 
and right heart catheterization for diagnostic purposes. None o f these patients had any 
evidence o f renal or endocrine disease, nor were they taking any medication known to alter 
plasma prolactin concentration. All renal artery and renal vein samples were assayed in the 
same batch.
Resting blood samples were also taken from 190 control subjects, comprising hospital staff 
and patients without endocrine disease or not taking drugs known to affect prolactin secre­
tion. Additional samples were taken from 20 ‘chronic sick’ patients who had chronic pro­
gressive arthropathy for at least 3 years, requiring numerous hospital admissions, and who 
were taking only non-steroidal anti-inflammatory drugs.
Assay
Serum prolactin was measured by a specific radioimmunoassay using MRC prolactin 
preparation 75/504 for standardisation, '^^l-labelled prolactin was prepared by lactoperoxi- 
dase iodination o f purified human prolactin (Dr H. Friesen, h PRL 75.7.10) and repurified 
by Sephadex G150 (15 cm X 0.6 cm) column chromatography immediately before each 
assay. FR AR7-13 antiserum (Dr H. Friesen) was employed at a final dilution of 1 ; 28,000.
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Labelled prolactin (50 pg) was added after one day pre-incubation o f antiserum with test 
sample and the incubation continued for a further 1 day. Bound and free fractions were 
separated by double antibody using a donkey anti rabbit serum (Wellcome Reagents Code 
RD I7). The detection limit o f the assay was 20 mU/L wliich corresponds to 1 ng/ml in the 
VLS-NIH preparation. The mean within assay coefficient o f variation was 5% and between 
assay variation 10% over the clinically relevant range.
Statistics
Since the distribution o f prolactin concentrations in control subjects and renal patients 
was non gaussian the Mann Whitney test has been used to assess statistical significance.
R E SU L T S
Control Subjects
The reference prolactin range obtained in hospital staff and patients and in the ‘chronic 
sick’ patients was 50-360 mU/L (mean 172). There was no significant difference between 
these groups nor was there a significant sex difference.
Table 1. Incidence o f  hyperprolactinaem ia in renal patients receiving one or more o f  
three com m only prescribed m edications
Group M ethyldopa Prednisolone
T ricyclic 
anti-depressants
Renal failure (n  — 63) 3 1 /5 0  (62%) 2 /8  (25%) 5 /5  (100% )
Renal disease (n =  33) 8 /21 (38%) 8 /1 2 (6 7 % ) —
Table 2. Prolactin concentrations in patients w ith  renal disease w ith or w ith ou t im paired renal function
Group N
Mean
creatinine
jumol/1
Mean
prolactin
m U /L
A bsolute  
range prolactin  
m U /L
N orm al renal ju n c tio n
GN 45 105 178 8 8 -1 4 0 0
CPN 30 96 175 6 8 -3 1 2
UTI 9 111 162 7 0 -3 6 6
Calculus 13 84 173 6 8 -3 2 4
P olycystic  kidneys 11 82 188 7 1 -3 6 0
SUE 7 99 197 11 7 -3 1 0
Im paired  renal function^'
C.R.F. creatinine <  6 0 0  jumo!/l 62 292 270 8 8 -1 6 7 0
C.R.F. creatinine >  6 0 0  nmol/1 13 1140 5 6 2 1 2 3 -1 3 0 0
RDT 37 1280 8 8 0 2 5 3 -4 5 0 0
Post renal transplantationf 43 159 382 1 0 0 -2 0 0 0
*Many patients in this group on oral iron, vitam ins, alum inium  hydroxide, 
f  All patients in this group on prednisolone and azathioprine.
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Renal Patients
Elevated prolactin concentrations (> 3 6 0  mU/L) were found in 113 (32%) o f all renal 
patients. In 53 (47%) o f tliese patients, elevated concentrations (range 400-6454  mU/L, 
mean 1849) were possibly attributable to drug therapy (methyidopa n — 39, prednisolone 
n — 8, tricyclic antidepressants n =  5). Not all patients on these drugs had elevated prolactin 
concentrations however, and the prevalence o f hyperprolactinaemia in patients receiving 
tliese drugs is shown in Table 1.
Excluding patients receiving one or more o f tliese three drugs, the prolactin concentrations 
were not significantly elevated in patients with renal disease and normal renal function 
(Table 2). The single exception was a 42-year-old female with glomerulonephritis, who 
was post-menopausal witli primary infertility and who had persistently elevated prolactin 
concentrations (mean 1400 mU/L). Further investigation o f  this patient has revealed that
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Fig. 1. Prolactin concentration in patients w ith  impaired renal function , w ho w ere receiving 
one or m ore drugs know n to affect prolactin level. •  M ethyidopa; o Prednisolone; □ T ricyclic  
antidepressants. (D otted  lines indicate the absolute reference range; horizontal bars indicate  
the mean prolactin concentration in each group studied.)
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1
although she has normal visual fields, there is marked asymmetry o f the pituitary fossa on 
tomography with evidence o f bone erosion, suggestive o f the presence o f  a pituitary tumour.
In contrast, plasma prolactin concentrations in patients with impaired renal function 
were significantly elevated ( f  <  0.005) (Table 2), both in patients on drug therapy (Fig. 1) 
and in those not taking any medication known to affect plasma prolactin (Fig. 2). There was 
a significant correlation {P <  0.005) between prolactin and creatinine concentrations {r — 
0.45) but no correlation was found between prolactin concentrations, and age, sex, under­
lying diagnosis or duration o f  uraemia. Patients who had undergone successful renal trans­
plantation had significantly lower prolactin concentrations than those patients undergoing 
regular dialysis treatment ( f  <  0 .001).
There was a significant decrease in prolactin concentration across the kidney in seven 
patients with non-renal, non-endocrine disease (Table 3) ( f  <  0.02, mean fall 16%, range 
8-29%).
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Fig. 2. Prolactin concentration  In patients witfi impaired renal function  w ho w ere on no  
m edication  k now n to  alter prolactin secretion . (D otted  lines indicate the absolute reference 
range; horizontal bars indicate the m ean prolactin concentration in each group studied.)
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Tabic 3. A rteriovenous concentration  difference o f  prolactin across the norm al
kidney
Prolactin m U /L
Patient Renal artery Renal vein
% fall 
in P R L
1 360 330 8
2 205 150 27
3 242 215 11
4 163 148 9
5 146 103 29
6 370 313 15
7 342 287 16
Mean 261 219 16
D I S C U S S I O N
We have demonstrated tliat hyperproîactinaemia is commonly associated v^ith renal disease, 
32% of all renal patients studied having concentrations above the upper limit o f the reference 
range (>  360 mU/L). Various commonly prescribed medications, e.g. methyidopa and neuro­
leptic drugs are known to affect prolactin concentrations (Steiner et al., 1976, de Rivera et 
al., 1976, Turkington, 1972) and in the present study drug therapy was a possible aetio- 
logical factor in 53 (47%) of all patients with hyperproîactinaemia. Methyidopa and tri­
cyclic antidepressants specifically were associated with hyperproîactinaemia but in addition, 
many patients, notably those with SLE, who were taking prednisolone therapy, had elevated 
prolactin concentrations. This may represent a true association between prednisolone and 
hyperproîactinaemia, or alternatively, the relationship may be between hyperproîactinaemia 
and SLE itself. However, in the case o f methyidopa administration our data indicate that 
62% of patients with impaired renal function have elevated prolactin concentrations com­
pared with 38% o f those patients with normal renal function. This suggests that within the 
renal failure group, some patients had hyperproîactinaemia which was not solely due to drug 
therapy. Excluding patients taking these drugs, it was found that renal patients with normal 
kidney function had prolactin concentrations within the reference range, indicating the renal 
p a t h o l o g y , se, was not associated with an elevated plasma prolactin concentration.
In contrast, patients witli impaired renal function had significantly elevated prolactin 
concentrations, confinning earlier reports (Chirito et al., 1972, Nagel et al., 1973). In 
addition we have demonstrated a progressive rise in prolactin concentrations as renal ftinc- 
tion deteriorates, in patients both on and o ff drug therapy known to affect prolactin secre­
tion, The correlation between creatinine and prolactin concentrations confirms that reported 
by Chirito et al. (1972) and the changes after renal transplantation support the view that 
restoration of renal function is associated with reversion o f prolactin concentrations towards 
normal.
These findings, in conjunction with the observation that there is a consistent fall in 
prolactin concentration across the noimal kidney, suggest that the hyperproîactinaemia 
of renal failure, is attributable, in part, to altered renal metabolism. This mechanism may 
also explain the elevated concentrations o f  other hormones found in chronic renal impair­
ment e.g. j3 MSH-like immunoactivity (Gilkes e t al., 1975, Smith et al., 1975). In man,
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there is evidence for the renal extraction o f other peptides, e.g. insulin (Fine et al., 1976) 
and the isolated, perfused dog kidney has been shown to degrade parathyroid hormone 
with production o f immunoactive fragments (Hruska et al,, 1977). Moreover, using a fluo­
rescein-labelled double antibody technique, it has been shown that in the rat, ovine prolactin 
gains access to the proximal tubular cells o f the kidney by means o f the glomerular filtrate 
(Donatsch & Richardson, 1975). It is therefore suggested that as the glomerular filtration 
rate falls with progressive renal failure, plasma hormone clearance also declines, resulting 
in elevated circulating concentrations.
These data do not exclude the possibility o f deranged hypothalamic-pituitary control 
mechanisms in chronic uraemia. Lim et al. (1977) have given a detailed account o f thyroid 
dysfunction in chronic renal failure, which includes a subnormal pituitary TSH response to 
TRH; this abnormality has also been noted by Czernichow et al. (1976) who, in addition, 
observed an impaired prolactin response to TRH stimulation.
The significance o f  the hyperproîactinaemia of renal failure in man remains speculative. 
It is established that prolactin has a fundamental osmoregulatory role in many species o f  
fish and amphibians (Lam, 1972) and Dobbie et al. (1977) have reported that the prolactin 
related ‘occlusive glomerular hyperplasia’ seen in migrating fish shares many features with 
proliferative glomerulonephritis in man. It has also been demonstrated that the prolactin 
concentration affects tire severity of the chronic progressive nephropathy seen in some 
species o f  rat (Richardson & Lu gin buhl, 1976). In man the possible role o f  prolactin as an 
osmoregulator remains controversial. Since the initial observation (Horrobin et al., 1971) 
that i.m. ovine prolactin reduced renal excretion of water, sodium and potassium in normal 
males, it has been reported that oral water loading o f normal subjects produces a 50% 
suppression o f serum prolactin from baseline concentrations and that this test is a useful 
discriminator between functional and tumour-associated hyperproîactinaemia (Buckman 
et al., 1973). These authors have also reported a decrease in osmolar clearance by the kidney 
in six subjects with small pituitary adenomas, associated with hyperproîactinaemia (Buck­
man et al., 1976). However, otlrers have failed to confirm these results (Adler et al., 1975, 
Baumann & Loriaux, 1976, Baumann et al., 1977). The latter authors conclude that prolactin 
is not an important osmoregulatory hormone in man. Further investigation o f the possible 
inter-relationship of prolactin and plasma osmolality in normal and hyperprolactinaemic 
individuals is clearly required to clarify the situation.
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Laboratory assessment of prolactin status
E L IZ A B E T H  A . C O W D E N  i ,  W E N D Y  A. R A T C L IF F E , G. H . B E A S T A L L , A N D  
J. G. R A T C L IF F E
From the ^University Department o f Medicine and Radioimmunoassay Unit, Department o f Biochemistry, 
Royal Infirmary, Glasgow G A QSF
SUMMARY The laboratory assessment o f  prolactin status was evaluated by detailed study o f  921 
subjects (587 normal subjects and 334 patients with pathological conditions). The effect on serum  
prolactin levels o f  age, sex, circadian rhythm, pulsatility o f secretion, stress, drug ingestion, and 
pregnancy was defined in normal subjects. The normal prolactin responses to stimulation (TRH, 
metoclopramide) and suppression (L-dopa, bromocriptine) were also determined. Basal prolactin 
levels were measured in patients with defined pathological conditions including prolactinoma, 
idiopathic hyperproîactinaemia, acromegaly, Cushing’s disease, chronic renal failure, primary 
hypothyroidism, pituitary ablation, Kallm an’s syndrome, N elson’s syndrome, growth hormone 
deficiency, gonadotrophin deficiency, craniopharyngioma, panhypopituitarism, and chronic 
progressive arthropathy. Based on these data, a strategy for the routine laboratory assessment o f  
prolactin status is outlined.
Measurement of serum prolactin concentration is 
now an essential part of the routine investigation 
of patients with suspected hypothalamic-pituitary 
dysfunction (Friesen et aL, 1972; Kleinberg et a i ,  
1977); indeed, hyperproîactinaemia is probably the 
most frequent hypothalamic-pituitary disorder seen 
in clinical practice, commonly presenting with 
amenorrhoea and infertility in women and impotence 
in men (Friesen and Hwang, 1973; Tyson et a l,
1975). Gross abnormalities of prolactin secretion 
are readily detected by the measurement of basal 
prolactin levels, and, in general, the higher the level, 
the greater the chance that the patient has a prolactin- 
secreting adenoma (Kleinberg et a l , 1977). However, 
pituitary microadenomas are often associated with 
relatively modest degrees o f hyperproîactinaemia 
and as such may be difficult to distinguish from the 
many physiological and pathological conditions 
also associated with this biochemical finding 
(Table 1).
We have assessed the importance of some of the 
factors that are relevant to the interpretation of 
basal prolactin levels by determining detailed 
reference ranges in defined groups of patients. We 
have also compared serum prolactin responses to 
standardised dynamic tests in normal subjects since 
these tests may be useful in the diagnosis of pituitary 
microadenomas in patients with modest hyper- 
prolactinaemia (up to 1000 m U/1) and normal 
pituitary tomography.
T able 1 H yperproîactinaem ia
Physiological, eg Pathological, eg
i Newborn i Hypothalamic disorders
ii Pregnancy ii Pituitary disorders
ii Nursing mothers iii Hypothalamic-pituitary stalk
‘irritation’, eg, head injury
iv Stress iv Primary hypothyroidism
V Sleep-related nocturnal rhythm V Renal disease
vi Drugs (a) dopamine receptor vi Idiopathic
blockers, eg,
phenothiazines,
metoclopramide
(6) dopamine depleting
agents, eg, a methyl
dopa, reserpine
(c) others, eg, oestrogens.
TRH
Subjects studied and methods
Prolactin levels were studied in 921 subjects. None 
was receiving drugs known to affect prolactin 
secretion unless stated. Samples were taken between 
0900 and 1200 unless otherwise indicated. Abnormal 
prolactin levels were confirmed on at least one 
further specimen. The following groups were studied :
N O R M A L  SU B JE C T S
{a) Basal levels
(i) Hospital personnel 100 subjects (50 men and 
50 women, mean age 31, range 17-55 years).
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(ii) Hospital inpatients 50 subjects (30 men and 
20 women, mean age 48, range 18-86 years) without 
evidence of renal, endocrine, or malignant disease.
(iii) Hospital outpatients 163 women (mean age 
39, range 17-71 years) attending a gynaecology 
outpatient clinic for the first time. Patients with 
amenorrhoea or infertility were excluded. If 
prolactin levels were elevated, a second specimen 
was taken at the next visit to obtain an estimate of 
possible stress factors related to hospital attendance,
(iv) Women on oral contraceptive preparations 
as the sole drug 54 women (mean age 32, range 
22-41 years). These patients were sampled between 
1800 and 2000.
(v) Women at various stages o f  uncomplicated 
pregnancies 104 women (mean age 28, range 17-38 
years). Samples were taken at routine clinic visits 
between 1400 and 1500.
(vi) Children with benign, non-endocrine disease 
11 normal babies (6M, 5F) aged less than 3 months 
and 30 children (13M, 17F) mean age 5, range 3-13, 
years.
clinical or biochemical evidence of any specific 
endocrinopathy.
(ii) Pituitary tumours This group consisted of 42 
patients (lOM, 32F, mean age 32, range 16-69 years) 
in the following categories: prolactinomas, n =  16 
(IM, 15F); acromegaly, n =  15 (6M, 9F); Cushing’s 
disease, n =  11 (3M, 8F). Diagnosis in all cases was 
established on clinical and biochemical grounds 
together with light and electron microscopy and 
immunoperoxidase studies on surgically removed 
tissue. In a number of cases, samples were obtained 
both before and after selective, curative surgical 
treatment.
Idiopathic hyperproîactinaemia 
This group consisted of 10 women (mean age 26, 
range 16-34 years) who presented with galactorrhoea 
and/or amenorrhoea and infertility and who had 
persistent hyperproîactinaemia (ie, elevated PRL 
levels on at least two separate occasions) with normal 
pituitary tomography, and no other factor identified 
to account for their elevated prolactin levels.
{b) Serial levels
(i) Within-day variation was studied in six subjects 
(4M, 2F, mean age 27, range 24-30 years). Blood 
samples were taken via an intravenous cannula at 
hourly intervals from 0800 to 2000 during which 
time subjects maintained normal activity,
(ii) Day-to-day variation was studied in 10 subjects 
(6M, 4F, mean age 28, range 19-39 years) sampled 
daily for five days between 0900 and 1200.
(iii) Possible stress o f venepuncture was studied in 
12 men (6 hospital staff and 6 patients, mean age 27, 
range 25-34 years). The patients were to undergo 
elective surgery for non-endocrine conditions the 
next day. Samples were taken from an intravenous 
cannula at 10-minute intervals for 90 minutes.
P A T H O L O G IC A L  C O N D IT IO N S
Hypothalamic-pituitary disease
(i) Miscellaneous hypothalamic-pituitary disorders 
This heterogenous group consisted of 27 patients 
(15M, 12F, mean age 31, range 12-64 years) with 
the following disorders: Kallman’s syndrome, 
n =  4 (4M); Nelson’s syndrome, n =  3 (IM , 2F); 
growth hormone (GH) deficiency, n ~  5 (4M, IF); 
craniopharyngioma, n =  5 (5F) (2 patients post- 
surgical treatment, 1 patient post radiation therapy) ; 
gonadotrophin deficiency, n =  4 (4M), pan­
hypopituitarism, n =  6 (2M, 4F). Diagnosis in all 
cases was made on clinical, biochemical, and 
radiological evidence, and all patients were untreated 
at the time of sampling apart from the three patients 
noted. Patients with ‘panhypopituitarism’ had no
Chronic sick
Twenty subjects (8M, 12F, mean age 42, range 
27-59 years) who had had chronic progressive 
arthropathy for more than three years were studied. 
All patients were taking non-steroidal anti-inflamma­
tory agents as the sole medication.
Renal failure
(i) Moderate chronic renal failure (creatinine 
<600 ^mol/l) 62 subjects (32M, 30F, mean age 41, 
range 14-75 years); (ii) severe chronic renal failure 
(creatinine >600 ju.mol/1) 13 subjects (9M, 4F, mean 
age 37, range 18-49 years); (iii) regular dialysis 
treatment (mean creatinine 1300 /u.mol/1) 37 subjects 
(17M, 20F, mean age 33, range 16-52 years). None of  
these patients was on any drug therapy known to 
affect prolactin levels, nor had they evidence o f  
clinical endocrinopathy apart from five of the male 
dialysis patients who were impotent.
Primary hypothyroidism
This group consisted o f 50 women (mean age 44, 
range 24-78 years) with gross primary hypo­
thyroidism (mean T4 =  27 nmol/1, range <11-48; 
mean T3 =  0 6 nmol/1, range <0*4-l-8; TSH all 
>50 mU/1). None of these patients had clinical 
evidence of any other endocrine abnormality.
Pituitary ablation
This group comprised five patients (3M, 2F, mean 
age 32, range 27-49 years) who were insulin- 
dependent diabetics and who had had total hypo- 
physectomy as a therapeutic manoeuvre for severe
L"iC g
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proliferative retinopathy. Macroscopically, hypo- 
physectomy had been complete, and samples were 
obtained from seven months to two years post- 
operatively.
Drug therapy
Samples were obtained from 68 patients (38M, 30F, 
mean age 37, range 16-72 years) who were on long­
term therapy with drugs which may affect basal 
prolactin levels, viz, phenothiazines, n =  21; 
a-methyl dopa, n =  35; tricyclic antidepressants, 
n =  8; metoclopramide, n =  2; reserpine, n =  2).
D Y N A M IC  TESTS OF P R O L A C T IN  S E C R E T IO N
(i) Thyrotrophin releasing hormone (TRH—Roche), 
200 jUg, was given intravenously to 24 healthy 
subjects (14M, lOF, meanage 29, range 24-33 years) 
and blood was collected by serial venepuncture at 
0, 20, and 60 minutes.
(ii) Maxolon (metoclopramide monohydro­
chloride—Beecham), 10 mg, was given intravenously 
to 12 subjects (6M, 6F, mean age 28, range 25-33 
years), and blood samples were withdrawn at 0 
15, 30, 60, and 120 minutes.
(iii) L-dopa (Roche), 500 mg orally, was taken by 
eight subjects (5M, 3F, mean age 29, range 26-33 
years), and blood samples were withdrawn at 0, 
1,1-5, 2, 3, 5, and 7 hours after ingestion of the drug.
(iv) Parlodel (Bromocriptine—Sandoz), 2-5 mg 
orally, was taken by three subjects (2M, IF, mean 
age 28, range 26-30 years) after a meal, and blood 
samples were collected at 0,1,  1*5, 2, 3, 5, and 7 hours 
thereafter.
Whereas in the TRH tests blood was collected by 
repeated venepuncture, in all other tests samples 
were taken via an indwelling, intravenous cannula 
kept patent by heparinised saline. All subjects 
studied were fit and healthy and on no drug therapy; 
they maintained normal activity during these tests. 
No side effects were noted apart from postural 
hypotension and vomiting after bromocriptine 
administration, thus restricting the number of 
subjects receiving this test.
R A D IO IM M U N O A SSA Y  OF P R O L A C T IN
Serum prolactin levels were measured by a specific 
radioimmunoassay using MRC prolactin preparation 
75/504 (650 mU/ampoule) as standard. Purified 
human prolactin (Dr. H. Friesen 75.7.10) was 
iodinated by the lactoperoxidase method and purified 
by Sephadex G150 chromatography; the monomer 
peak was retained for use as tracer. Before its addi­
tion to an assay, the tracer was further repurified by 
Sephadex G 150 chromatography in a 10 ml dispos­
able pipette. 50 pA aliquots of standard or sample 
were incubated with 50 pA rabbit anti-prolactin
serum (FR AR 7-13, Dr. H. Friesen) at a final 
dilution of 1:28 000. After overnight incubation 
at 4°, repurified ^^H-labelled prolactin (50 pA) was 
added, and the mixture was incubated for 24 hours 
at 4°. Bound and free fractions were separated after 
a further overnight incubation with precipitating 
donkey anti-rabbit serum.
The detection limit of the assay was 30 mU/1, 
and mean precision was 5 % CV (within batch) and 
10% CV (between batch).
Prolactin levels in serum and plasma were not 
significantly different, nor in specimens frozen 
immediately in a dry ice mixture or allowed to 
freeze at —20°. Serum samples were routinely 
assayed, blood being separated within 12 hours of 
sampling, and serum was stored at — 20° until assay.
S T A T IS T IC A L  M ETH O D S
Since the distribution of prolactin levels within the 
groups studied was non-Gaussian, the Mann- 
Whitney test was used to assess statistical significance.
Results
N O R M A L  S U B JE C T S — B A SA L S A M P L IN G  
The range of prolactin levels seen in hospital 
personnel and inpatients (the control range) was 
60-375 mU/1 (Table 2, Fig. 1). Compared with 
controls, significantly elevated prolactin levels
10 000
Log PRL 
m u/l
1000
300
200
Q  ab so lu te  range
—  m ean value
—  9 5  th centile
hospital
personnel
hospital
inpat.
50
drug therapy 
othersoral con. 
54 68
p regn an cy
3
trimester 
39
Fig. 1 B asa l pro lactin  levels in * nor m a r  subjects.
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T able 2 B asa l pro lactin  leve l {m U jl)
Subjects group* H Mean Absolute range Upper 95th centile
Hospital personnel 100 168 50-375 340
Hospital inpatients 50 169 50-360 320
Children <3mth 11 4133 543-13 000 —
3mth-I2yr 30 128 85-299 250
Normal pregnancy
Trimester 1 20 590 290-1750 830
2 45 1962 304-4760 4200
3 39 3166 770-5700 5000
Oral contraceptive 54 356 90-1720 750
Drug therapy 68 370 100-710 680
Pat/iologicai conditions
Chronic sick 20 185 70-370 310
Miscellaneous hypothalamic-pituitary disorders 27 368 115-2800 700
Pituitary tumours
Prolactinomas 16 8140 590-18 000 10 000
Acromegaly 15 490 62-2400 684
Cushing’s syndrome 11 320 68-560 450
Idiopathic hypei-prolactinaemia 10 826 440-1240 1189
Chronic renal failure
Moderate 62 270 88-1670 700
Severe 13 562 123-1700 1100
Dialysis 37 880 253-4500 4000
Primary hypothyroidism 50 491 115-2400 1400
Pituitary ablation 5 <50 <50 —
*As defined in text
(p < 0-0005) are noted even in the first trimester 
of pregnancy, and concentrations rise until term 
with a wide scatter. Oral contraceptive therapy and 
long-term therapy with other defined drugs are 
associated with significant hyperproîactinaemia 
(p < 0-005).
Eighteen o f 163 patients (11%) attending a 
gynaecology clinic for the first time were found to 
have prolactin levels outwith the control range. On 
subsequent sampling 12 of these patients (7%) were 
found to have levels within the upper end of the 
control range while the remaining six patients had 
persistent hyperproîactinaemia. Four of these 
patients were found subsequently to be taking drugs 
known to be associated with hyperproîactinaemia 
(oral contraceptive therapy n =  3, metoclopramide 
n =  1). Two patients (1000 and 1614 mU/1) had 
unexplained hyperproîactinaemia and are now 
undergoing detailed assessment of their hypothala­
mic-pituitary function.
N o significant sex difference in basal prolactin 
levels was observed, as may be seen in Fig. 2, which 
shows the relationship between prolactin level and 
age in both men and women as well as in children. 
Significantly elevated prolactin levels (p < 0-005) 
are seen in infants under the age of 3 months when 
compared both with older children and with adults. 
Although, in male subjects, there is a trend towards 
lower basal prolactin levels with increasing age, this 
does not reach statistical significance. In female 
subjects, however, the trend is more marked, and 
women of over 50 years have significantly lower 
prolactin levels (p  < 0-005) than younger women.
N O R M A L  S U B JE C T S — S E R IA L  S A M P L IN G
There was no significant trend in basal prolactin 
concentration in any of the 12 subjects in whom 
venesection was carried out at 10-minute intervals 
after insertion of an indwelling intravenous cannula,
Log PRL 
m u/l
1000
<3 months 3m -13yr. 15 -3 0 y r s .
Q  absolute range
—  m e an  value 
 95  th cen tile
N.S, N.S.
3 0 - 5 0  yrs.
N.S.
^  P<0005
M F
5 0 +  yrs.
F ig. 2 A ge and sex  re la ted  pro lactin  levels.
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the mean CV for the group being 11 % (range 7-17%).
Throughout the day, however, a clear circadian 
pattern of prolactin secretion was observed (Fig. 3). 
Between 0800 and 0900 (mean PRL 236m U/1, 
range 100-414) and between 1700 and 2000 (mean 
PRL 195 mU/1, range 86-291) prolactin levels were 
significantly higher (p < 0-005) than between 0900 
and 1200 (mean PRL 133 mU/1, range 71-208).
In addition, circulating prolactin varies in the 
same individual from day to day, the degree of 
variability being slightly, though not significantly, 
more marked in female (mean CV 28%, range 
25-32%) than in male subjects (mean CV 20%, 
range 9-29 %).
PRL mu/l
\
e a n S  absolute 
■ ratigo
noruial
IflOO Î000 
Time - hours
F ig . 3 W ithin-day variation in pro lactin  levels.
HYPOTHALAMIC -
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80,000
IDIOPATHIC
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• • •••
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pre
post
PRIMARY
HYPOTHYROIDISM
• ••••»••••» ••••}• 
• •••
CHRONIC RENAL 
FAILURE
creatinine <600p mol/1
creatinine >600)jmol/l # *# 2 #•••
RDT •••
CHRONIC SICK • :••••••• •••••: *1
PITUITARY
ABLATION
normal range
100 1000 10,000
log PRL mu/i
F ig . 4  B asa l pro lactin  levels in pa th o log ica l conditions. % K allm an’s ;  O N elso n ’s;  
■  G H  deficiency; A  craniopharyngiom a; *  Gn deficiency; x  panhypopitu itarism .
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P A T H O L O G IC A L  C O N D IT IO N S
The range of prolactin levels seen in a defined 
selection of pathological conditions is shown in 
Table 2 and Figure 4.
Of patients with miscellaneous hypothalamic- 
pituitary disease, only tliree diagnostic categories 
were associated with abnormal prolactin levels, 
viz:
(i) Craniopharyngioma—in which one untreated 
patient had an elevated prolactin level of 600 mU/1, 
and a further patient, treated by external irradiation, 
had a grossly elevated level of 2800 mU/1.
(ii) One out of four patients with isolated gonado­
trophin deficiency had a persistently modestly 
elevated basal prolactin level at 480 mU/1.
(iii) Tliree of the five patients who otherwise 
showed panhypopituitarism were found to have 
modestly elevated prolactin levels (up to 750 mU/1), 
in contrast to the uniformly undetectable levels seen 
in patients with panhypopituitarism after elective 
surgical pituitary ablation.
Most patients who had prolactin-secreting tumours 
of the pituitary gland, as expected, had grossly 
elevated circulating prolactin levels. However, 
five of these patients (31 %) had only moderately 
elevated levels (up to 1200 mU/1), and there was 
overlap in basal prolactin levels with patients who 
had idiopathic hyperproîactinaemia.
Seven of 15 (47%) untreated acromegalic patients 
were found to have hyperproîactinaemia; in all but 
two of the nine patients who underwent selective 
curative surgical treatment, prolactin levels were 
significantly (p < 0*005) reduced by the treatment. 
A group of patients with active Cushing’s disease 
had a mean prolactin level significantly higher 
(p < 0*05) than that of a group of control subjects, 
although only three of the patients had frankly 
abnormal levels. As in acromegalic subjects, 
selective, curative microsurgery was associated with 
a fall in prolactin level.
The prevalence of hyperproîactinaemia in female 
patients who were hypothyroid was 40% (20 
patients), the levels ranging from 360 to 2400 mU/I.
Hyperproîactinaemia occurred in 10 patients 
(16%) with moderate chronic renal failure but was 
more common both in severe chronic renal failure 
(77%) and in dialysis patients (78%).
Patients with chronic progressive arthropathy 
had prolactin levels within the reference range.
D Y N A M IC  TESTS OF P R O L A C T IN  S E C R E T IO N
Administration of TRH (Fig. 5a) and metoclopra­
mide (Fig. 5b) resulted in a prompt rise in circulating 
prolactin levels. The response evoked was greater 
in magnitude (p < 0-005) and more prolonged in 
duration after metoclopramide administration. In
mean 1 SÈM
moan ± SEM
Fig. 5a P rolactin  response to T R H  stim ulation  in 'normal' 
subjects.
Fig. 5b P rolactin  response to m etoclopram ide stim ulation  
in 'norm al' subjects.
response to both stimulation tests, female subjects 
had significantly greater prolactin reserve than did 
male subjects. This finding is in contrast to the 
prolactin response to suppression tests which was 
similar for both male and female subjects. Bromo­
criptine administration resulted in a more profound 
and prolonged suppression of prolactin levels than 
did L-dopa (Table 3).
Table 3 P rolactin  responses to  stim ulation and suppres­
sion test: norm al subjects
Sex n
Mean PRL  
concentration 
(tiffcrence % Range
Stimulation tests*
TRH M 14 278 64-474
F 10 528 272-955
Metoclopramide M 6 721 428-1039
F 6 1940 1267-2946
Suppression tests* *
L-Dopa M +  F 6 63 44-72
Bromocriptine M +  F 3 86 73-95
, , , J Peak PRL after stimulation♦Response calculated as : --------------------------------
Basal PRL
* * Response calculated as :
100 — /T rough PRL after suppression
Basal PRL
X 100
lo o )
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Discussion
The basal prolactin levels seen in healthy neonates, 
children, and adults in this study are consistent with 
those previously described in smaller groups of 
subjects (Friesen and Hwang, 1973; Guyda and 
Friesen, 1973). Even in healthy individuals, however, 
several factors may affect prolactin status, and 
appropriate interpretation of a given result demands 
adequate reference data in relation to factors such 
as sex, age, circadian rhythm, pulsatility of secretion, 
stress, and drug ingestion (Jeffcoate, 1978).
Mean basal prolactin levels are usually higher 
in female than in male subjects (Ehara e t  a l.,  1973; 
Friesen and Hwang, 1973) though with a considerable 
overlap in their ranges (Frantz, 1978). In our study, 
no statistically significant sex différence was observed, 
although no account was taken of the stage of the 
menstrual cycle in women. Some authors have 
demonstrated significantly higher prolactin levels 
in the peri-ovulatory and luteal phases of the cycle 
when compared with follicular phase levels (Franchi- 
mont e t  a l . ,  1976) but other investigators have failed 
to demonstrate any consistent pattern in circulating 
prolactin during the menstrual cycle (Ehara e t  a l., 
1973; McNeilly and Hagen, 1974). It is of interest, 
however, that in postmenopausal women we have 
observed a significant fall in prolactin levels, which 
may well be oestrogen-related, since no similar fall 
is seen in ageing males; Thorner and his colleagues 
have demonstrated a rise in serum prolactin levels, 
which correlates with oestradiol levels in pubertal 
girls, but not boys (Thorner e t  a l . ,  1977). Thus, age 
is also a factor that may affect basal prolactin status, 
at least in female subjects. The origin of the hyper- 
prolactinaemia in neonates is not clear but is pre­
sumed to be of fetoplacental origin (Guyda and 
Friesen, 1973) although it may also be oestrogen- 
related.
It is established that considerably elevated 
prolactin levels occur during the hours of sleep 
(Ehara e t  a l.,  1973; Sassin e t  a l . ,  1973), and it has 
been reported that, in the early hours of the morning, 
prolactin levels may still be significantly elevated 
(Friesen and Hwang, 1973). Our data confirm 
this and, in addition, suggest a diurnal variation in 
prolactin secretion during waking hours, with 
higher prolactin levels in the early morning and a 
trend towards higher levels again in the evening. 
The ideal sampling time thus would be between 
0900 and 1200, when prolactin levels are at their 
nadir. The degree of individual variability in pro­
lactin secretion from day to day is modest but is 
more marked in female than in male subjects, an 
observation which again may be related to the 
oestrogen status of the subject. This modest varia­
tion in prolactin levels from day to day, together 
with the relative consistency in prolactin concen­
trations noted over a much shorter period of time 
(90 minutes), suggests that for confirmation of 
hyperproîactinaemia repeated sampling on several 
different days may be of more value than the 
usually advocated repeated sampling over a short 
period via an indwelling cannula.
Prolactin release arising from the stress associated 
with major surgery or insulin-induced hypoglycae- 
mia is well established (Noel e t  a l . ,  1972). The 
incidence of hyperproîactinaemia, attributable to 
the ‘psychic’ stress of either hospital attendance 
or venepuncture is poorly documented however, 
although a recent study suggests that 19 % of women 
attending an infertility clinic have elevated prolactin 
levels after clinical interview (Koninckx, 1978). 
In the present study we have failed to demonstrate 
any rise in prolactin levels as a result of venepuncture 
p e r  se ,  but 7% of women attending a general 
gynaecology clinic for the first time were noted to 
have elevated prolactin levels, which were normal on 
subsequent sampling and which may have been 
related to the stress of hospital attendance. It is 
clearly necessary, therefore, to confirm consistent 
elevation of prolactin levels before attributing any 
clinical abnormality to hyperproîactinaemia.
The relation between prolactin and oestrogen 
levels in pregnancy is familiar, and the stimulant 
effect of oestrogens on prolactin secretion has also 
been demonstrated experimentally (Carlson e t  a l., 
1973). Hence, it is not surprising that patients taking 
oestrogen-containing, oral contraceptive prepara­
tions have a mean prolactin level higher than that of 
control subjects. Indeed, 44% had frankly abnormal 
levels. Similarly, other drugs have been associated 
with hyperproîactinaemia, for example, a-methyl 
dopa (Steiner e t a l . ,  1976), phenothiazines (do 
Rivera e t  a i ,  1976), and metoclopramide (McCallum 
e t  a l.,  1976), and in the present study, long-term 
therapy with a-methyl dopa phenothiazines, tri­
cyclic antidepressants, metoclopramide, and reser­
pine were all associated with significantly elevated 
prolactin levels. The degree of hyperproîactinaemia, 
however, was modest, 95% of patients having levels 
less than 700 mU/1. This finding may account for 
the fact that none of these patients had any symptoms 
or signs that might be attributed to hyperprolactin- 
aemia.
We have confirmed that several pathological 
conditions may be associated with elevated prolactin 
levels although not chronic ill health p e r  se . The 
postulated aetiological mechanisms involved in 
the production of hyperproîactinaemia are diverse: 
for example, disruption of the hypothalamic- 
pituitary stalk as may occur in pituitary tumours
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with suprasellar extension; deranged hypothalamic 
control mechanisms to account for idiopathic 
hyperproîactinaemia ; excessive stimulation by natur­
ally occurring agents such as TRH in primary 
hypothyroidism; and altered renal metabolism 
of prolactin with progressive uraemia. Autonomous 
production of prolactin by pituitary adenomas 
clearly results in the highest circulating levels of 
prolactin (Kleinberg et al,, 1977; Franz, 1978), 
but, in our series, 30% of confirmed tumours were 
associated with minor elevations in basal prolactin 
levels, such that they could not be distinguished 
from other causes of hyperproîactinaemia on this 
basis alone.
Since the early reports that TRH and L-dopa 
evoked, respectively, stimulation and suppression 
of prolactin levels in normal individuals (Friesen 
et al., 1972; L’Hermite et al., 1972), it has been 
hoped that tests of the autonomy of prolactin 
secretion would prove of value in the identification 
of tumour-associated hyperproîactinaemia. Initial 
results were disappointing (Lamberts et al., 1976) 
but recently we, and others, have found dynamic 
tests, particularly stimulation tests, to be of value 
in the identification of prolactin-secreting tumours, 
particularly when the degree of hyperproîactinaemia 
is modest and pituitary radiology is entirely normal 
(Healy et a l ,  1977; Kleinberg et al., 1977; Cowden 
et a i ,  1979).
It is now established that metoclopramide is a 
potent stimulus to prolactin secretion (Delitala 
et al,, 1976; Judd et al., 1976; McCallum et al.,
1976), and indeed not only is the magnitude of 
prolactin response greater than that seen after TRH, 
but it is also more prolonged in duration. In response 
to both TRH and metoclopramide stimulation, 
prolactin release is considerably greater in women, 
a finding that may reflect greater oestrogen-related 
prolactin reserve despite remarkably similar basal 
levels in men and women. Acute administration of 
L-dopa and bromocriptine results in prompt 
suppression of prolactin levels; the extent and 
duration of suppression of prolactin levels, however, 
are much greater after bromocriptine. These different 
patterns of prolactin suppression in response to 
the acute administration of L-dopa and bromo­
criptine may well be related to the respective 
failure and success of these agents observed in 
the long-term treatment of hyperprolactinaemic 
syndromes (Friesen etal., 1972; Thorner etal., 1977).
In conclusion, we suggest the following strategy 
for the laboratory assessment of prolactin status:
1 Draw blood sample, under resting basal conditions, 
ideally between 0900 and 1200, though sampling 
between 0900 and 1700 is acceptable.
2 If an elevated prolactin level is demonstrated,
when compared with appropriate age and sex 
related control subjects, exclude:
(i) drug therapy (including oral contraceptive)
(ii) pregnancy
(iii) primary hypothyroidism
(iv) chronic renal failure
(v) hypothalamic-pituitary disease
Relate level to appropriate reference ranges in 
groups (i) to (v).
3 Repeat sample:
(i) If both levels > 700 mU/1, this is unlikely to be 
due to stress
(ii) If both levels > 1000 mU/1, this is likely to be 
due to pituitary tumour.
4 If levels are modest and unexplained, and pituitary 
tomography is normal, undertake stimulation tests 
of prolactin secretion and compare responses with 
appropriate male or female control subjects.
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TESTS OF PROLACTIN SECRETION IN 
DIAGNOSIS OF PROLACTINOMAS
E l i z a b e th  A. C o w d en  
J. A. T h o m so n  
D , D o y le
J . G . R a t c l i f f e  
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G. M . T e a s d a le
University Department of Medicine and Radioimmunoassay 
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\  Hospital, Glasgow
S u m m a r y  Prolactin-secreting tumours o f  the pitui­
tary were identified and treated by 
transsphenoidal microsurgery in fourteen infertile 
females with hyperproîactinaemia. Resting prolactin  
levels were 5 9 0 -9 0 0 0  mU/1 (mean 3400). In seven pa­
tients, tomography o f  the pituitary fossa was normal 
and resting prolactin levels were 590—6000 mU/1 (mean 
3400). In these patients the pre-operative diagnosis o f  
prolactinoma in these patients was made by demonstrat­
ing loss o f  the normal circardian prolactin profile and 
impaired prolactin response to intravenous thyrotro- 
phiri-releasing hormone ( t . r . h . )  and metoclopramide sti­
mulation. Prolactin response to the acute oral adminis­
tration o f  L-dopa and bromocriptine was o f  less 
diagnostic value. Preoperative assessment o f  anterior 
pituitary function identified abnormalities other than  
, hyperproîactinaemia in  four patients (28%). Post-opera­
tive assessment indicated that microsurgery was curative 
in  twelve patients (86%), selective in  all, and w ithout
significant side-effect. It is concluded that dynamic tests 
such as T .R .H . and metoclopramide stimulation have 
considerabe value in identifying hyperprolactinaemic pa­
tients with prolactin-secreting adenomas, particularly 
those which are radiologically occult.
Introduction
T h e  clinical syndrome o f  amenorrhœa, galactorrhœa 
and infertility, due to hyperproîactinaemia, is increas­
ingly recognised.*"^ Hyperproîactinaemia and its associ­
ated clinical features may arise in a variety o f  conditions 
— e.g., drug therapy, hypothyroidism, chronic renal fail­
ure— but when these have been excluded it is important 
to distinguish between patients who have discrete prolac­
tin-secreting tumours and those who have not. Radio­
logical abnormality o f  the pituitary fossa has been 
judged the most useful diagnostic criterion o f a pituitary 
tumour'* but small changes revealed by radiology are dif­
ficult to interpret.^ T he diagnosis o f  sm all prolactinomas 
is important, because treatment o f  large pituitary 
tumours with gross changes m ay be less effective.®*'* We 
have studied fourteen infertile hyperprolactinæmic 
females and investigated the value o f  dynamic tests o f  
prolactin secretion in the diagnosis o f  pituitary aden­
omas.
Patients
Clinical details of the fourteen patients (mean age 29, range 
16-40), are shown in table i. All had hyperprolactinæmia on 
at least two separate tests (mean basal prolactin 3400mU/l, 
range 590-9000; normal reference range 60—360). No factor
TABLE I CLINICAL DETAILS
Patient
Age at 
diagnosis 
(yr)
Duration of 
symptoms
(yr) History! Amenorrhœa
Galact­
orrhœa Infertility Other
Group 1
(normal radiology) 
1 • 21 1 + + + Secondary infertility
2 23 1 + • + -— '  + Primary infertility
3 27 2 + + — ■ + .Primary infertility
4 39 u + + + —
5 35 18 — + + —
6 24 3 — + — Primary infertility
7 36 11 — — — + Anovulatory bleeding
Mean (range)
Group 2
(abnormal radiology) 
1
29(21-39) 
16
6-8 (1-18) 
■' 5 +
2 34 14 — + + —
3 32 6 + + — + Secondary infertility
4 28 4 + + — + Primary infertility ■
5. 30 14 — — — + Anovulatory bleeding
6 31 10 — + — —
7 40 16 + + + _
Mean (range) 30(16-40) 98* (4-16)
*’p<0*05. fPostpartum or after oral contraceptive use.
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TABLE II PROLACTIN-SECRETING TUM OURS OF TH E PITUITARY
L A N C E T , JU N E  2,
Basal
prolactin
(mU/1) Radiology
Fossa
volume
(mm )^
% change from basal prolactin level
j
Anterior pituitary 
function
1
Tumour
size
(mm)
Sleep
peak T.R.H.
Meto­
clopramide* L-dopa
Bromo­
criptine
Group 1 !
1 900 Normal 1000 16 19 47 50 77 Impjaired g.h.
response
Impaired cortisol . 3-5
response ■
2 590 Normal 900 46 ■ 89 65 64 86 Imi^aired g.h . 6 0
response 
Impaired cortisol
response
3 1000 Normal 1080 Nil Nil 31 34 86 Noimal • '4.0
4 .2500 Normal 1020 Nil 37 12 25 81 Normal 30
5 2990 Normal 940 Nil Nil Nil 57 66 Boirderline g.h . 80
Delayed t.s.h .
response
6 6000 Normal 1200 Nil Nil ■ Nil 67 66 Normal 50
7 1600 Normal 1050 Nil 68 85 65- 85 Normal 5.5
Mean 2200 1028 34 34 52 78 ( 50
Group 2 I
1 1200 Loss of 860 Nil 15 37 63 86 Normal 8.0
definition in - j
cortex [
2 5800 Asymmetry 1700 Nil Nil 13 46 78 Impaired g.h . 80
[response
3 4900 Double floor 1500 Nil Nil 7 54 67 l^ormal 6 0
4 4200 Double floor 1300 Nil Nil Nil 44 78 Normal 8.5
5 1690 Asymmetry 1300 Nil Nil Nil 43 66 Normal 6 0
6 9000 Enlarged fossa 1780 Nil Nil Nil 63 78 Normal 100
7 5500 Asymmetry 1600 ' Nil 80 67 84 93 Normal 10.5
Mean 4600* 1434 t 13 18 57 78 1 8.0t
Reference 112 528 1920 63 86 1
mean I
(range) (60-360) «1500) «1500) (92-257) (272-955) (1267-2946) (44-72) (73-95)
i
* p<0-005;fp<0-05; (group Itu. group 2).
other than pituitary tumour was identified to account for their 
clinical abnormalities and persistent hyperprolactinæmia. 
These patients were identified within a larger, consecutive 
group of women presenting with hyperprolactinæmia and its 
associated clinical syndrome; the rest had no radiological or 
biochemical evidence of pituitary tumour.
Methods
Se7'ial L inear Totnography o f  P itu ita ry  Fossa
Alt patients were investigated by tomography with the 
Mimer unit (thickness of cut 0 27 cm). Films were indepen­
dently reviewed without knowledge of the clinical or operative 
findings and the appearance and volume of the pituitary fossa 
were determined (normal <1500 mm^).
A nterior P itu ita ry  Fimctio?t
This was assessed by hormone measurements after an intra­
venous bolus of soluble insulin (0-1 U/kg) combined with thyr- 
otrophin-releasing hormone ( t . r . h . )  (200 |xg, Roche) and 
gonadotrophin-releasing hormone (100 [ig, Ayerst). Normal 
minimal responses were defined as: cortisol increment >200 
nmol/1 and peak growth hormone levels >16 mU/1 in response 
to hypoglycæmia <2 2 mmol/l; t . s . h .  increment'>3-6 mU/ï at 
20 min; luteinising hormone increment >3 0 U/1 and follicle- 
stimulating hormone increment > 1 0  U/1. The test was done 
with the patient at rest, after an overnight fast, Samples were 
obtained via an indwelling cannula at 0, 20, 45, 60, 90, and 
120 min after administration of the drugs. Cannulæ were in 
situ for at least 30 min before the test.
D yjiajtiic Tests o f  Prolactin  Secretion
Circadian variation was assessed by blood sampling via an 
indwelling cannula during sleep and at mid-morning, mid­
afternoon, and mid-evening during a 24-h period.
Stimulation tests (see fig. 1 for sampling details and table ii 
for reference data) were t . r . h .  (Roche) 200 jjig intravenously 
and metoclopramide (Beecham) 10 rng intravenously.
Suppression tests (see table iij for reference data) were 
L-dopa (Roche) 500 mg orally and bromocriptine (Sandoz) 2 5 
mg orally. Samples were taken 0, 1, 1-5, 2, 3, 5, and 7 h after 
ingestion of both drugs. Subjects had not fasted and main­
tained normal activity during these tests. No side-effects were 
observed.
T reatm en t
Treatment was by transsphenoidal microhypophysectomy.
T um our H isto logy  |
Histology was investigated by light and electron microscopy 
and immunoperoxidase staining fob prolactin-secreting cells.
Female
controls
J  Group 1 
^  Group 2
, 60
Time (mins)
I
Fig. 1— Prolactin response to T.R.H. stimulation.
M e a n (a n d s .E .M .) .
f ;  L A N C E T , JU N E  2, 19,79 ' 1157
P ostoperative'A ssessm ent' ; . -r ■ ; :
Basal prolactin levels were measured i-3  weeks post-opera- ' 
lively and anterior pituitary function was assessed as described 
above to define selectivity of therapy. Objective clinical re­
sponse'was taken as the return of normal function— i.e., regu­
lar ovulation and/or restored fertility.
H orm one A ssays
Serum-prolactin was measured by a specific radioimmunoas­
say standardised with MRC preparation 75/504 (650 mU/ 
ampoule).® The assay detection limit was 30 mU/1 with mean 
precision coefficients of variation of 5% within batch and 10% 
between batch. All other hormones were measured by standard 
radioimmunoassays except serum-cortisol which was measured 
by the method of Mattingly.^,
Results
In all fourteen patients, a presumed pre-operative 
diagnosis o f prolactin-secreting tumour was confirmed 
at operation (table ii). H istologically, seven tumours 
Wefe chromophobe, five were amphophilic, and two were 
eosinophilic. Immunoperoxidase staining showed that all 
tumours were composed o f  prolactin-secreting cells.
C linical D etails ( table I) ■
Irrespective o f  the size o f  the tumour and the degree 
o f hyperprolactinæmia, the commonest presenting com­
plaints were amenorrhoea and infertility, galactorrhoea 
occurring in only 29%. T he onset o f symptoms was 
related either to childbirth or cessation o f  an oral con­
traceptive in h a lf the patients.
R adiology (  table II)
In seven o f the fourteen patients the pituitary fossa 
\yas normal on radiology (group 1). At operation, direct 
observation, confirmed that six o f  these seven patients 
had no bony abnormality, while a minor alteration in 
bone texture was detected in one.
The remaining patients had either general enlarge­
ment or localised abnormality o f  the pituitary fossa 
(group 2). In one patient there was simple enlargement 
o f the pituitary fossa, in one there was a minor loss o f  
corticol definition, and in five the floor o f  the fossa was 
asymmetrical. In group 2, basal prolactin levels were sig­
nificantly higher, tumours were larger^ and the duration 
o f symptoms was longer than in those patients with  
normal radiology.
A nterior P itu itary  Function
Abnormalities o f  anterior pituitary function, other 
than hyperprolactinæmia, were identified in  three group 
1 patients; two patients had â significantly impaired corti-
fe- 1500
I Female 
I controlsB 1000
Time (mins)
Fig. 2— Prolactin response to metoclopramide stimulation. 
Mean (and S.E.M .).
sol . and growth-hormone response to adeqiiate hypo­
glycæmia and one had a delayed t . s . h .  response to t . r . h .  
In two o f these patients, anterior pituitary function  
became normal after successful removal o f  the tumours. 
One patient ,in group 2 had an impaired growth-hor­
mone reserve which was not affected by tumour resec­
tion.
D ynatnic Test ofP rolactm  Secretion
A consistent abnormality in both groups was the com­
plete absence o f sleep-associated increment in prolactin 
levels. Both groups had grossly impaired prolactin re­
sponses to T .R .H .  (fig. 1) and metoclopramide stimula­
tion (fig. '2) with minimal ' responses in patients with 
larger tumours.
Prolactin suppression patterns were less consistently 
abnormal although the mean prolactin response to 
L-dopa was low normal in both groups. Only four pa­
tients failed to suppress normally with bromocriptine.
T reatm ent
Removal o f  the pituitary tumour was “curative” in 
twelve o f  fourteen patients (mean basal prolactin 227 
mU/1, range 88 -340). In the other patients, one from 
each group, prolactin levels were significantly reduced 
(2500 mU/1 to 600; 9000 mU/1 to 1000).
Treatment was “selective”— i.e., anterior pituitary 
dysfunction did not develop in any patient postopera- 
tively. No operative morbidity was observed apart from 
transient diabetes insipidus. Five patients are now preg­
nant (four from group I), six are ovulating (three from 
group 1), and galactorrhœa has been abolished in all 
who had it.
Discussion
Our results suggest that prolactin-secreting tumours 
o f the pituitary gland can be identified reliably by bio­
chemical methods pre-operatively even in patients in 
whom conventional-tomography is normal. Impairment 
o f the sleep-associated increment in prolactin levels and 
prolactin responses to stim ulation by intravenous t . r . h .  
and metoclopramide provide an accurate means o f  diag­
nosing radiologically occult microadenomas. Hitherto, 
the diagnosis o f  pituitary tumours has relied on radio­
logical studies'" w hich even experienced neuroradiolo­
gists find notoriously difficult to interpret because the 
anatomy o f  the fossa varies and the characteristic radio­
logical changes associated w ith micro-adenomas are sub­
tle.'* In addition, minor changes are frequently seen .in 
skull radiographs o f  patients in whom there is no sus­
picion o f endocrine abnormality.® Furthermore, small 
pituitary tumours may not result in surrounding bony 
abnormalities and so would elude the most sophisticated  
techniques.®’"  This was so in six o f  our patients in group 
1 in whom pituitary tomography was normal and in 
whom at operation the absence o f  a defect in bone struc­
ture around the tumour could be seen directly.
Gross abnormalities o f  prolactin secretion are readily 
detected by measuring basal prolactin levels and, in 
general, the higher the level the greater the chance that 
the patient harbours a prolactin-secreting adenom a."  
However, 35% o f  our patients w ith confirmed prolac­
tinomas had modest hyperprolactinæmia (590 -1 2 0 0  
m U /l) with levels characteristic o f  many associated phy­
siological and abnormal conditions,"  Although it was
riBRAKX
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hoped that tests o f  autonomy o f  prolactin secretion 
might help in the recognition o f  prolactinomas'** recent 
reports have concluded that such tests have little diag­
nostic v a l u e . H o w e v e r ,  several o f  these studies 
have assumed that normal radiology excludes a pituitary 
tumour. Thus the significance o f  altered prolactin re­
sponsiveness in hyperprolactinæmic patients with nor­
mal tomography may have been overlooked. T he results 
in patients with radiologically occult prolactinomas con­
trast with those in patients with physiological hyperpro­
lactinæmia— e.g., post-partum lactating women, in 
whom significant prolactin responses to stim ulation"  
and suppression*® have been demonstrated. We con­
clude, therefore, that dynamic tests such as t . r . h .  and 
metoclopramide stimulation are o f considerable value in  
identifying hyperprolactinæmic patients with prolactin- 
secreting microadenomas, particularly those which are 
inapparent radiologically.
T he ideal treatment for prolactinomas remains to be 
determined although several therapeutic approaches, o f  
varying success, have been described.*"’’*"""* Early 
recognition o f  such tumours should ensure optimal 
results from microsurgical techniques®® and in our series 
transsphenoidal microhypophysectomy has proved effec­
tive, selective, and safe. The dopamine agonist bromo­
criptine is also advocated for the treatment o f  the 
amenorrhœa-galactorrhœa syndrome but unfortunately 
its use has been associated occasionally with rapid 
expansion o f  pre-existing tumours in subsequent preg­
nancies.®®’®** T he identification o f  radiologically occult 
microadenomas by biochemical tests might allow selec­
tion o f  patients who require detailed slipervision during 
and after bromocriptine-induced pregnancy.
In general, a reliable practical method o f  identifica­
tion o f small prolactinomas, irrespective o f radiological 
findings, will permit the choice between alternative 
methods o f  management to be made more rationally. It 
will provide also an objective criterion for comparing 
groups o f patients treated in different ways. T he diag­
nostic strategy described in this study has been reliable 
and clinically useful. For routine purposes, the complete 
range o f  tests may not be necessary and we now rely on 
assessment o f  the circadian prolactin profile and prolac­
tin responsiveness to t . r . h .  and metoclopramide stimu­
lation, together with tests o f  anterior pituitary reserve.
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S u m m a r y  Reaginic antibodies to antigens from the 
human filarial parasites Wuchereria 
hatter o fti and Brugia m alayi and the animal parasite 
Dirofilaria immi'tis were studied by histamine release 
from basophils in 7 patients with tropical eosinophilia 
( t . e . )  and 18 patients with other m inifestations o f  filar­
ial infection (lymphatic changes or isymptomless rnicrofi- 
laræmia). All the patients had antibodies to all three 
filariæ but t . e .  patients were more highly sensitised, t . e .  
patients responded more to antigens from microfilariæ  
than did patients with non-T.E. fila'riasis and responded 
more to microfilarial antigens frorajthe human parasites 
than to those from the animal parasite.- These findings 
support the view that t . e .  is a form o f  occult filariasis 
which results from host hypersensitivity to the microfi­
larial stage o f  parasites which, in other individuals, 
cause the more common lymphatic manifestations o f  
filarial disease. i
Introduction i 
T r o p i c a l  eosinophila ( t . e . )  is a chronic lung disease
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TABLB 4
Radioismunoaasay of Human Routine System
1$ Diluent buffer
2. Standard prolactin
3. Ant ise37mm
4. Tracer
5. Separation
O.OSM phosphate buffer pH 7»5
0,25% %yv BSA
0,02% w/v sodium azide
MRG 7S/S04 (650 mU/ampoule) was used
to give working assay standards
in the range O-lOOO mU/1, stored at 20^,
PR AR 7-13 rabbit anti human prolactin 
sérum used at final dilution 1%Z8#000
FR 75.7.10 }j pRL, approximately
50 pg/tub©
Donkey anti rabbit serum 1:80 
final dilution.
Normal rabbit serum 1:1000 final dilution
Procedure 
Day 1
Day 2 
Day 3
Day 4
Diluent
Standard or sample
Antiserum 
0,Incubate at 4 G
Tracer 
Incubate at 4^G
Normal, rabbit serum ; 
Donkey anti rabbit serum
Incubate at 4^C
250 ul 
50 ul
50 p.|
50 hi
50 hi 
50 ul
Centrifuge* separate and count 
Calculate results
TABLB 5
Radioimmunoassay of Human Prolactin: Sensitive System
Reagents
1. Diluent buffer
2# Standard prolactin
3. Antiserum 
4* Tracer 
5, Separation
Procedure 
Day 4
Day 4 
Day S
Day 6
0.05M pboéphatb buffer pH 7.5
0.25% w/v BSA
0,02% w/v sodium azide
MRÇ 75/504 (650 mU/ampoulej wqs used 
to give working assay standards PQ-Pg 
in the range 0-500 mU/1# stored at 
-20°
PR AR 7-13 rabbit anti human prolactin 
serum used at final dilution 1:56,000 
PR 75.7,10 i2Si PRL, approximately 
SO pg/tube
Donkey anti rabbit serum 1:80 
final dilution
Normal rabbit serum 1:1000 final 
dilution
Diluent 200 pi
Standard or sample 100 pl
Antiserum 50 pi
■n" " '
Incubate at 4 C
Tracer . , SO pi
Incubate at
Normal rabbit serum 50 pi
Donkey anti rabbit serum 50 pi
Incubate at 4^C
Centrifuge, separate and count 
Calculate results
TABLE 6 " '
Lactoperoxidase Iodination of Human Erblactin
METHOD
REAGENT
h PKL 
^ PBS# azide free
I 1 mCi 
5 Pg LPO
HgOg (50 hi 30% + 750 ml dH^O, freshly 
made just prior to addition)
MIX FOR 3 MINS,
HgPg (as above)
MIX FOR 3 MINS,
0,1% BSA (w/v) in O.OSM PBS
5 hg
O.SM
125
MIX THOROUGHLY
VOLUME 
10 hi 
10 hi
10 pi 
5 hi
5 hi
5 hi
1 ml
2 X 10 hi aliquots 
for assessment of ' 
^^^I incorporation 
and specific activity
0150 Sephadex column 
chromatography for 
isolation of assay 
tracer
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FIGURE 1
"Occlusive glomerular hyperplasia" 
in a salt water fish.
An electron micrograph showing 
crescent formation.

FIGUllB 2 ,
Giomorulus of a fresh water fish.
An electron micrograph showing open 
glomerular structure with no 
evidence of crescent formation.

' figure; 3 .,, .
Schematic comparison between glomerular structure 
in fresh and salt water fiah and in human 
proliferative glomerulonephritis.
MCGN: mesangio-capillary glomerulonephritis *
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FIGURE 5
The linear amino acid sequence of human prolactin
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A  concept of the p h y s 16l o g 1çal c ph t r6 1 b f 
prolactin secretion. r . : ;
(a) Central connections t
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A  concept of the% h y logIçal control of 
prolactin secretion. '
(b) Final common pathway.
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RadibïmiEimoassay of human prolactin î Standard Curves 
Assay conditions as described in text.IL
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Human prolactin FR, 75 » 7 • 1 0 î Iodlnation F r p f l i e .
Me t h od  as described in.:text-
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FIGURE 10
human prolactin 75.7.10: Serial ÿ
profiles.
Label prepared on 5.Iv77 and repurified, as described 
in texf, from 5-40 days after preparation.
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FIGURE : 11 ^
A nt i bo d y  dilution.curve for FR A R 7 “i3 rabbit 
anti human prolactin serum.
Routine working antibody dilution 1:28,000.
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L i n e a r  regressiori curves comparing sérum prolactin 
levels me as ur e d iri three s y stems (1) Prié sep ( Rout in e ) 
system (11) NIH system (111) Mixed system.
Assay systems as described ill rext*
Values in FrieSeiv system plotted on thé X axlsi
y
—  NIH system
r= 0 88 
m = 151 
c= 3 66
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FIGURE 13
Radiqlinmtmoassay o£ Muman prolactin; Specificity 
of FR A R  7-13 antiserum.
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(a) Radioiimîiùhoassay of humaa prolactin : Sei?m B 1.
Coded linos represent thé moan suppressipn of diluent 
standard curve by 50 ji 1 horse sera::;.(n 
50 pl human **prblactih free", sera : :
(b) Radioimmunoassay 6f human prpiàçtin: Serûm Bffocts 2
Coded lines represent thé mean ..-suppression - of. dliUehtr^  
standard curve by varying volumes of horsé sëré (n » 4).
SERUM EFFECTS 1 diluent standard curve
diluent +  5 0 }j I horse serum
"  100  "
"  150 "
diluent +  50p i human
“ pro iactin free  "  serum
Per cent 
Tracer bound
60
50
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20
SERUM EFFECTS 260
50
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PROLACTIN mU/j
Radioimmuïïpassaÿ proTactin: Parallelism studiëa*
Serial diliitioiis of èëra from patients with uraemia 
and the amenofrhpea-gàlactorrhoeâ syndrome, inhibit 
binding p f u  I:human prolactin tracer to antibody 
in parallei with MRC; 75/50& pefefence préparation•
PROLACTIN R.I.A. STANDARD CURVE & PARALLELISM STUDIES.
I--------------- 1----------- 1-------- 1-----1--------- 1----------- — 1
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6 0
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FIGURE 16 ; >■■■■■
Basal prolactin levels in normal sub jects . : :
Groups as def Ined in text, ' ' L
Numbers in each group indie ate d at bottom bf e ach column.
BASAL PROLACTIN LEVELS IN'NORMAL'SUBJECTS.
Log PRL 
mu/l
1000
300
200
100
[~] absolute range
— mean value
—  95 th centile
hospital
personnel
100
hospital
inpat.
50
drug therapy
oral con. 
54
Others
68
1
20
pregnancy
45
3
trimester 
39
, fïGÜRB 17 " ;
Age and sex I'eiatod prolactin levels 
M males .' F females;
N.Sv- hot significant 
p <0,005, female s aged 15-30 years 
versus females aged 50+ years.
'1-' .■tv-
AGE AND SEX RELATED PROLACTIN LEVELS.
10.000
Log PRL 
mu/l
1000
100
<3 months 3m - 13yr
M F
15 -30yrs.
D absolute range
—  mean value 
 95 th centile
N.S. N.S.
N.S.
P <0-005
M F
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M F
50+ yrs.
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\ FIGURE 19 
pay to day variations in prolactinLlev®^.®;
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FIGURE ,20 ; L y
Basai prolactin levels in patholpgicàl conditions 
Groups as defined in text '
, Tx:■ treatment 
RDTî regular dialysis treatment T ;
Gn: gonadotrophin
• Kallman’s. oNelson's. iiG  H deficiency ^Craniopharyngioma * G n  deficiency.xPanhypopituitarism .
HYPOTHALAMIC -
PITUITARY
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1 *  X A 1|X 0^«]kX*XA X
1 1
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PROLACTINOMA 1 .............................................. :  •"7
1 80,000
IDIOPATHIC
HYPERPROLACTIN-
AEMIA
1 1 *
1 I * :  :
1 1 1 t
pre
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•
CUSHINGS pre 
DISEASE post 
Tx
1 ■
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HYPOTHYROIDISM 1 ............... • * !
1 ‘
• •
CHRONIC RENAL 
FAILURE
creatinine <600pmol/l •  *
1 1
•
creatinine >600jjfnol/l
1 1 
1 # * # 2  • • • •  #2
1 i
•
R D T
\ 1 
1 • f i t *
] :•
1 1
:v • • • •
CHRONIC SICK
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I • viA* •esx *j
1 1
PITUITARY
ABLATION |i I1 U— normal range—^•  1 — 1---------------------- 1----------------- 1—
100 1000 10,000 
log PRL mu/l
PIGqRE 21 TT " ' ::
Prolactin response 16 TPPÎ stImulation : Normal sub j ects •
SBM:, standard, error :pf; mean ; - T
Increment 
over basal
600
500
400
300
200
100
0
0 20 60
Females n=10 
mean ± SEM
Males n =14 
mean ± SEM
 Time -  mins
PIGURB.ZZ/"
Prolactin response to metoclopramide stimulât ion:
(Normal subjects
SBM; standard error of mean.
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Prolactin suppression by L-dopà: ; Normal sub jects• 
Gdntrols as dëflnèd in text, s
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Prolactin suppression: by; BroWcriptine t Nomal subjects. 
Controls as clefinéd in text.
J-----
o
0X0 i  ^
II
C/D ^
j —
O
c\j
o
_1_
o
CD
-t-
oco
N .  C/DV»
3
0  
JZ
1
CO CL)
L fD
C O
C \ J
O
oo
CC3
C/D
C\D
/-y" FiGum 25 ,  ^ '--v.-/-
Prolactin secreting tumours o£ the pituitary: 
Light.microscopy*. /-y;
À; Chromophobe adenoma 
B : " E o s inoiih i 1 ic adenoma .
C; Amphophilic adenoma 
Magnification X 2 50*

Prolactin secreting tumours of the pituitary: 
ïmmunoperoxidase staining.
(i) Normal/ scattered distribution of prolac 
cells in 27y old male who died in/'à ^.rbad.' ' 
traffic accident..
(ii) Pi'olactin: cells of increased;size, number 
and activity in^^^^ 2^  ^ female iVlio died
sixteen weeks advanced in pregnancy, ;%■
(iii) Profuse/ variably active prolactin secreting 
tumour cells with loss of normal pituitary
■ architecture, i ''
Magnification X 5b5,..:;i, ■
%#
€
■ * * \
'V r
■ ^  „ y  : FIGtJRE 2 7  : V . ; >
Prolactin secreting tumours of the pituitary; 
Blectronuiiicroscopyi, , y-
Plentiful large pieomorphic secfetorÿ gfàiiules • 
Magnification ic 9000 • ' O' .

Radiograidis of the pituitary fossa are arranged 
as follows, unless otherwise stated:
View À Lateral Xray of skull v
View B Lateral tomogram
View C . Antero-posterior tomogram, y ; .

; \  MGURE. 28 : ; . .
Normal pituitary tomography: Patioht 3
.1'; p i tu it ary f ô s s # / - \ y
2 dor Sim soli ao
3 sphenoid 3 inuA  y . .
4 \ floor of the pituitary: fossa {

■' : ::ÿiGURH;;29..
Norma.l ;pitultàry tômdgfaphy>; . Patient 4 /
n
l i .
>■. ■ --V-
y . y : '..y
, , V FïGURB: 30'y" ' : y > v y : # y
Normal pituitàry toàographÿ;:. ; Pat'âen
■y;
■ -y -y';:

- FIGURE 31 (a)d--.d.y/' y 
Pituitary radiology? Patiçnt 18 d
Yiei-i A Lateral tomogram sHowin|
’ of the iJituitary fossa axid erdsl^ ^
of bony margin.v, - '
View Ji Antero"post6i'ior tomogfam during air
encephalography showing bulging of the 
y fossa floor and large supfà sellàr y 
extension of tumour.. - -:d - .

: FIGURE 31 ' (b)
; - E M l :  ^ c a n : x ' \ P a t i W :  '
: A fluid lève! is clearly demonstrated supfà;
seliar extension of the pituitary tumourë
jrT;*-S
I
FIGURE 32 (a) ,
Pituitary radiology; Patipnt 16
An enlarged pituitary fossa-with an inferior bulge 
seen on lateral tomogram I - ; , ^

Pituitary radiology : Pationi 16 \ ■
A comparison of 19 74 and 1978 : filBisi
View A ;■, Latpral Xi'ay of : skull 19 74ÿR-'.) ■
View. B ; ; Lateral. Xray of #nll 19.78,;
showirig e x t e n s i o n  o V  i n f e r i o r  b u l g e ^ ^
A
■ FIGURE 33
Pituitary ; radiology; Patient 12 
Lateral tomogram showisig erosion 
of bony margins and bulge into ; 
sphenoid sinus•
- X.V,

FIGURE 34 (a)
Pituitary radiologyr-Patlent 13 
The floor of the fossa is;double i^  ^
contour both in the lateral Xray of 
skull and lateral tomogram which 
also shows a thin dorsum : sellae .
An t e r o pp s t er i6r t pinog f aphy c on £ i rms 
asymmetry of the fossa floorV

FIGURE 64 # )
Pituitary fadiplogy; Patient 13*
A comptaii idh o f  xprp and p o s t  o p e r a t iv e  f i lm s*
View A Pte-operative lateral Xray of skull 
View B Pdsv oppratiyo.y 1 ?lray of skull
i : shWiiig diaphragma sellao marker in 
- 'if'situ' and:%romodoiiing of dorsum sellae.
. f Film taken six months post operatively,

■ 'y y: / FIGURE 35 , ^
Pituitary râdiology: Patient 14
A pituitary fossa of normal size but with a floor 
of double contour.

- X y .y y,.3ic:um 3g:Yy':y#:;yyyr^ 4-%;:'-.?
■:-'x;:.,:'-_; .Pituitary!radiplogyr' vPatyeùtfdi- yi'^ yyy/!■' - 
Pituitary fossa- of aormàï ..sizo ;wrkh aysuggëstion y 
of loss of cortical definition ihforiorlyyp 
lateral Xray of skull. This ià confirmed dii ! 
lateral tomogram. '/.y-.-1." % ' !!,.. y-y-y^ yy'' ^yy.-: .y" 
Note also failure Uf pneumatisation of the 
sphenoid sinus and soft tlssue Swé1lih^ pf vadéhdids
F*:.
rîi'V:
. y -  y
Prolactlsiomas ; Absence d£ diurnal variatiBn in 
prolactin levels.
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Prolactinomas; Prolactin response to Metoclopramido 
stimulation,.
Groups as defined rn text.
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Prolactinomas : Prolactin response ^to L-dopa,
Groups as •■de£ine4'-;;inj''text.;-,; ' - 'À.-v 
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Prolactinomas . Proiactiii response to Bï'omoçriptine^  ^
Groups as defined in text.
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Strategy for,the elucidation of unexplained, 
hyperprolactihapsnla.  ^^ ^
\ >!
CLINICAL SYNDROME +  HYPERPROLACTINAEMIA
TUMOUR 
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 1-----------------------------
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Sprum pr.olaxtiii concentrâtipiis in, pàtiéîxts with 
renal disease-but normal renal tunetion^Cv 
Groups as defined in text.:: t v - ' r ' -
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Serum prolactin concentrations in patients with 
impaired renal function, who were receiving 02ie 
or more.drugs known to affect prolactin level. ^
(i) .Groups as defined in text.
(ii) Horizontal bars, indicate the.mean prolactin 
concentration in each group/
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Sérum prolactln concentrations rà patients; with 
impaired renal functièn,; who on no therapy
known To alter prolactin secretion. ; ; /
(i) Groups as defined in .textV^|.y'\ ' ^
(ii) Horizontal bars.indicate;t prolàctin
concentration: in each group.; > .
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across the normal kidney. ; <
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FIGURÉ 47 :
Basal goiiadar status,with progressive uraemia 
and after successful renal transpiahtatipn^
(,i) Groups as defined in text. Z; T •
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FIGURE: 48
Basal thyroid status with progressive uraemia aiid 
after successful rénal transplantation..
Groups as defined in text. '
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FIGURE 49
Basal thyroid status in dialysis patients• 
Dotted lines indicate the absolute range 
o£ values in control subjects. :
Horizontal bars indicate the mean 
concentration in each group.
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TSH response to TRHî Uraemic subjects and controls 
mean + standard error of mean plotted*
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GH response to TEH: Hraomic subjects and controls.
Individual responses plotted for each uraemic subject.
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FIGURE 52
Basal gonadal status in male dialysis patients* 
Dotted lines indicate the absolute range of values 
in control subjects*
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FIGURE" 53;./
Basal gonadal status in female dialysis patients• 
Dotted lines indicate the absolute range of values 
in control subjects* i
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FIGURE 54
LU and FSH response to Gn RH: Uraemic males
and controls* ■
Mean + standard error of moan plotted.
00
LU
O
Ô W
V 
Q .
O
c
p
a  y
o
CD
O
CM
CO
C
X
X
c
O
X
c/)X
LD
Z3
X oLO o
CD CM
O
O  3
o
6
V
CL
N.
■s,
o
à)
V
CL
o
CD
o
CM
CD
S  I
o
CM
o
o
; FIGURE '55 y ^ T.//::"'
XH and FSH ;rospouse to Gn RH: Uraemic females
and controls. c
Mean v standard error of mean, plotted.
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FIGURE 56 '
Prolactin response to TRU; Uraemic subjects and controls
-- A:.''-':, -  \  .
Mean + standard error of mean plotted, ,
CD
c\j
LU
LL
O
C\J
OC\J
O  3
o
o ooo
C\J
c0
E
Eoc
Prolactin response to Motbclopramide î Uraemic; 
subjects and controls*
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Prolactin response to L-dopa and Bromocriptine; 
Uraemic subjects and controls* ■
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I-iumaa prolactin heterogeneity after gél filtration : IV 
MRG 75/504 h PRL reference preparation^ normal 
pituitary extract and pregnancy sera,^^^ / ; ; \
Methods as described in . text. t f
.
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FIGUim 60
Human prolactin heterogeneity after gel filtration; 2. 
Prolactinoma patient S.C: Pituitary extract and serum*
Methods as described in text.
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FIGURE 61
Human prolactin heterogeneity after gel filtration î 3.
Prolactinoma patient P$C : Pituitary extract aid, ,serùm-
Methods' as described in text. - < ■ t;
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Human prolactin heterogeneity; after gel filtration: 4 
Uraemic sera A .and B.
Methods as described in text. ;
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